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ABSTRACT 
 
 Since there is a limited literature base concerning individuals admitted with a 
potentially preventable hospitalization (PPH) who acquired a healthcare associated 
infection (HAI), this research identified the prevalence and costs of individuals admitted 
to Texas hospitals in 2011 for a PPH and acquired an HAI. Based on IOM identified 
associations between PPH and uninsurance, the analytic evaluation draws from 
theoretical models that link insurance status to outcomes such as PPH.  Using the 
hypothesis that the cost of preventive care for the uninsured with ambulatory care 
sensitive conditions (ACSC) that lead to PPH would be less than the incremental cost of 
healthcare for HAI in individuals admitted with a PPH and acquired an HAI, I estimated 
costs for ACSC related preventive care, PPH, and the incremental cost of HAI. The 
Agency for Healthcare Research and Quality (AHRQ) Quality Indicator modules 
identified PPH using administrative inpatient discharge data and private insurer claims 
data. Adjusting for demographic, community and hospital characteristics, logistic 
regression analysis estimated odds ratios of PPH individuals acquiring an HAI, and 
generalized least squared regression estimated costs needed to address the hypothesis. I 
identified 1,031 individuals in the 2011 Texas inpatient discharge data with both a PPH 
and an HAI. 66% of the PPH with HAI population identified Medicare as their primary 
payer, and 7% identified Self-pay or Charity as primary payer. Most PPH individuals 
had lower odds of acquiring an HAI. However, individuals admitted with diabetes 
related lower extremity amputation demonstrated a significantly higher odds of 
acquiring either Clostridium difficile infection (OR: 2.9, CI95% 2.16, 3.91) or ventilator 
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associated pneumonia (OR: 1.4, CI95% 0.95, 2.18).  The adjusted mean cost per 
hospitalization for PPH was approximately $2,000 less than the general inpatient 
population. The estimated incremental cost of HAI for the 97 uninsured individuals in 
the PPH and HAI population was $2.1 million. The cost of preventive healthcare for 
uninsured individuals in Texas with an ACSC was estimated at $66.8 billion. Given the 
large proportion of insured within the PPH with HAI population, and the incremental 
cost of HAI quantified, I recommend additional research focusing on the Medicare 
population affected.   
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CHAPTER I 
INTRODUCTION  
When barriers in access to quality primary care exist, especially for ambulatory 
care sensitive conditions (ACSC), potentially preventable hospitalizations (PPH) can 
occur (Agency for Healthcare Research and Quality, 2007; Basu, Friedman, & Burstin, 
2002; Bindman et al., 1995). During 2010, in 44 states more than 3.5 million hospital 
admissions were identified as potentially preventable, translating to a PPH rate of 1,493 
per 100,000 individuals (Batelle, 2013). In addition to potentially misallocated resources 
associated with PPH, any hospital admission carries with it the risk of acquiring a 
healthcare associated infection (HAI). It is estimated that one in twenty hospital patients 
will acquire an HAI, translating to an increased risk of death and direct medical costs 
that were estimated nationwide at $9.8 billion annually in 2012 dollars (Centers for 
Disease Control and Prevention, National Center for Emerging and Zoonotic Infectious 
Diseases, & Division of Healthcare Quality Promotion, 2010; Klevens et al., 2007; Scott 
II, 2009). While both PPH-related access issues and HAI-related quality issues have 
been studied, there is little in the literature that examines the patient population that is 
admitted for a PPH and acquires an HAI during the same hospital stay. This gap in our 
knowledge is the focus of the literature review and analyses in the coming pages.  
Individuals admitted to a hospital with a PPH are often thought to have a limited 
ability to pay for care but nonetheless are driven to seek care due to severity of illness 
(Bindman et al., 1995). For individuals already limited in their ability to pay for care, the 
additional costs both physically and financially of an HAI add to the insurmountable 
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issues related to poverty. It follows that the Patient Protection and Affordable Care Act 
of 2010 (ACA), as it is implemented, is likely to increase access to preventive healthcare 
services through increased insurance coverage for preventive healthcare services, which 
should translate to reductions in PPH. The reduction of PPH in turn should translate to 
reduced exposure to and incidence of HAIs. However, the impact of ACA on the rate of 
PPH and HAI is likely to vary across states, due to differences across states in the pre-
ACA proportion of the state population without health insurance, coupled with the 
decision by some states to not expand state Medicaid coverage, as encouraged by the 
ACA (The Henry J. Kaiser Foundation, 2013).  
This anticipated chain of circumstances leads to a central question addressed by 
this dissertation: Following the full implementation of ACA, will the increase in 
preventive care cost attributable to improved insurance coverage for individuals with 
ACSCs be offset by reductions in costs associated a reduced rate of HAI during a PPH? 
To better characterize the population of people that acquire an HAI during a PPH, Figure 
1 illustrates the overlap between the ACSC, PPH, and HAI populations (Figure 1). The 
shaded region represents the population of people who acquire an HAI during a PPH, 
and this population is the focus of the following analyses. 
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Figure 1. Relationships between the ACSC, PPH, and HAI populations. 
 
The primary focus of ACA is to reduce the proportion of the population without 
health insurance, which in turn will improve access to care, including preventive 
services. Accordingly, I have elected to analyze the PPH with HAI population through 
an access lens (Ansell & Schiff, 1987; Hall, Harman, & Zhang, 2008; Kaiser 
Commission on Medicaid and the Uninsured, 2011; Vigdor, 2003). The access 
perspective is appropriate at this time for two reasons. First, the goal of the ACA is to 
enable or improve access to healthcare by creating options for the uninsured or 
underinsured to secure affordable health insurance. The ACA strives to accomplish its 
goal by focusing legislation on insurance market reform and mandates individuals to 
secure health insurance (Patient protection and affordable care act, 2010). Second, third-
party payers influence the provision of healthcare through payment incentives linked to 
outcomes. For example, Medicare uses its market share power to dictate non-payment to 
ACSC PPH HAI 
All Texas Hospital Admissions 
Residents of Texas 
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providers for unacceptable outcomes such as nosocomial hospital events that are deemed 
preventable (Lee et al., 2012). While payment incentives such as Medicare’s non-
payment policy should create positive externalities for patients with other insurance, it is 
important to tease out differences by payer. 
Since little has been reported about the PPH with HAI population, I elected to 
limit the analyses to the state of Texas for two reasons. First, while Texas was not alone 
when it declined to expand Medicaid under the provisions of the ACA, the 
administrative implementation of Medicaid does differ from state to state (The Henry J. 
Kaiser Foundation, 2013). To create a baseline understanding, I determined that using a 
single state would eliminate the need to account for variation associated with state-based 
cultural normative values related to healthcare and Medicaid administrative 
implementation differences between states. Second, Texas has the highest percentage of 
uninsured at 24%, accounting for 6.1 million individuals in the state of Texas or 12.6% 
of the nations’ uninsured (Kaiser State Health Facts, 2012). As such, it provides 
researchers with a rich source of information regarding the uninsured. 
With the analytic focus of access and study population limited to the state of 
Texas, the analyses will provide several significant contributions to our base of 
knowledge. First, the study establishes a method and a baseline measurement in the 
prevalence and cost of PPH with HAI. The baseline estimation includes a comparison of 
demographic and payer characteristics between the population at risk and other hospital 
patients. Further, the baseline cost estimates include an adjusted incremental cost 
analyses to understand the effect of HAI on the PPH population. Finally, the baseline 
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metrics will allow for comparisons of prevalence and costs between states and after full 
implementation of the ACA.  
Second is the development of a method for identifying HAIs and HAIs 
associated with PPH from administrative data. While identification of HAI through 
administrative discharge data alone is not recommended for surveillance purposes, a 
method that closely approximates more exact surveillance estimates will provide 
researchers and policy makers with the ability to estimate costs without increasing 
reporting burden. Further, with payment linked to nosocomial events, coding and billing 
methodologies should evolve. The anticipated evolutions in coding would then make the 
use of administrative data more feasible and reliable especially for the purposes of policy 
and cost estimates. 
This dissertation consists of seven chapters, including this introductory chapter 
(Chapter I).  Chapters II and III will review the existing literature and outline the 
theoretic basis of the evaluation. The topics in Chapter II provide a brief overview of the 
ACA, categories of insurance status relevant to this evaluation, a consolidated review of 
ACSCs and PPH, associations with insurance status, the effects each has on access to 
quality preventive healthcare, types of HAI found in hospital settings, and established 
metrics and benchmarks for PPH and HAI. Chapter III describes the evolution of the 
conceptual model used as the basis of the analytic framework including relevant theory 
for the behavior of vulnerable populations in their acquisition of healthcare.  Chapter IV 
describes the methodological and analytic approach used to address the research goals of 
the dissertation, while Chapter V provides a summary of findings from the data analysis. 
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Chapters VI and VII provide a discussion of the results, the potential implications on 
future research and policy, and summarizes the key findings and conclusions.   
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CHAPTER II 
LITERATURE REVIEW 
Insurance 
In a series of reports by the Institute of Medicine (IOM), the IOM highlighted 
several associations between insurance status and health status. These included insurance 
status associated with better care and access across preventive, chronic, and acute health 
services, improved health outcomes, and individuals with continuous health insurance 
coverage lived longer with a lower rate of decline in health status over the years of life 
(Institute of Medicine, 2003, p. 13). Also identified in the IOM reports, were 
associations between uninsurance and forgone health care due to financial and access 
barriers. According to the IOM reports, forgone healthcare resulted in approximately 
18,000 avoidable deaths per year for uninsured adults (Institute of Medicine, 2003, p. 
13). 
In 2009, the Council of Economic Advisors to President Obama presented an 
economic justification for market reform of healthcare (Council of Economic Advisors, 
2009). The analysis identified slowing growth of healthcare costs through expansion of 
health insurance coverage as the keys to market reform (Council of Economic Advisors, 
2009). Since health insurance has been associated with cost containment, access, and 
health status, the following review of health insurance briefly describes the ACA and the 
major types of third party payers that influence the provision of healthcare, including the 
uninsured. 
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Patient Protection and Affordable Care Act of 2010 
The Patient Protection and Affordable Care Act (ACA) passed in 2010 included 
provisions intended to improve access to healthcare through disallowing insurers to 
refuse insurance coverage to individuals with pre-existing conditions, allowing families 
to continue covering children until age 26, and by providing mechanisms for the 
uninsured to obtain health insurance (Patient protection and affordable care act, 2010). 
Since having health insurance has been linked to better health and quality of life, 
availability of health insurance options potentially addresses societal inequities in access 
to healthcare (Streeter et al., 2011; Vigdor, 2003). 
In an effort to meet its intended goals of cost containment and improved access 
to healthcare, the ACA, a large and complex piece of legislation, includes provisions 
such as an individual health insurance mandate, creation of health insurance 
marketplaces, individually and employer based subsidies to support premium payments, 
and the expansion of state Medicaid programs(Patient protection and affordable care act, 
2010). To finance the provisions in the ACA, the legislation included a variety of fees 
and penalties intended to underwrite, at least in part, the financial burden created by the 
law. Some mechanisms include: 
 Penalties phased in from 2014 to 2016 for individuals not in compliance with the 
health insurance mandate (in 2016, $695 per year or 2.5% of household income) 
 Penalties on large employers (50 or more full-time employees) with employees 
utilizing premium tax credits  
 Fees on the insurance industry 
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 Increased Medicare Part A tax rate  
 Increase tax on non-qualified expenditures from health savings accounts  
 Limit contributions to $2,500 for flexible health spending accounts  
 On federal tax returns, increased itemized deductions threshold for non-
reimbursed healthcare expenses  
 Excise tax on insurers with “Cadillac” health plan premiums  
(Kaiser Commission on Medicaid and the Uninsured & Healthcare Marketplace Project, 
2011; Patient Protection and Affordable Care Act, 2014).  
The ACA facilitates federal financing for the coverage of all individuals not 
previously eligible for Medicaid and living at or below 133% of the FPL. Starting in 
2014, the federal government intends to fund 100% of states’ expanded Medicaid 
population until 2016. Between 2017 and 2019, the federal funding rate is legislated to 
decline from 95% to 93% of the cost of the expanded Medicaid population. For 2020 
and beyond, the ACA is legislated to fund 90% of the Medicaid expansion population 
(Kaiser Commission on Medicaid and the Uninsured & Healthcare Marketplace Project, 
2011). Additionally, the ACA legislates that the federal government will finance 
increased payments to providers so that Medicaid payment rates are equivalent to 
Medicare payment rates (Kaiser Commission on Medicaid and the Uninsured & 
Healthcare Marketplace Project, 2011). Despite the significant financial incentives by 
the federal government to pay for new beneficiaries under the Medicaid expansion, it is 
estimated that states will incur a 17.8% increase in payments to hospitals for care 
associated with the Medicaid expansion between 2013 and 2022 (Holahan, Buettgens, 
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Carroll, & Dorn, 2012). In Texas, the estimate is higher at 22.2% increase in payments 
to hospitals during the same time frame (Holahan et al., 2012). 
Another facet of the ACA establishes health insurance exchanges or health 
insurance marketplaces for individuals who do not qualify for Medicaid or Medicare and 
are not covered by employer-sponsored health insurance. Currently, individuals in 
households with income between 134- 400% of the FPL should have access to premium 
tax credits and cost-sharing subsidies to lower the cost of health insurance. Qualified 
health plans are required to include health benefits defined as “essential,” including 
ambulatory patient services, emergency care, hospitalization, obstetric, newborn, 
pediatric care, mental health services, prescription drug coverage, laboratory services, 
rehabilitation services, and preventive services that include chronic disease management 
services (42 U.S.C. §18022). 
Although the Supreme Court ruling validated the constitutionality of the 
individual health insurance mandate in July 2012, the Supreme Court also determined 
that the legislation could not force states to expand their Medicaid programs in order to 
continue receiving existing funds (Roberts, 2012).  Given the choice to expand, to date, 
Texas along with 18 other states have declined to expand Medicaid under the terms 
outlined by the ACA (Perry, 2012; The Henry J. Kaiser Foundation, 2013). Texas was 
also among 27 states that opted to participate in the federal health insurance exchange 
(The Henry J. Kaiser Foundation, 2013).   
Accordingly, eligible Texans should have access to health insurance through a 
federal health insurance exchange. However, the implementation of the ACA met with 
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substantial political resistance and roll-out issues resulting in delays of some portions of 
the law, and difficulties in opening the federal insurance exchange for individuals to the 
public (Burgess, 2013; Hu, 2013; Morelli, 2013). At the end of the rollout period, states 
enrolled 25.4% of the estimated federal exchange eligible population (Kaiser Family 
Foundation, 2014). State-base exchanges appeared to have more success in signing up 
exchange eligible individuals at 29.5% of the exchange eligible population, while the 
state of Texas was just below the national average with 23.3% of the 3.1 million Texans 
estimated to be eligible to participate in the exchange (Kaiser Family Foundation, 2014). 
Medicare and the Medicare population  
 Entitlement legislation passed in 1965 established the federally based insurance 
program we know as Medicare (42 U.S.C, chapter 7 subchapter XVIII). The insurance 
program covers individuals 65 years of age and over, individuals with certain 
disabilities, and individuals with end-stage renal disease (Centers for Medicare and 
Medicaid Services, 2013a).  The program includes hospital insurance, medical 
insurance, and prescription drug coverage and accounted for 28.4% of the health 
insurance market in 2012 or $572.5 billion (Centers for Medicare and Medicaid 
Services, 2013a; Centers for Medicare and Medicaid Services, 2014)  
While private health insurance accounts for nearly half of the health insurance 
market, it is estimated that Medicare beneficiaries accounted for 47% of inpatient costs 
nationally in 2011 (Centers for Medicare and Medicaid Services, 2014; Torio & 
Andrews, 2013). As the largest consumer of inpatient services nationally, the Medicare 
program has moved from being a passive payer to a more active consumer of healthcare, 
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working to incent quality cost-effective healthcare for its beneficiaries through payment 
structures and payment incentive programs. Payment structures include the prospective 
payment system, fee-for-service, and capitated Medicare known as Medicare Advantage 
(Averill et al., 1998; Averill, Goldfield, Muldoon, Steinbeck, & Grant, 2002; Averill et 
al., 2009). Incentives pay providers for evidence-based quality care or penalize providers 
through reduced payments by using programs such as pay for performance, pay for 
reporting, and value-based purchasing (Centers for Medicare and Medicaid Services, 
2009; CMS Hospital Pay-for-Performance Workgroup, 2007; Maio, Goldfarb, Carter, & 
Nash, 2003). As cost of healthcare has escalated, the Medicare program has used its 
purchasing power in the healthcare marketplace to implement and revise incentive 
programs intended to contain rising costs and improve outcomes for its beneficiaries.    
Medicaid and the Medicaid population 
 Established through federal legislation in 1966, Medicaid is a state run 
federal/state matching funds program designed to help ensure access to healthcare for 
the poor and impoverished (42 U.S.C., chapter 7 subchapter XIX). Currently, Medicaid 
in Texas covers the federally mandated populations including: (a) the categorically 
needy as defined by participation in Temporary Aid to Needy Families (TANF); (b) 
pregnant women and children up to six years with a family income up to 133% of the 
federal poverty level (FPL); (c) children six to 19 years with family income under 100% 
of the FPL; (d) parents of qualified children living at or below 42% of the FPL; and (e) 
the aged, blind and disabled living at or below 74% of the FPL (Rowland, 2005). 
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Under Medicaid legislation, Texas opted to expand the population covered to 
include: (a) family members of qualified TANF recipients with incomes up to 14% of 
the FPL; (b) individuals denied TANF funds because of extended family resources with 
incomes up to 185% of the FPL; (c) pregnant women who would otherwise be eligible to 
receive TANF funds with incomes up to 185% of the FPL; (d) pregnant women through 
their postpartum period who may have otherwise lost funding due to an increase in 
family income; (e) the aged, blind and disabled receiving cash assistance through 
Supplemental Security Income (SSI) funds with incomes up to 74% of the FPL; (f) 
individuals denied SSI funds due to changes in definitions of disability with incomes up 
to 74% of the FPL; (g) institutionalized individuals who meet state Medicaid eligibility 
criteria with incomes up to approximately 220% of the FPL; (h) Medicare beneficiaries 
with income that does not exceed 100% of the FPL; (i) individuals eligible for buy-in 
participation through the BBA Work Incentive Group with incomes up to 250% of the 
FPL; and (j) individuals eligible for buy-in participation through the Family Opportunity 
Act with incomes up to 300% of the FPL (State of Texas, 1980; Tavenner, 2011; Texas 
Health and Human Services Commission, 2008; Texas Health and Human Services 
Commission, 2012a; Texas Health and Human Services Commission, 2012b; Texas 
Health and Human Services Commission, 2012c; Texas Health and Human Services 
Commission, ).  
Medicaid was distributed to Texans through four programs including traditional 
Medicaid using a fee-for-service payment structure, Children’s Health Insurance 
Program (CHIP), State of Texas Access Reform (STAR) and STAR+PLUS using a fully 
14 
 
capitated managed care payment structure, and the Women’s Health Program(Texas 
Health and Human Services Commission, 2008; Texas Health and Human Services 
Commission, 2012b; Texas Health and Human Services Commission, 2012c; Texas 
Health and Human Services Commission, ). Additionally, Texas has created the Health 
Insurance Premium Payment (HIPP) program and the Medical Transportation Program 
to aid the impoverished in Texas (Texas Health and Human Services Commission, ; 
Texas Health and Human Services Commission, ). To qualify for these programs, 
individuals must be U.S. citizens or a qualified legal permanent resident, and a Texas 
resident. Other qualifications relate to the specific population served by the program. For 
all programs, qualifying income level changes with the number of family members to 
allow more money to stay with larger families. Qualifying income levels were assigned 
using the FPL. For 2012, the FPL for a family of four was $23,050 (U.S. Department of 
Health & Human Services, 2012). 
There are two additional topics relevant when discussing the Medicaid eligible 
population in Texas. First, Texas has moved to phase out or significantly reduce fee-for-
service payment in the Medicaid population (Wool, 2012). Until March 2012, STAR and 
STAR+PLUS were available primarily in urban areas. In March 2012, the state 
transitioned the majority of qualified beneficiaries from traditional Medicaid FFS to the 
STAR capitated payment structure with STAR+PLUS expanding statewide in 2014 
(Wool, 2012). The transition primarily affected Medicaid beneficiaries in rural settings. 
Texas also removed state level Upper Payment Limit funding mechanisms from its 
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Medicaid program to allow those funds to be used more effectively in managed care 
(McKethan & Menges, 2006; State of Texas, 1980; Wool, 2012).  
Second, national Medicaid participation rates identified were below 80% of the 
number of eligible individuals (Weil, 2003). By eligibility category, participation rates 
were 72% of eligible children, 51% of eligible non-elderly adults, 78% of qualified 
Medicare beneficiaries, and 16% of the eligible specified low-income Medicare 
beneficiaries (Weil, 2003).  A more recent examination of participation compared 
different definitions and estimates. Estimates for adults nationally ranged from 32.3% to 
81.3%, and child participation rates were 57.0% to 96.1% (Sommers et al., 2012). 
Uninsurance and the uninsured population 
Nationally, more than 48.6 million individuals were uninsured in 2011 (Kaiser 
State Health Facts, 2012).  While the state of Texas accounted for only 8.2% of the 
national population, it accounted for 6.1 million or 12.6% of the nations’ uninsured and 
had the highest state uninsurance rate of 24% (Kaiser State Health Facts, 2012). Only 
California had more uninsured individuals, approximately 7.3 million individuals or 
20% of California’s population. Behind Texas with 3.8 million uninsured individuals 
was Florida (Kaiser State Health Facts, 2012). Together California, Texas, and Florida 
accounted for more than a third of the uninsured population in the United States.  
 When the uninsured in Texas were examined by demographic and economic 
characteristics, more than half of the 6.1 million individuals were male and 
approximately 80% were adults. When examined by race, 59% were Hispanic. 
Additionally, 69% of the Texas uninsured lived in households with at least one full-time 
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worker. And even though most households had at least one worker, total income for 52% 
fell at or below 138% of the FPL (Kaiser State Health Facts, 2012).  It is unclear from 
the literature, how many of the working uninsured are eligible and not enrolled in 
insurance programs such as Medicaid. But, we do know that approximately 3.6 million 
individuals were enrolled in the Texas Medicaid program in 2011, and of the uninsured 
population in Texas in 2011, an estimated 782 thousand were eligible but not enrolled in 
Medicaid (Texas Department of State Health Services, 2013a; Texas Health and Human 
Services Commission, 2013). While the rate of uninsured by gender and age are similar 
to the United States’ rates, the proportion of the Texas population that is uninsured is 
consistently higher in all other economic categories compared to the United States 
average with the exception of full dual eligibles and the disabled population (Kaiser 
State Health Facts, 2012). 
In border states such as Texas, the uninsured population includes undocumented 
immigrants and their use of healthcare. Although undocumented immigrants utilize less 
healthcare than their citizen counterparts, the immigrant population both legal and illegal 
account for approximately 22% of the uninsured (Hoffman, Schwartz, Tolbert, Cook, & 
Williams, 2007; Lorden, 2008).  Representative Michael C. Burgess (R-Texas) cited the 
large numbers of immigrants in Texas as a primary reason Medicaid expansion would 
not address all of the relevant issues in Texas especially concerning reductions in 
Disproportionate Share Hospital (DSH) funds through the ACA guided expansion of 
Medicaid (E. Smith, 2012). 
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Potentially preventable hospitalizations 
Definition of and existing metrics for PPH 
ACSC are defined as chronic health conditions that if managed with timely 
primary care, hospitalization could be avoided (J. Billings et al., 1993). Hospitalizations 
that result from untreated or under-treated ACSC are commonly known as PPH (Basu, 
Friedman, & Burstin, 2006; Bindman et al., 1995; Bindman, Chattopadhyay, Osmond, 
Huen, & Bacchetti, 2005; Oster & Bindman, 2003). PPH accounted for 3.9 million 
hospitalizations and an estimated $31.9 billion in total hospital costs in 2010 (Torio, 
Elixhauser, & Andrews, 2013).  
 Initially, six expert physicians defined PPH by performing a medical chart 
review and identifying the ICD-9-CM codes thought to reflect hospital utilization by the 
indigent and other individuals with healthcare access barriers (J. Billings et al., 1993; 
Friedman & Basu, 2004). The identification of PPH has evolved, and can be identified 
through 13 adult and 5 pediatric measures using the Prevention Quality Indicators (PQI) 
and Pediatric Quality Indicators (PDI). The Quality Indicators were developed by the 
Agency for Healthcare Research and Quality (AHRQ) Evidence-based Practice center, 
the University of California San Francisco, and Stanford University (Agency for 
Healthcare Research and Quality, 2007; Agency for Healthcare Research and Quality, 
2008; Friedman & Basu, 2004).  
Developed through comprehensive literature review and validation testing, the 14 
PQI and 4 PDI use inpatient administrative discharge data including ICD-9-CM 
diagnoses codes, Medicare Severity-Diagnosis Related Groups (MS-DRGs), and All-
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Patient Refined Diagnosis Related Groups (APR-DRGs) with associated severity 
measures to identify inpatients with hospitalizations where an ACSC is the principal 
reason for admission (Agency for Healthcare Research and Quality, 2013c; Batelle, 
2013). The 13 adult and 5 pediatric Quality Indicators reflecting PPH include diabetes 
short-term complications, perforated appendix both adult and pediatric, pediatric 
diabetes,  diabetes long-term admissions, chronic obstructive pulmonary disease, 
hypertension, congestive heart failure, low birth weight, dehydration, pediatric 
gastroenteritis, bacterial pneumonia, urinary tract infection both adult and pediatric, 
angina without procedure, uncontrolled diabetes, asthma both adult and pediatric, and 
lower-extremity amputation among diabetes patients (Agency for Healthcare Research 
and Quality, 2013b). Since development and refinement, ten of the PQIs are endorsed by 
the National Quality Forum as validated and nationally recognized measures of quality 
and access to healthcare (National Quality Forum, 2013b). 
PPH as a reflection of access to healthcare and the role of insurance status 
 ACSC and the PPH associated with them are two indicators known to reflect 
access to primary care (J. Billings et al., 1993; J. Billings & Anderson, 1996; Bindman et 
al., 1995; Friedman & Basu, 2004; Ricketts, Randolph, Howard, Pathman, & Carey, 
2001; Saha, Solotaroff, Oster, & Bindman, 2007; Shi, Samuels, Pease, Bailey, & Corley, 
1999).  The evolution of using the PQI to understand preventive healthcare access 
through ACSC related PPH began when early studies explored PPH to understand 
underlying determinants of access. In an early study of ACSCs and PPH by Billings et 
al. (1993), hospital admissions were blocked into three categories: Conditions where 
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primary care had a limited ability to prevent the admission, ACSC where primary care 
may have prevented the admission, and referral sensitive procedures reflecting surgery 
that was potentially the result of barriers to access or specialty care. The study found 
determinants of access were income, race, and age, with the low-income black 
population in the age range of 25-44 years most affected. (J. Billings et al., 1993). 
 In 1996, Bindman et al. examined five ACSC that resulted in PPH for 250 ZIP 
codes in San Francisco, California. Validating PPH as a measure of access, Bindman et 
al., (1996), like Billings et al., (1993), found race and income predicted PPH. Through a 
regression analysis, an inverse relationship between insurance status and PPH was 
attributed to inferior access to healthcare among the uninsured. (Bindman et al., 1995). 
The subsequent focus to reduce PPH through insurance related access to preventive care 
has been associated with a decrease of PPH by 6.2 percent from 2005 to 2010 in the 
United States (Ayanian, Weissman, Schneider, Ginsburg, & Zaslavsky, 2000; Bharmal 
& Thomas, 2005; Hadley & Cunningham, 2004; Kaiser Commission on Medicaid and 
the Uninsured, 2011; Torio et al., 2013; Vigdor, 2003). 
Effects of payment structure  
Since identifying an association between insurance status and PPH, evidence 
suggests insurance structured through managed care payment models do better than fee-
for-service payment structures to reduce PPH (Backus, Moron, Bacchetti, Baker, & 
Bindman, 2002; Basu, Friedman, & Burstin, 2002; Basu, Friedman, & Burstin, 2004; 
Basu et al., 2006; Basu, Thumula, & Mobley, 2012; Bindman et al., 2005; Bindman, 
Chattopadhyay, & Auerback, 2008a; Bindman, Chattopadhyay, & Auerback, 2008b; 
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Laditka & Laditka, 2001). When examining vulnerable populations, at least two studies 
substantiated where vulnerable populations were part of managed care programs 
significant decreases in PPH resulted (Backus et al., 2002; Zeng et al., 2006). For the 
elderly, Medicare Advantage, the Medicare managed care program, did not demonstrate 
reduced hospitalizations in one recent study (Baicker, Chernew, & Robbins, 2013). 
However, in markets with increased Medicare Advantage penetration, spillover effects 
included younger populations experiencing lower hospitalization costs and shorter 
lengths of stay (Baicker et al., 2013). Additionally, reduced expenditures offset the 
higher payment rates for Medicare Advantage patients (Baicker et al., 2013).  
 In another recent study of Medicare Advantage, the effects of payment structure 
and selection bias on hospital admissions were examined. A differentiating characteristic 
was whether or not the market was in a county within a Metropolitan Statistical Area 
(MSA) where the county population was above or below 250,000 individuals (Afendulis, 
Chernew, & Kessler, 2013). In counties above the 250,000 threshold, increased payment 
levels facilitated providers in offering more services while simultaneously encouraging 
greater market penetration. The payment incentive produced reductions in 
hospitalizations including those associated with ACSC in the MSA counties with 
populations over 250,000 (Afendulis et al., 2013).  
In rural and underserved areas, the presence of a Rural Health Clinic or a 
Federally Qualified Health Clinic was associated with reductions in PPH compared to 
underserved communities with no public clinics (Epstein, 2001; Falik, Needleman, 
Wells, & Korb, 2001; Zhang, Mueller, Chen, & Conway, 2006). Since Rural Health 
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Clinics and Federally Qualified Health Clinics are federally supported preventive care in 
underserved communities, and exist in both managed care and fee-for-service markets, it 
is unclear whether the effects are related to payment structure.   
Effects of Medicare on PPH 
 For the elderly, the primary insurance provider is Medicare with the poor elderly 
also covered by Medicaid. Individuals covered by both Medicare and Medicaid are 
known as dual eligibles. Nationally, two-thirds of dual eligibles fully qualify for both 
programs with the remaining portion qualifying for assistance with Medicare premium 
and cost sharing payments (Clemans-Cope & Waidmann, 2011). While dual eligibles 
accounted for about a sixth of each population, they simultaneously accounted for 40% 
of each programs’ spending estimated to exceed $315 billion in 2011 (Clemans-Cope & 
Waidmann, 2011). 
In 1998, individuals with Medicare as their only insurer had fewer PPH 
compared to other Medicare beneficiaries with Medicaid or private insurance as part of 
their insurance coverage (Culler, Parchman, & Przybylski, 1998).  Other factors for the 
Medicare population identified with increased odds of a PPH included increased age, 
black, less than college education, reduced health status, diabetes, coronary heart 
disease, two or more ADLs, and living in either a core metropolitan statistical area or a 
rural county (Culler et al., 1998). When diabetic Medicare beneficiaries’ claims data 
were analyzed for PPH, comorbid conditions, especially heart failure related 
comorbidities, were associated with an increased odds of a PPH (Niefeld et al., 2003).  
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A more recent study of PPH for the Medicare population measured the 
relationship between PPH and continuity of care measures (Nyweide et al., 2013). The 
results demonstrated improved continuity of care was inversely related to PPH when 
adjusted for demographics, Medicare only verses dual-eligibility, and comorbidities as 
measured through CMS hierarchal condition categories score (Nyweide et al., 2013). 
While the hazard ratio by insurance status for Medicare verses dual-eligibles was 
significant, where Medicare only were less likely to have a PPH, the reported hazard 
ratio was 1.06 (Nyweide et al., 2013). Other research suggested that lower rates of PPH 
for individuals 65 years of age and older may be due to participation in Medicare 
(Laditka & Laditka, 1999). 
Effects of Medicaid on PPH 
 Although access to preventive healthcare has improved for low-income 
populations through expansions of Medicaid and the introduction of the State Children’s 
Health Insurance Program (SCHIP), it does not completely equalize access to healthcare 
due to limits associated with economic status, rurality, or market availability of services. 
For example, interruptions in Medicaid coverage were associated with higher rates of 
PPH for certain conditions (Bindman, Chattopadhyay, & Auerback, 2008a). While 
consistently higher rates of ACSC and PPH are associated with low-income, non-white, 
urban populations (J. Billings et al., 1993; J. Billings & Anderson, 1996; Bindman et al., 
1995; DeLia, 2003; Friedman & Basu, 2004; Oster & Bindman, 2003; Shi et al., 1999).   
Counter to expectations, in 2007 a study examining expansion of Medicaid in 
Oregon found an increase in PPH for Medicaid patients (Saha et al., 2007). Another 
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more recent study of the 2008 Medicaid expansion by lottery in Oregon, allowed for the 
examination of Medicaid insurance status on clinical outcomes (Baicker et al., 2013). 
While utilization of preventive services, including the detection and management of 
diabetes increased, two-year results found little evidence of improved outcomes (Baicker 
et al., 2013). The study did find lower rates of depression and near elimination of 
personal catastrophic healthcare-related financial events for Medicaid participants as 
compared to the eligible but not selected by lottery in the Oregon Medicaid expansion 
(Baicker et al., 2013).  
Healthcare-associated infections 
 Healthcare-associated infections (HAI) are defined as an infection that was not 
present or incubating at the time of admission to a healthcare setting (Center for Disease 
Control and Prevention & National Healthcare Safety Network, 2013; Centers for 
Disease Control and Prevention, National Center for Emerging and Zoonotic Infectious 
Diseases, & Division of Healthcare Quality Promotion, 2010; Horan, Andrus, & 
Dudeck, 2008; Sydnor & Perl, 2011). Infections transmitted by healthcare providers 
were first identified in 1847 by Ignaz Semmelweis (Dixon, R.E, 2011; Sydnor & Perl, 
2011). Since that time to the outbreak of nosocomial penicillin-resistant staphylococcal 
in the 1950s, improvements in the hospital setting focused on creating and maintaining a 
sanitary environment (Dixon, R.E., 2011; P. W. Smith, Watkins, & Hewlett, 2012; 
Sydnor & Perl, 2011). However, with the emergence of drug-resistant pathogens and 
subsequent increases in HAIs, the need for more rigor in tracking HAI became apparent 
(Hughes, 1987; P. W. Smith et al., 2012; Sydnor & Perl, 2011).  
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In response to emerging drug-resistant pathogens and the need for more rigorous 
methods to contain them, the CDC took several steps to address HAI. One of the first 
was to establish the National Nosocomial Infections Surveillance (NNIS) system 
(Hughes, 1987). Eventually incorporated into the National Health Safety Network 
(NHSN) with the National Surveillance System for Healthcare workers and the Dialysis 
Surveillance Network in 2005, NHSN is an electronically-based HAI tracking system 
(Centers for Disease Control and Prevention, 2011; Centers for Disease Control and 
Prevention, 2013). Functions of NHSN include collecting data, providing support, 
measuring progress, and providing information to providers, states and regions regarding 
status of infection prevention (Centers for Disease Control and Prevention, 2011; 
Centers for Disease Control and Prevention, 2013). 
While NHSN started as a voluntary reporting system to track HAI, 32 states now 
mandate reporting to NHSN including Texas (Center for Disease Control and 
Prevention, 2013; Texas Department of State Health Services, 2013b). Additionally, the 
Centers for Medicare and Medicaid Services (CMS) require HAI reporting to NSHN for 
hospitals participating in the Hospital Inpatient Quality Reporting (IQR) program 
(Malpiedi et al., 2013; Vinyard, 2013). Using a phased-in approach, mandated data 
collection began in late 2011 to be complete in 2013 for selected HAI (Malpiedi et al., 
2013; Texas Department of State Health Services, 2013b). 
The CDC also developed and implemented the Study on the Efficacy of 
Nosocomial Infection Control (SENIC) (Haley, Quade, Freeman, & Bennett, 1980; 
Hughes, 1987; Sydnor & Perl, 2011).  A ten-year study that measured the effectiveness 
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of infection control programs found the following four elements necessary for a 
successful infection control program: 
1.  Feedback to staff regarding surveillance rates 
2.  Adherence to infection prevention practices 
3.  Presence of Infection Prevention Specialist to supervise collection and 
dissemination of surveillance information 
4.  Presence of a physician or microbiologist specially trained for infection 
prevention  
(Hughes, 1987; Sydnor & Perl, 2011) 
 Today, the CDC tracks numerous HAI pathogens with the majority traced to one 
or more of five types of HAI: Surgical Site Infections (SSI), Central Line-Associated 
Blood Stream Infection (CLABSI), Catheter-Associated Urinary Tract Infection 
(CAUTI), Ventilator Associated Pneumonia (VAP), and Clostridium difficile Infection 
(CDI) (Centers for Disease Control and Prevention, National Center for Emerging and 
Zoonotic Infectious Diseases, & Division of Healthcare Quality Promotion, 2012; 
Centers for Disease Control and Prevention, National Center for Emerging and Zoonotic 
Infectious Diseases, & Division of Healthcare Quality Promotion, 2013). Described 
below, these five types of HAI affected more than 1.7 million individuals causing nearly 
99,000 deaths in 2002 with more recent cost estimates ranging from $9.8 billion to $45 
billion annually (Klevens et al., 2007; Scott II, 2009; Zimlichman et al., 2013).  
Also included in the description of each HAI type is a listing of Health and 
Human Services (HHS) and National Quality Forum (NQF) recognized measures. The 
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National Quality Forum (NQF) endorses public use healthcare measures through expert 
committees that include various stakeholders including patients. Considered the gold 
standard, measures endorsed by the NQF reflect relevant measurement of identified 
healthcare issues and are used in payment and public reporting strategies (National 
Quality Forum, 2013c). While HHS measures are used in the same way, not all are 
endorsed by the NQF. 
Surgical site infections (SSI) 
 An SSI is an infection that occurs in or around the area where a surgery was 
performed, develops within 30 to 90 days of surgery, and is categorized as superficial, 
deep tissue, or organ space in nature (Center for Disease Control and Prevention & 
National Healthcare Safety Network, 2013). For SSI, HHS uses three outcome measures 
(Department of Health and Human Services, 2013). The first uses NHSN data to target 
specific types of surgery including colon surgery and abdominal hysterectomies. Used 
by CMS in its pay-for-reporting initiative, the NQF endorsed measure reported on the 
Hospital Compare website for inpatient quality reporting (Department of Health and 
Human Services, 2013; National Quality Forum, 2013a). The second SSI measure is an 
observed over expected ratio also using NHSN data. Only ratios for surgical sites 
specified in the Surgical Care Improvement Project (SCIP) are calculated for this NQF 
endorsed measure (Department of Health and Human Services, 2013; National Quality 
Forum, 2013a). The final measure is Patient Safety Indicator 13 – Postoperative Sepsis 
rate. Developed by AHRQ for use with inpatient discharge data, this measure reflects the 
rate of surgeries that discharge with a secondary diagnosis of sepsis where the length of 
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stay is four days or more (Agency for Healthcare Research and Quality, 2013c; 
Department of Health and Human Services, 2013). While the last measure is not 
endorsed by the NQF, it is used in national quality reports such as the National 
Healthcare Quality Report and the National Healthcare Disparities Report (Department 
of Health and Human Services, 2013). 
Central line-associated blood stream infection (CLABSI) 
 CLABSI is an infection that manifests in the bloodstream and enters the body 
through a line inserted into a major vein for the delivery of medication and fluids during 
an inpatient stay (Center for Disease Control and Prevention, National Center for 
Emerging and Zoonotic Infectious Diseases, & Division of Healthcare Quality 
Promotion, 2012b). HHS identified 12 measures to track CLABSI. Four measures 
developed by AHRQ’s Quality Indicator (QI) program are included in the HHS measure 
inventory. Patient Safety Indicator (PSI) 7 and PSI 23 reflect adult CLABSI rates by 
provider and geographic area respectively, while Pediatric Quality Indicator (PDI) 12 
and Neonate Quality Indicator (NQI 3) reflect CLABSI for children and neonates 
respectively (Agency for Healthcare Research and Quality, 2008; Batelle, 2013; 
Department of Health and Human Services, 2013). All four of the AHRQ QI measures 
are endorsed by the NQF (Department of Health and Human Services, 2013; National 
Quality Forum, 2013a). Of the remaining eight measures, six use NHSN data, and five 
of the six are endorsed by the NQF (Department of Health and Human Services, 2013; 
National Quality Forum, 2013a). The six measures based on NHSN data are used for 
public reporting, accountability, pay-for-reporting, pay-for performance, quality 
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reporting, and surveillance. While five of the six NHSN based measure use total central 
line days in the denominator, the measure used for surveillance is a ratio of observed 
over expected CLABSI (Department of Health and Human Services, 2013). 
Catheter-associated urinary tract infection (CAUTI) 
 Urinary tract infections are the most common HAI reported, and include 
infections anywhere in the urinary system (Center for Disease Control and Prevention, 
National Center for Emerging and Zoonotic Infectious Diseases, & Division of 
Healthcare Quality Promotion, 2012a; Saint et al., 2006). Fifteen to twenty-five percent 
of patients receive urinary catheterization during their inpatient stay subjecting them to 
the risk of a CAUTI (Center for Disease Control and Prevention, National Center for 
Emerging and Zoonotic Infectious Diseases, & Division of Healthcare Quality 
Promotion, 2012a; Saint et al., 2006). Increased duration of catheterization is associated 
with higher risk of a CAUTI (Center for Disease Control and Prevention, National 
Center for Emerging and Zoonotic Infectious Diseases, & Division of Healthcare 
Quality Promotion, 2012a; Saint et al., 2006; Wald, Epstein, Radcliff, & Kramer, 2008). 
Three of the four CAUTI measures used by HHS are endorsed by NQF and use NHSN 
data (Department of Health and Human Services, 2013; National Quality Forum, 2013a). 
All three of the NHSN measures are based on an observed over expected method and are 
used in quality reporting, pay-for-performance, or surveillance. The fourth measure uses 
claims data for its calculations and is used in pay-for-performance, and public reporting 
such as Hospital Compare (Department of Health and Human Services, 2013). 
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Ventilator associated pneumonia (VAP) 
 Infections of the lung related to ventilator use fall into the VAP type of HAI 
(Center for Disease Control and Prevention, National Center for Emerging and Zoonotic 
Infectious Diseases, & Division of Healthcare Quality Promotion, 2012c). Estimated to 
occur in 8% to 28% patients requiring mechanical ventilation, VAP that occurs after four 
or more days of mechanical ventilation is more likely to be associated with a drug 
resistant pathogen (Amin, 2009). With mortality associated with VAP estimated between 
24% and 40% , it is interesting that HHS and the NQF do not have any active measures 
for VAP(Amin, 2009; Department of Health and Human Services, 2013; National 
Quality Forum, 2013a). While the AHRQ QI program does track pneumonia related 
death rates (Inpatient Quality Indicator 20), it has not developed a measure to assess 
whether an HAI related VAP has occurred (Batelle, 2013). 
Clostridium difficile infection (CDI) 
 Unlike the other HAI types tracked by the CDC, CDI is not associated with a 
mechanical device or invasive procedure. CDI is a diarrhea causing spore-based 
infection associated with antibiotic use and hospitalization (McDonald et al., 2007; 
Sunenshine & McDonald, 2006). Nearly 14,000 deaths are associated with CDI each 
year (Center for Disease Control and Prevention, National Center for Emerging and 
Zoonotic Infectious Diseases, & Division of Healthcare Quality Promotion, 2013). HHS 
houses two measures for CDI. The NQF endorsed measure used in pay-for-reporting, 
Hospital Compare, and the Hospital Inpatient Quality Report follows the NHSN 
Surveillance Infection Ratio (SIR) where the total number of HAI CDI cases are divided 
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by either total patient days or admissions for the month observed (Department of Health 
and Human Services, 2013; National Quality Forum, 2013a). The second HHS measure 
also used NHSN data and is used as an accountability measure in Quality Improvement 
Organizations (Department of Health and Human Services, 2013). 
Identifying HAI from administrative data 
 Identification of HAI through the use of administrative data has met with little 
success (Jhung & Banerjee, 2009; Klevens et al., 2007; Patrick et al., 2013; Sherman et 
al., 2006; Stevenson et al., 2008; Stone, Horan, Shih, Mooney-Kane, & Larson, 2007). 
With CLABSI as the exception, a method with the ability to use administrative discharge 
data to consistently identify other HAIs has had varied results (Jhung & Banerjee, 2009; 
Sherman et al., 2006; Stevenson et al., 2008; Stone et al., 2007). For CDI, there is only 
one ICD-9-CM code making it easy to identify from administrative data. However, 
difficulties arise in determining whether the Clostridium difficile pathogen was 
community-acquired or healthcare-acquired. Indicators now included within the 
administrative data identify whether a diagnosis was present at the time of admission. 
The present on admission information should make it possible to achieve better 
concordance between administrative data and NHSN data.  
More difficulties arise for SSI, CAUTI, and VAP. Due to multiple pathogens and 
settings in which these infections arise, it has been difficult to establish a consensus on 
which coding schemes are consistent across providers to identify SSI, CAUTI, and VAP. 
Limitations in identifying HAI from administrative data have been attributed to limited 
number of diagnosis fields to capture payment information, coders with limited clinical 
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expertise, and multiple diagnosis fields being required to identify a single condition 
(Jhung & Banerjee, 2009; Sherman et al., 2006). With 25 diagnosis fields now available, 
present on admission information, procedure codes, and day of hospital stay a procedure 
was performed, it may be possible to refine administrative identification methods of HAI 
to align more accurately with NHSN or TxHSN. Despite mixed results in using 
administrative data for HAI identification, Jhung et. al, 2009, recommend using as many 
as possible diagnosis fields, validating against other data sources, using multiple codes 
for diagnosis and procedures, and report results as a range of estimates (Jhung & 
Banerjee, 2009).  
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CHAPTER III 
CONCEPTUAL AND THEORETICAL FOUNDATION 
Behavioral model of health services utilization 
 When initially developed in the late 1960’s, Andersen’s behavioral model of 
health services utilization used the family as the unit of analysis to predict the use of 
healthcare (R. M. Andersen, 1995; R. M. Andersen, 2008). The model categorized 
factors that lead to healthcare utilization as predisposing characteristics, enabling 
resources, and needs. Predisposing characteristics included demographics, social 
structure, and health beliefs; enabling resources included ability to pay and were 
measured at the family or community level; and need was delineated as perceived by the 
individual or evaluated by a healthcare provider (R. M. Andersen, 1995; R. M. 
Andersen, 2008). As the theory evolved, the level of analysis moved from family to 
individual using family characteristics such as income to measure enabling resources. 
 The purpose of developing the behavioral model was to uncover factors that 
affect utilization, resulting in a model that ultimately addressed access (R. M. Andersen, 
1995; Culler, Parchman, & Przybylski, 1998). In particular, Andersen (1995) articulated 
and differentiated three key concepts adding a fourth as the model evolved. These 
include potential verses realized access, equitable verses inequitable access, the concept 
of mutability, with the role of effective and efficient access coming in later versions of 
the model (R. M. Andersen, 1995; R. M. Andersen, 2008). While these four concepts are 
not the only articulated by Andersen’s model, they quantify levels of the access 
construct that are of interest to this study. 
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 For the first concept, access was delineated into two levels including potential 
access and realized access. Potential access was equated to the presence of enabling 
resources such as income, health insurance, or proximity to providers, while realized 
access was equated to the utilization of healthcare. Although enabling resources 
facilitate realized access, need can drive individuals to access healthcare despite lack of 
sufficient enabling resources.(R. M. Andersen, 1995; R. M. Andersen, 2008; Ricketts, 
Randolph, Howard, Pathman, & Carey, 2001) 
According to Andersen’s behavioral model of healthcare utilization, we can 
assess whether access is equitable based upon what predicts realized utilization (R. M. 
Andersen, 1995). Where need or demographics predict realized access, Andersen (1995) 
defined access as equitable within the population studied. Where health beliefs, social 
structure, or enabling resources predict realized access, Andersen (1995) defined access 
as inequitable (R. M. Andersen, 1995; R. M. Andersen, 2008; Gaskin & Hoffman, 2000; 
Shi & Stevens, 2005). 
Third, the concept of mutability addresses how easily the factors that affect 
access can be changed (R. M. Andersen, 1995; R. M. Andersen, 2008). Of predisposing 
characteristics, enabling resources and need, enabling resources are identified as the 
most easily changed or mutable through policy initiatives or economic incentives (R. M. 
Andersen, 1995). Insurance status and income are examples of enabling resources that 
have recently been affected by policy and legislation such as the ACA and changes in 
the minimum wage (Sudano & Baker, 2003). 
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Finally, with the increased emphasis on outcome measures, the behavioral model 
evolved in the 1980s and 1990s to account for efficient and effective access to healthcare 
(R. M. Andersen, 1995; R. M. Andersen, 2008). Where access translates to improved 
health status, effective access is said to exist, and where gains in health status are 
consistent or increasing with the amount of healthcare consumed, efficient access is said 
to exist (R. M. Andersen, 1995; Ricketts et al., 2001; Sudano & Baker, 2003). 
Difficulties in adapting the behavioral model to measure access are varied. While 
variables such as age, race, and gender cannot be changed and are easy to identify as 
predisposing characteristics, more difficulty arises when assessing other predisposing 
characteristics such as health beliefs and social structure especially when datasets are not 
comprehensive at the individual level (R. M. Andersen, 2008; Carrillo et al., 2011). 
Recognized as both an outcome and determinant of healthcare utilization, health status 
when used as a proxy for evaluated need can introduce endogeneity as health status is 
also an outcome measure (Figure 2) (Gelberg, Andersen, & Leake, 2000). Given these 
considerations, appropriate causal conceptualization of access is imperative when using 
the behavioral model.
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Figure 2. Andersen’s behavioral model of healthcare utilization. (Revisited) 
Source: Andersen, R.M. Medical Care 2008; 46: p.651 
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Behavioral model for vulnerable populations 
 Contributors to Andersen’s evolving behavioral model for healthcare utilization 
also created a version specifically for vulnerable populations (Gelberg et al., 2000). 
Because of a variety of barriers, vulnerable populations are at higher risk of poor health 
and health outcomes (Aday, 1994). While the behavioral model of healthcare utilization 
conceptualizes access in general terms, the behavioral model for vulnerable populations 
adapts for the differences in access due to vulnerabilities (Aday, 1994; Gelberg et al., 
2000). To address the differences between vulnerable and other populations, the 
vulnerable population model differentiates between traditional and vulnerable domains 
within predisposing characteristics, enabling resources and needs when predicting 
healthcare utilization (Figure 3) (Gelberg et al., 2000). Additionally, the behavioral 
model for vulnerable populations includes health behaviors as contributing information 
for healthcare utilization (Gelberg et al., 2000). 
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Figure 3. The behavioral model for vulnerable populations. 
Source: Gelberg, L., Andersen, R.M., and Leake, B.D., HSR:Health Services Research 2000;34:6 p.1278 
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In addition to the usual predisposing characteristics of age, race, gender, marital 
status and health beliefs, the vulnerable domain contains other measures of social 
structure such as immigration status, literacy levels, sub-standard living conditions, 
criminal or high risk behaviors, and childhood history related to neglect, abuse or non-
traditional living arrangements (Figure 3)  (Gelberg et al., 2000). Enabling resources for 
vulnerable populations would include measures of competing needs, public benefits and 
availability of other relevant community resources such as transportation (Figure 3) 
(Gelberg et al., 2000). Finally, differences in needs for vulnerable populations include 
concerns related to increased incidence of conditions such as sexually transmitted 
disease, chemical abuse, and mental health status. While some of these factors are 
normally considered part of the predisposing health status group of variables, for 
vulnerable populations they are more appropriately placed in the needs category of 
healthcare care utilization predictors (Figure 3) (Gelberg et al., 2000). 
Conceptualization of utilization for PPH with HAIs 
 In developing a conceptual model to identify and measure relationships for this 
study, it was important to build upon a model that fit the hypothesized chain of events. 
Given the hypothesized chain of events as increased insurance coverage leading to 
increased preventive care utilization leading to decreased PPH and associated HAI, I 
first defined the primary outcome measure as PPH. With the primary outcome measure 
identified, it became evident that an appropriate explanatory model must identify health 
outcomes in terms of access giving adequate consideration to other causal variables 
related to the uninsured. Since the uninsured and underinsured are considered vulnerable 
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populations, the behavioral model for vulnerable populations uses outcomes such as 
perceived and evaluated health status, and the model considers characteristics such as 
insurance status in predicting outcomes, the behavioral model for vulnerable populations 
was an appropriate basis for evaluating the research question (Aday, 1994; Bindman, 
Chattopadhyay, & Auerback, 2008a; Gelberg et al., 2000).  
Identification of PPH for this study was based upon deidentified administrative 
discharge data. As such, the ability to tease out variation in utilization is limited to 
information in the discharge record and other information sources that can be linked at 
the hospital or community level. With this limitation in mind, I developed the following 
conceptual model to capture variation in utilization using the individual as the unit of 
analyses (Figure 4). Building on the behavioral model of healthcare utilization and the 
behavioral model for vulnerable populations, the model incorporates the most 
meaningful individual and community measures to reflect important predisposing 
characteristics, enabling resources, and needs. Where possible, measures reflecting 
vulnerability were included. For example, availability of public benefits was captured 
using the variable for Health Services Region (HSR), county of residence and 
administration of health services to create two public benefits variables. Since public 
benefits vary by HSR in Texas, the administrative regions were used as a proxy for 
available services. Additionally, availability of services can be measured through 
distance to public health service offices. As a proxy for distance to public benefits, the 
second public benefits variable categorized distance to services by identifying county of 
residence as containing an HSR office, a county public health office, or no public health 
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offices. By accounting for these variations, I intended to generate the most accurate 
reflection of how payer policies affect utilization of healthcare for PPH admissions. 
   
 
 
 
 
 
 
 
 
 
 
Figure 4. Conceptual model of healthcare utilization for potentially preventable 
hospitalizations with healthcare-associated infections 
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CHAPTER IV 
METHODS 
Any hospitalization exposes patients to the risk of an HAI, but for an individual 
admitted for PPH, the exposure to HAI risk is by extension also potentially preventable. 
Given the implementation of the ACA, the identified relationship between insurance 
status and PPH, what little is known about individuals admitted with a PPH and acquire 
an HAI, my hypothesize question is: following the full implementation of the ACA, will 
the increase in preventive care cost attributable to improved insurance coverage for 
individuals with ACSCs be offset by reductions in costs associated with reduced rate of 
HAI during a PPH? To answer this question and facilitate the primary goals of my 
thesis, to ascertain the incidence of the co-occurrence of a PPH and an HAI during one 
inpatient stay, and to estimate the costs attributable to an HAI during a PPH, I have 
developed the following four specific aims for my thesis research: 
Specific Aim 1 Quantify the incidence of PPH and HAI in Texas, identifying 
characteristics of the PPH, HAI, and PPH with HAI populations. 
Specific Aim 2 Estimate costs associated with PPH and the incremental cost of 
HAI during hospitalization. 
Specific Aim 3 Estimate total utilization and costs for PPH, PPH with HAI, and 
preventive healthcare for insured individuals with similar ACSCs and no PPH 
using private insurer claims data. 
Specific Aim 4 Examine the differences in prevalence and cost for the insured and 
uninsured. 
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With the ultimate goal of answering the hypothesis question, each of the specific 
aims fulfills a goal. The goal of specific aim one is to identify and quantify how 
individuals with a PPH, HAI and PPH with HAI differ from one another and the rest of 
the inpatient population. Specific aim two provides us with a base measure of 
hospitalization cost and the incremental cost differences for PPH and PPH with HAI. 
Specific aim three uses the BCBSTX claims data to generate the remaining cost 
estimates needed to answer the hypothesis question. To answer the hypothesis question 
we need preventive care costs and the incremental cost of the additional care required 
after hospitalization, in particular incremental costs for HAI. For the non-PPH ACSC 
population, estimated preventive care costs potentially reflect the cost of healthcare 
required to control ACSC. The second cost included the cost of preventive care used by 
individuals prior to a PPH. The final cost generated as part of specific aim three is the 
post-hospitalization healthcare utilization for the PPH population. An additional 
component of the post-hospitalization cost is to differentiate between PPH and PPH with 
HAI populations in order to calculate the total incremental cost associated with and HAI 
for the PPH population. Finally, since the analytic focus is access through insurance, 
specific aim four examines all costs estimates through the lens of primary payer to 
determine the role insurance status and the type of insurance play.  
Data 
Texas Hospital Inpatient Discharge Public Use Data File, 2011 
 The 2011 Texas Hospital Discharge Public Use Data File (PUDF) contains more 
than 2.9 million summary abstracts of patient level information from administrative 
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forms reflecting care provided during hospital stays in one of 576 Texas hospitals(Texas 
Health Care Information Collection, 2013). While the majority of Texas hospitals are 
required to report discharge summary data to the Texas Health Care Information 
Collection (THCIC), under Chapter 108 of the Texas Health and Safety Code, there are 
hospitals that are exempt. Exemptions account for 46 Critical Access Hospitals and 34 
other hospitals in Texas that meet one of the following criteria:  
 Located in a county with less than 35,000 people 
 Hospital in a United States Census Bureau defined rural county with more than 
35,000 people and less than 100 licensed hospital beds 
 Hospital that does not receive payment from insurers or government funds for 
care 
(Texas Department of State Health Services, 2011; Texas Health Care 
Information Collection, 2014).  
For hospitals that do report, information was collected with the uniform bill (UB-92) or 
the THCIC 837 format. Data elements reflect patient discharge quarter, length of 
hospital stay in days, patient demographic information, ICD-9-CM codes for up to 25 
diagnoses with corresponding present on admission information, up to 25 procedure 
codes with day the procedure occurred during the hospitalization, anticipated payer 
information, and charges associated with the inpatient stay. Of the 576 hospitals that 
reported inpatient discharge summary, 34 were Critical Access Hospitals, and 29 
hospitals included discharges from other hospital facilities affiliated with the reporting 
hospital (Texas Health Care Information Collection, 2014). 
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National Health Safety Network and Texas Department of State Health Services 
annual report on health care-associated infections 
While the National Health Safety Network (NHSN) warehouses the most 
healthcare associated infection (HAI) surveillance information in the United States, it 
does not share event detailed data for analyses. It does publish annual reports reflecting 
Standardized Infection Ratios (SIRs) and state based aggregated data. Aggregated 
information includes number of events in each state, number of events in HAI relevant 
departments, and number and types of facilities reporting (Dudeck et al., 2013).  
Mandated reporting of certain HAIs began in 2012 for Texas hospitals. With a 
focus on central line-associated bloodstream infection and surgical site infection, 
hospitals also report other HAI information through NHSN’s electronic reporting 
system. While Texas uses NHSN as the initial repository and collection mechanism for 
its HAI information, it also provides additional validation checks when it downloads 
data from NHSN into the Texas HAI data warehouse known as the Texas Health Care 
Safety Network (TxHSN) (Vinyard, 2013). 
Blue Cross/Blue Shield of Texas claims data, 2010-2012 
 Available for years 2008 to 2012, the Blue Cross/Blue Shield of Texas 
(BCBSTX) claims data includes information for over 3 million enrollees (University of 
Texas School of Public Health, 2012). Warehoused at the University of Texas Health 
Science Center at Houston, the claims data includes variables reflecting enrollee 
demographics, dates of service, billed, allowed and paid amounts, diagnoses and 
procedures reflected by ICD-9-CM codes, Healthcare Common Procedure Coding 
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System (HCPCS) and diagnosis related group (DRG) codes. Just over 30 thousand 
BCBSTX enrollees were excluded from the evaluation due to participation in a managed 
care or capitated payment structure. These enrollees were excluded due to incomplete 
information about healthcare utilization across the continuum of care. 
Centers for Medicare and Medicaid Services cost reports 
 Medicare certified hospitals are required to annually report facility information, 
utilization, and comprehensive cost and charge data to the Healthcare Cost Report 
Information System (HCRIS)(Centers for Medicare and Medicaid Services, 2013b). The 
information collected from hospitals on form CMS-2552-10 and reported through 
Medicare Administrative Contractors are available for download from the Centers for 
Medicare and Medicaid Services (CMS) website (Centers for Medicare and Medicaid 
Services, 2013c). Hospital cost reports updated quarterly and available for 1996 to 2013 
include schedule C of form CMS-2552-10. Schedule C includes the cost and charge 
information necessary to calculate hospital specific cost-to-charge ratios.  CMS provides 
a publically available file that includes hospital Medicare identification number, fiscal 
year beginning and ending dates and the cost and charge variables reported in schedule 
C including  total costs, total inpatient charges, and total outpatient charges.  Not all 
hospital fiscal calendars align with a calendar year, therefore CMS cost report data from 
2010, 2011, and 2012 were used to create a proportionally weighted 2011 cost-to-charge 
ratio.  
 Also available in the CMS cost reports are the number of licensed beds by 
Medicare identifier. Where number of beds were missing, the values were imputed using 
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an estimation of average daily hospital census from the PUDF and the 2011 staffed bed 
occupancy rate reported by the Texas Department of State Health Services (Center for 
Health Statistics - Hospital Survey Unit, 2013). 
Data management 
Although all data described was deidentified and contained no personal 
identifiers, data was stored, utilized, and reported using methods consistent with data 
that includes personal identifiers. Methods include secure storage and aggregate 
reporting of results. Data transfer adhered to security protocol measures as defined by 
the owner of the data. While the study data and protocols meet the definitions of exempt 
status research, Institutional Review Board (IRB) approval from Texas A&M Research 
Compliance was obtained. 
Identification of potentially preventable hospitalizations and comorbid conditions 
Using SAS® version 9.3, PPH were identified from the PUDF using SAS® 
programs PQSAS1and PDSAS1 from the AHRQ Prevention Quality Indicator and 
Pediatric Indicator, version 4.5 websites (Agency for Healthcare Research and Quality, 
2013c). PQSAS1 is one of a suite of programs in the Prevention Quality Indicator (PQI) 
zipped file used to identify the discharges with one of 14 PPH and calculate rates of 
occurrence by geographic area. PPH for children are identified through the Pediatric 
Quality Indicator (PDI) programs. For the purposes of this research only the PQI and 
PDI programs necessary to identify PPH discharges were modified as specified by the 
software instructions (Batelle, 2013).  
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Comorbidity software also included in the AHRQ Quality Indicator software 
identifies 30 comorbid conditions from the discharge data (Agency for Healthcare 
Research and Quality, 2013a; Elixhauser, Steiner, Harris, & Coffey, 1998).  
Identification of healthcare associated infections 
 To facilitate the analyses proposed, the following definitions of HAI have been 
identified from the literature and other known and validated methods of identifying HAI 
from inpatient discharge data. With no definitive or validated methods available for SSI, 
CAUTI, and VAP, as suggested by Jhung et. al, (2009), I used data with as many 
diagnosis fields as possible, a combination of codes, and validated findings where 
possible against the TxHSN data. I also consolidated ICD-9-CM codes used to identify 
infections and procedures from other studies (Jhung & Banerjee, 2009; Sherman et al., 
2006; Stevenson et al., 2008). Figure 5 is a data flow diagram representing the process 
for identifying the PPH and HAI from the 2011 THCIC inpatient PUDF. 
  
 48 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Data flow to identify PPH and HAI from administrative discharge data  
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Surgical site infections (SSI) 
 While no definitive or validated methods are available for identifying SSI from 
administrative data, the Centers for Disease Control and Prevention (CDC) does provide 
a publically available list of ICD-9-CM codes to identify procedures associated with SSI 
including 10 cardiac bypass graft surgery codes, 10 hip prosthetic codes, and 7 knee 
prosthetic codes listed in the Appendix  (Centers for Disease Control and Prevention, 
National Center for Emerging and Zoonotic Infectious Diseases, & Division of 
Healthcare Qualtiy Promotion, 2014).  Since the definition of SSI includes infections 
that occur up to 90 days after surgery, identifying hospitalizations for SSI from the 
PUDF are limited to infections that occur within the hospitalization. While infections 
can be identified within the initial hospitalization, these are usually of the superficial 
nature. Following the methods of Sherman et al. (2006) and Stevenson et al.(2008), 
infections codes listed in the Appendix that were not present on admission were used in 
combination with the CDC procedure codes to identify SSI (Figure 6) (Centers for 
Disease Control and Prevention, National Center for Emerging and Zoonotic Infectious 
Diseases, & Division of Healthcare Qualtiy Promotion, 2014; Sherman et al., 2006; 
Stevenson et al., 2008). 
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Figure 6. Identification of HAI from administrative inpatient data, SSI  
  
2011 
THCIC 
Inpatient 
PUDF 
Is there evidence of 
cardiac by-pass, 
hip, or knee 
surgery? 
 Is there another 
admission to 
evaluate? 
Is there evidence 
of infection? 
Was the infection 
POA? 
Assign HAI SSI as ‘NO’ 
Assign HAI SSI as ‘YES’ 
Select discharge record for evaluation 
Evaluate next HAI 
Yes 
Yes 
Yes 
Yes 
No No 
No 
No 
Was the infection 
in the surgical 
site? 
No 
Yes 
 51 
 
Catheter associated urinary tract infection (CAUTI) 
 To identify CAUTI, no procedure codes have been identified for catheterization 
or removal during a hospitalization. However, there is one code, 996.64 for complication 
related to infection from an indwelling catheter. Unfortunately, the literature 
demonstrates an underreporting of CAUTI if this code alone is used for identification. In 
an effort to capture an accurate measure of CAUTI, 17 infection codes were identified 
and used in combination with ICD-9-CM code 996.31 (Agency for Healthcare Research 
and Quality, 2013b; Sherman et al., 2006). Code 996.31 represents mechanical 
complications due to an indwelling catheter. Since the likelihood of a CAUTI increases 
the longer it is in place, a discharge was classified as a CAUTI if code 996.64 was 
present, or code 996.31 was listed with one of the 17 infection codes where the infection 
was not present on admission and the estimated duration of catheterization was longer 
than two days (Figure 7) (Centers for Disease Control and Prevention, National Center 
for Emerging and Zoonotic Infectious Diseases, & Division of Healthcare Quality 
Promotion, 2014a). Infection codes for CAUTI are listed in the Appendix. 
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Figure 7. Identification of HAI from administrative inpatient data, CAUTI 
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Ventilator associated pneumonia (VAP) 
 To assign a discharge as having VAP, four things were evaluated. First, 
diagnoses fields were examined for the presence of diagnosis code 997.31, ventilator 
associated pneumonia. Since this code historically underreports VAP, the next item 
evaluated was codes for mechanical ventilation or intubation (Restrepo et al., 2010; 
Stevenson et al., 2008). Once mechanical ventilation was identified, diagnoses codes 
were evaluated for one of 29 pneumonia type infections not present on admission 
(Sherman et al., 2006; Stevenson et al., 2008). Finally, duration of ventilation was 
calculated. An admission was determined to have VAP with a diagnosis code of 997.31 
or the presence of mechanical ventilation for more than 4 days and a pneumonia type 
infection that was not present on admission (Figure 8) (Centers for Disease Control and 
Prevention, National Center for Emerging and Zoonotic Infectious Diseases, & Division 
of Healthcare Quality Promotion, 2014b). Infection and procedure codes for VAP can be 
found in the Appendix. 
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Figure 8. Identification of HAI from administrative inpatient data, VAP 
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Central line-associated blood stream infections (CLABSI) 
 Also considered a patient safety issue that can be identified from inpatient 
discharge data, AHRQ has included in its Quality Indicator modules three indicators to 
identify CLABSI. From the Patient Safety Indicator (PSI) module, I used the definition 
associated with PSI 7 – central venous catheter-related blood stream infection rate 
(Figure 9). To identify CLABSI in children, I used two indicators from the Pediatric 
Quality Indicator (PDI) module including PDI 12 – central venous catheter-related blood 
stream infection rate for patients 3 months through 17 years of age and NQI 3 – neonatal 
blood stream infection rate for neonates. All three measures are National Quality Forum 
endorsed measures of CLABSI (Department of Health and Human Services, 2013; 
National Quality Forum, 2013). 
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Figure 9. Identification of HAI from administrative inpatient data, CLABSI 
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Clostridium difficile infection (CDI) 
 Clostridium difficile infection (CDI) can be identified from the PUDF by using 
an ICD-9-CM diagnosis of 008.45 in any of the 25 diagnosis field variables. A discharge 
with a diagnoses of CDI was considered an HAI if not present on admission and hospital 
length of stay was greater than two days (Figure 10). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10. Identification of HAI from administrative inpatient data, CDI 
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Exclusion criteria 
Discharge records were excluded from evaluation when age, gender, race, 
primary payer, or principal diagnosis codes were missing or invalid. While I did not 
want to lose valuable information about the effect PQI and HAI have on length of stay 
(LOS), I also did not want LOS outliers to exert disproportionate influence on estimates 
drawn from the study data. Therefore, I excluded patients with LOS greater than 180 
days as I considered them extreme LOS outliers (three standard deviations above the 
mean LOS was 36 days). The PQIs for perforated appendix were excluded as there is no 
ACSC that precedes appendicitis, and hospitalization is required for treatment. While 
perforation may be avoided with timely care, hospital care is part of successful treatment 
protocol. Finally, I eliminated PPH with less than five HAI from extensive evaluation 
due to the inability of statistical analyses to make meaningful inferences about the 
population. 
Incidence and odds ratios of PPH with HAI 
 To address specific aim 1, I used data mapping conventions from the AHRQ 
Quality Indicator package for age, race and gender, the PQI programs, and the above 
definitions of HAI to estimate the incidence of PPH and HAI. Once identified, 
potentially significant relationships were identified through a correlation matrix 
including PPH, HAI, and other independent variables.  Additionally, preliminary 
analyses included bivariate regression between the outcome variables cost and the 
probability of an HAI with each independent variable. Odds ratios were calculated for 
each PQI and HAI combination adjusting for the effects of age, gender, race, health 
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status as measured by the vector of comorbid conditions, healthcare characteristics such 
as hospital ownership, hospital size, and the additional risks associated with sharing a 
room for HAI, and community characteristics such availability of public benefits, 
distance to services, and rurality. The following model was specified to generate the 
odds ratios and standard errors using SAS® 9.3.  
 
      (      )                                                    
                           
                                  
 
Where  
i   = ith patient 
hai   = HAI odds ratio being estimated  
β1 thru 6   = coefficients for corresponding variables  
age   = patient age group at discharge 
gender   = patient gender 
race   = patient’s reported race category 
health status  = vector of comorbid conditions  
hospital characteristics = vector including room type (private, semi-private or ward 
room), average daily census of hospital, hospital ownership  
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community characteristics = vector including rurality, administrative Health Service 
Region, location of public health benefits (HSR office in county, county 
public health, no public service office within county of residence) 
εi  = error term associated with individual i  
PQIi,j  = indicator variable for patient i with PQI j,  
where j = one of the PQIs. 
I excluded relevant comorbid conditions from the regression models when the PQI under 
evaluation was similar to the comorbid condition. For example, I excluded the comorbid 
condition diabetes from the regression models when evaluating the PPHs for short-term 
complication due to diabetes, long-term complications due to diabetes, and diabetes 
related lower-extremity amputation. 
Identifying ACSC utilization from BCBSTX claims data 
 To meet specific aim 3, an estimation of preventive care costs for the PPH 
population and the non-PPH ACSC population were necessary. Additionally, an 
estimation of follow-up care cost was necessary including the differentiation between 
follow-up care cost for the underlying ACSC and follow-up costs associated with 
acquisition of an HAI. To identify PPH associated costs, I used the BSBCTX claims data 
by identifying relevant beneficiaries following similar methods to those used with the 
PUDF to assure comparability of information obtained. First, institutional claims 
indicating hospitalization during 2011 followed the same process depicted in Figure 5. 
Next, the AHRQ Quality indicator programs flagged PPH admissions and comorbid 
conditions. Finally, I applied the definitions for HAI to identify admissions with HAI. 
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Once I identified hospitalizations for PPH, HAI, and PPH with HAI, the relevant unique 
patient identifiers acted as the identifier for other utilization claims across the continuum 
of care. For the PPH population, I identified two categories of utilization and costs, pre-
hospital preventive care and post-discharge follow-up care. Pre-hospital preventive care 
for the PPH population included physician visits, outpatient visits, lab fees, and 
medications for six months prior to admission date. Follow-up utilization included 
physician visits, outpatient visits, lab fees and medications for six months post-
discharge. Two limitations existed within the BCBSTX data. First, limitations existed in 
the ability to quantify costs and utilization for beneficiaries over age 65. Since most 
individuals over age 65 years are assumed to participate in Medicare, I assumed the 
BCBSTX claims were supplemental to Medicare coverage. Second, not all BCBSTX 
beneficiaries have pharmaceutical coverage, therefore estimations of pharmaceutical use 
and cost are assumed to be under-reported. 
 For the ACSC population, I identified ten ACSC conditions consistent with the 
PPH identified by the AHRQ PQI. For example, PQI 1, 3, 14, and 16 identify short-term, 
long-term, uncontrolled, and lower-extremity amputation related to the ACSC of 
diabetes. The ACSC conditions included diabetes, chronic obstructive pulmonary 
disease, asthma, heart failure, hypertension, angina, urinary tract infection, dehydration, 
pneumonia, and prenatal care. With the exception of prenatal care, diagnosis codes 
identifying ACSC came from the AHRQ technical specifications for the PQI or the CMS 
Chronic Condition Warehouse condition categories (Agency for Healthcare Research 
and Quality, 2013a; Buccaneer, 2014). Prenatal care identification followed pre-natal 
 62 
 
care diagnoses codes as specified by Blue Cross/ Blue Shield (BlueCross BlueSheild of 
Texas, 2014). When identifying beneficiaries with ACSC conditions, I excluded 
individuals with hospitalizations within the study period, 2011, with the exception of 
prenatal care, since delivery related hospitalization is normal. However, I did exclude 
beneficiaries from the prenatal ACSC population for non-delivery related 
hospitalizations.   
Similar to the PPH, HAI, and PPH with HAI groups, I identified preventive 
healthcare utilization for physician visits, outpatient visits, lab fees, and medications 
using the unique patient identifier. With the diagnoses codes for each ACSC, claim lines 
associated with each ACSC were identified and summarized by beneficiary as illustrated 
in Figure 11.  
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Figure 11. Data flow to identify ACSC utilization with the BCBSTX data. 
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Cost  
Identifying cost for inpatient discharge data 
Cost-to-charge ratios 
Needed to estimate costs from the PUDF and fulfill specific aim 2, I used total 
costs, total inpatient charges and total outpatient charges from the CMS cost reports to 
calculate cost-to-charge ratios. Medicare identification numbers corresponding to the 
acute care facilities listed in Texas were used to identify all necessary data from the 
CMS abstracts of Schedule C.  
 A hospital specific cost-to-charge ratio was calculated with the following 
formula: 
                      
           
                                                
 
    
Because both inpatients and outpatients utilize some hospital cost centers, and 
costs on Schedule C are reported collectively, limitations arise in using only inpatient 
charges in calculating a cost-to-charge ratio. To account for this limitation, the sum of 
total inpatient charges and total outpatient charges were used in the denominator.  
Additionally, not all hospital fiscal calendars align with a calendar year, therefore CMS 
cost report data from 2010, 2011, and 2012 were used to create a proportionally 
weighted 2011 cost-to-charge ratio. Where cost reports were unavailable for the full 
year, the partial year cost-to-charge ratio was used to estimate costs for the entire year 
since cost-to-charge ratios do not change drastically from year to year. For hospitals with 
no cost or charge information, the median Texas hospital-specific cost-to-charge ratio 
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was assigned for the purpose of estimating cost of hospital care. The median cost-to-
charge ratio was selected over the mean as a more representative measure of centrality 
for the distribution of Texas hospital cost-to-charge ratios.   
Total and incremental costs 
To generate the cost estimates necessary to fulfill specific aim 2, a cost estimate 
of each discharge in the PUDF was necessary. To estimate total costs for each discharge, 
the total charges were multiplied by the facility specific cost-to-charge ratio. Once 
estimated costs were identified for all discharges, mean costs were calculated for each 
mutually exclusive group of PPH, HAI, and PPH with HAI. To quantify variation within 
the general inpatient population, I used a generalized linear regression model that 
adjusted for age, race, gender, health status, hospital characteristics, and community 
characteristics to estimate mean hospitalization cost and the incremental differences 
associated with PPH, HAI and payer type. By pulling out differences by payer in the cost 
models, I partially address specific aim 4. 
Identifying costs from BCBSTX claims data 
 Since claims data includes billed, allowed and payment information, for each 
ACSC, a range of mean annual preventive care payments were estimated for patients 
with and without a PPH. Cost estimates of preventive care for the PPH and ACSC 
groups were necessary to identify within payer variation. For patients with no PPH in 
2011, mean preventive care payment consisted of 2011utilization. For patients with a 
PPH in 2011, mean preventive care payment included utilization for six months prior to 
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the PPH event. To account for the effects of age, gender, health status, and payment 
structure the Generalized Linear Regression model specified the following: 
                         
                                                    
 
Where  
pph  = PPH group (PPH/no PPH) 
i   = ith patient 
β1 thru 4  = coefficients for corresponding variables  
age  = patient age group at discharge 
gender  = patient gender 
health status = vector of comorbid conditions defined by the AHRQ comorbidity 
measures  
plan type = BCBS structure of PPO or PPO+ 
εi   = error term associated with individual i  
  
 In using the AHRQ comorbidity measures in the cost model, I accounted for 
health status and additional risk factors such as obesity or depression. Since ACSC 
conditions are frequently considered comorbid conditions for other health issues, the 
condition was not included in the regression model as a comorbidity when it was defined 
as the ACSC of interest (Braunstein et al., 2003; Chang, Weiner, Richards, Bleich, & 
Segal, 2012; Mokdad et al., 2003; Wolff, Starfield, & Anderson, 2002). For example, 
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when estimating the preventive care cost for diabetes, the comorbidity variable for 
diabetes was not included in the regression model.  Additionally, within an ACSC 
population, if a comorbid condition was not identified within the population, it was not 
included in the regression model. For example, when estimating an adjusted mean for 
diabetes, if no diabetes patients had depression, depression was not be included in the 
model. By using this approach, relevant health status information was included without 
over specification of the regression model.  
The cost estimates fulfill specific aim 3, and facilitate answering the research 
question by providing proxy costs of healthcare for the uninsured population with an 
ACSC, a PPH or a PPH with HAI.   
Comparison of preventive care costs to incremental HAI costs 
 To answer the hypothesis question, I needed to calculate the anticipated 
difference in two costs: the incremental increase in preventive care costs for the 
uninsured ACSC population after attaining insurance and incremental HAI costs for the 
uninsured individuals with PPH and HAI. For the preventive care calculation, I used the 
estimated mean preventive care cost for each ACSC within the non-hospitalized 
BSBCTX population and multiplied it by the uninsured population estimated with each 
ACSC. For an accurate reflection of the increased cost of preventive care, I needed to 
estimate and subtract the amount of healthcare potentially consumed by the uninsured 
for ACSC and PPH. I accomplished this by first subtracting the identified number of 
uninsured with a PPH from the estimated uninsured ACSC population in Texas. Then 
the estimated number of uninsured individuals with an ACSC and no PPH was 
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multiplied by the estimated cost of preventive services used by the BCBSTX PPH 
population. The BCBSTX PPH preventive care cost acts as a proxy that reflects similar 
utilization by the uninsured. For the uninsured with a PPH, I added six months of 
BCBSTX PPH preventive care cost to six months of BCBSTX PPH follow-up cost and 
the cost of a PPH for each ACSC condition to create an annual cost of care for the 
uninsured ACSC population with a PPH. I then multiplied this per person cost times the 
number of uninsured individuals with the corresponding PPH. The following equation 
depicts the anticipated aggregated incremental preventive care cost (AIPCC) for the 
uninsured in the state of Texas. 
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Where 
i   = one of the seven ACSC conditions 
preventive care costACSC = the adjusted annual preventive care cost estimated using the 
BCBSTX data for each ACSC  
preventive care costPPHacsc = the adjusted annual preventive care cost estimated using the 
BCBSTX data for each ACSC limited to beneficiaries with a PPH 
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followup costACSC  = the adjusted six month healthcare cost estimated using the 
BCBSTX data for each ACSC after a PPH  
PPH costACSC  = the adjusted cost of the PPH associated with each ACSC  
Uninsured in TexasACSC= the number of uninsured individuals estimated to have an 
ACSC in Texas 
Uninsured in TexasACSCpph = the number of uninsured individuals with an ACSC and a 
PPH in Texas 
Next, I calculated the incremental cost of HAI in the uninsured PPH population. 
Using adjusted estimates of the incremental cost of HAI, I first added the incremental 
cost of HAI during hospitalization to the incremental cost of follow-up care for HAI. I 
then multiplied the sum of incremental costs by the number of PPH with each HAI. 
After summing across the four HAIs, I multiplied the estimated total incremental cost of 
HAI by the percentage of uninsured individuals in the PPH with HAI population. The 
following formula depicts the aggregated incremental HAI cost (AIHAIC): 
                                          
 ∑                      
 
   
                                             
                                             
Where 
i = one of the four HAI conditions 
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Use of these two equations provided a maximum estimate of both costs assuming 
all the uninsured elected to participate in insurance and all PPH were preventable 
through preventive care. To determine how the estimate might fluctuate relative to 
uptake rates in the insurance market place or expansion of Medicaid under the ACA, I 
allowed the number of uninsured to fluctuate based on differing levels of uptake in the 
insurance market place translating to changes in the numbers of uninsured. To allow for 
the fact that insurance status may not translate directly to the number of individuals with 
PPH and HAI, I also allowed the percentage of uninsured with a PPH and HAI to 
fluctuate. The adjustments to insurance rates provided an opportunity to examine the 
sensitivity of costs related to preventive care, PPH and PPH with HAI. 
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CHAPTER V 
RESULTS 
Descriptive analyses 
 To meet the goals of specific aim one and because relatively little is known about 
the PPH with HAI population, the following descriptive analysis includes demographic 
descriptions and frequency of occurrence in the Texas inpatient and BCBSTX data. For 
the purposes of reporting descriptive analyses collectively and comparatively, the 
descriptive portion of specific aim three covering the BCBSTX PPH and ACSC 
populations’ demographic and preventive care utilization is also included in this section. 
Texas inpatient population, 2011 
Demographics 
 Of the 2,937,134 discharges in the THCIC inpatient PUDF 2011 data, 202,511 
(6.9%) were excluded for missing or invalid data in evaluation variables.  Exclusions 
included 6 for missing age, 7,048 missing race, 190,529 for missing gender, 2,087 for 
missing principal diagnosis, 3,054 for missing primary payer, and 1,077 for length of 
stay greater than 180 days. Among the remaining 2,734,623 discharges, the AHRQ’s 
PQI programs identified 179,797 (6.6%) as PPH. Using the methodologies described in 
the chapter four for identifying HAI, 16,274 (0.6%) of all discharges included evidence 
of an HAI. The number of individuals who acquired an HAI during a PPH admission 
was estimated at 1,034 (6.4% of PPH discharges). 
 Compared to the general 2011 Texas inpatient population, individuals with a 
PPH were older, with a noticeably higher proportion of patients using Medicare as their 
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primary insurer (Table 1). The proportion of males was greater in the PPH, HAI, and 
PPH with HAI populations when compared to the general inpatient population. 
However, all groups consisted of more females than males (Table 1). We observed a 
slightly greater proportion of Whites when comparing the inpatient population moving 
from total discharges to PPH to HAI to PPH with HAI (Table 1). Blacks demonstrated a 
higher proportion within the PPH population, while the Other race category had nearly 
double the proportion in the HAI population compared to the PPH, PPH with HAI and 
the general inpatient populations (Table 1). Another observation included a greater 
proportion of discharges with Medicare as primary payer of 54%, 59% and 64% for 
PPH, HAI admissions, and PPH with HAI admission respectively (Table 1). These 
proportions are higher than the general patient population with 34% of discharges with 
Medicare as primary payer (Table 1). All observed differences from the general inpatient 
population were statistically significant at a p<.001 level. 
After exclusions, the final study population exhibited the same demographic 
characteristics with the exceptions of a larger proportion of the HAI population 
identifying Medicare as their primary payer (61% vs. 59%) (Table 2). 
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Table 1. Texas inpatients by PPH, HAI, PPH with HAI and general inpatient population for 2011, before exclusions. 
  With PQI   With HAI   With Both   Total Discharges 
 
N = 280,657 % of total 
discharges  
N = 16,274 % of total 
discharges  
N = 1,034 % of total 
discharges  
N = 2,935,047 
 
n % 
 
n % 
 
n % 
 
n % 
Gender 
              male 119,712 43% 4.08% 
 
7,339 45% 0.25% 
 
443 43% 0.02% 
 
1,076,967 37% 
missing 0 0% 0.00% 
 
1,244 8% 0.04% 
 
0 0% 0.00% 
 
190,528 6% 
Age Group 
              under 1 Year 20,696 7% 0.71% 
 
470 3% 0.02% 
 
39 4% 0.00% 
 
412,027 14% 
1-17 Years 15,099 5% 0.51% 
 
430 3% 0.01% 
 
9 1% 0.00% 
 
167,577 6% 
18-24 Years 6,166 2% 0.21% 
 
258 2% 0.01% 
 
7 1% 0.00% 
 
196,741 7% 
25-44 Years 27,853 10% 0.95% 
 
1,516 9% 0.05% 
 
72 7% 0.00% 
 
610,661 21% 
45-64 Years 74,419 27% 2.54% 
 
4,953 30% 0.17% 
 
313 30% 0.01% 
 
684,437 23% 
65-74 Years 48,808 17% 1.66% 
 
3,703 23% 0.13% 
 
222 21% 0.01% 
 
364,699 12% 
75-84 Years 52,114 19% 1.78% 
 
3,345 21% 0.11% 
 
224 22% 0.01% 
 
321,593 11% 
85+ Years 35,502 13% 1.21% 
 
1,599 10% 0.05% 
 
148 14% 0.01% 
 
177,306 6% 
missing 0 0% 0.00% 
 
0 0% 0.00% 
 
0 0% 0.00% 
 
6 0% 
Race 
              White 147,527 53% 5.03% 
 
8,948 55% 0.30% 
 
576 56% 0.02% 
 
1,476,635 50% 
Black 44,503 16% 1.52% 
 
2,124 13% 0.07% 
 
140 14% 0.00% 
 
383,711 13% 
Hispanic 71,416 25% 2.43% 
 
3,479 21% 0.12% 
 
258 25% 0.01% 
 
840,708 29% 
Asian/ Pacific Islander 2,804 1% 0.10% 
 
224 1% 0.01% 
 
10 1% 0.00% 
 
48,357 2% 
Amer. Indian./Eskimo/Aleut 2,235 1% 0.08% 
 
63 0% 0.00% 
 
7 1% 0.00% 
 
20,858 1% 
Other 11,351 4% 0.39% 
 
1,347 8% 0.05% 
 
42 4% 0.00% 
 
157,756 5% 
missing 821 0% 0.03% 
 
89 1% 0.00% 
 
1 0% 0.00% 
 
7,022 0% 
Primary Payer 
              Private payer 57,827 21% 1.97% 
 
3,337 21% 0.11% 
 
155 15% 0.01% 
 
927,566 32% 
Medicare 151,025 54% 5.15% 
 
9,673 59% 0.33% 
 
681 66% 0.02% 
 
992,145 34% 
Medicaid 37,800 13% 1.29% 
 
1,681 10% 0.06% 
 
111 11% 0.00% 
 
627,776 21% 
Other Gov't 6,053 2% 0.21% 
 
408 3% 0.01% 
 
17 2% 0.00% 
 
92,893 3% 
Self-pay or Charity 27,882 10% 0.95% 
 
1,114 7% 0.04% 
 
69 7% 0.00% 
 
291,172 10% 
missing 6,056 2% 0.21%  61 0% 0.00%  1 0% 0.00%  3,495 0% 
 Source: Texas Healthcare Information Collection Inpatient Public Use Data File, 2011 
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Table 2. Texas inpatients by PPH, HAI, PPH with HAI and general inpatient population for 2011, after exclusions. 
  With PPH 
 
With HAI 
 
With Both 
 
Total Discharges 
 
N = 279,767 % of total 
discharges 
 
N = 14,884 % of total 
discharges 
 
N = 1,031 % of total 
discharges 
 
N = 2,734,623  
n % 
 
n % 
 
n % 
 
n % 
Gender 
              
Male 119,405 43% 4.37% 
 
7,254 49% 0.27% 
 
440 43% 0.02% 
 
1,072,429 39% 
Age Group 
              
under 1 Year 20,678 7% 0.76% 
 
453 3% 0.02% 
 
39 4% 0.00% 
 
411,468 15% 
1-17 Years 15,067 5% 0.55% 
 
384 3% 0.01% 
 
9 1% 0.00% 
 
159,566 6% 
18-24 Years 6,151 2% 0.22% 
 
255 2% 0.01% 
 
7 1% 0.00% 
 
196,292 7% 
25-44 Years 27,768 10% 1.02% 
 
1,223 8% 0.04% 
 
71 7% 0.00% 
 
529,424 19% 
45-64 Years 74,192 27% 2.71% 
 
4,284 29% 0.16% 
 
313 30% 0.01% 
 
599,668 22% 
65-74 Years 48,625 17% 1.78% 
 
3,478 23% 0.13% 
 
221 21% 0.01% 
 
348,814 13% 
75-84 Years 51,928 19% 1.90% 
 
3,220 22% 0.12% 
 
223 22% 0.01% 
 
312,836 11% 
85+ Years 35,358 13% 1.29% 
 
1,587 11% 0.06% 
 
148 14% 0.01% 
 
176,555 6% 
Race 
              
White 147,491 53% 5.39% 
 
8,225 55% 0.30% 
 
575 56% 0.02% 
 
1,373,336 50% 
Black 44,493 16% 1.63% 
 
1,928 13% 0.07% 
 
140 14% 0.01% 
 
348,035 13% 
Hispanic 71,404 26% 2.61% 
 
3,198 21% 0.12% 
 
258 25% 0.01% 
 
798,534 29% 
Asian/ Pacific Islander 2,804 1% 0.10% 
 
218 1% 0.01% 
 
10 1% 0.00% 
 
47,414 2% 
Amer. Indian./Eskimo/Aleut 2,230 1% 0.08% 
 
59 0% 0.00% 
 
6 1% 0.00% 
 
19,918 1% 
Other 11,345 4% 0.41% 
 
1,256 8% 0.05% 
 
42 4% 0.00% 
 
147,386 5% 
Primary Payer 
              
Private payer 57,543 21% 2.10% 
 
3,038 20% 0.11% 
 
155 15% 0.01% 
 
874,094 32% 
Medicare 150,554 54% 5.51% 
 
9,192 62% 0.34% 
 
679 66% 0.02% 
 
940,666 34% 
Medicaid 37,751 13% 1.38% 
 
1,456 10% 0.05% 
 
111 11% 0.00% 
 
596,050 22% 
Other Gov't 6,050 2% 0.22% 
 
347 2% 0.01% 
 
17 2% 0.00% 
 
81,201 3% 
Self-pay or Charity 27,869 10% 1.02%   851 6% 0.03%   69 7% 0.00%   242,612 9% 
Source: Texas Healthcare Information Collection Inpatient Public Use Data File, 2011  
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THCIC PUDF inpatients identified as PPH with HAI 
 Because we are interested in the PPH with HAI population, and little is known 
about this group of individuals, I identified HAI across the PPH admissions (Table 3). 
When examining the PPH population, we observe the most frequently occurring PPHs 
are heart failure (HF), bacterial pneumonia (PN), and COPD or Asthma in adults with 
over 49, 43, and 41 thousand cases respectively. HF, PN, and COPD also accounted for 
the PPH with the most cases of an HAI, at 270,144, and 139 respectively (Table 3).  
We also observed less than five HAI cases in almost all pediatric PPH 
admissions. Because of these limited cell counts, I elected to discontinue further 
evaluation of all of the pediatric PPHs due to the inability to draw meaningful statistical 
conclusions. Adult PPH excluded from further individual evaluation due to small case 
counts of HAI included hypertension, angina without procedure, uncontrolled diabetes, 
and asthma in younger adults. Based upon sample size calculations, PPH for low birth 
weight and dehydration were also excluded from further individualized analyses. The 
sample size necessary to detect a large effect in the presence of multi-covariates was 
estimated at over two million observations. Because individualized analyses of PPH 
were limited to the adult or pediatric population, logistic regression models were 
unlikely to estimate the maximum likelihood function reliably. Where cases existed for 
these PPH, the cases were included in evaluations that aggregated to an all PPH level of 
reporting. 
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Table 3. Frequency of HAIs in the PPH population for the state of Texas, 2011 
PPH Type CDI SSI CLABSI CAUTI VAP 
PPH 
with 
HAI 
PPH 
with No 
HAI 
Total 
PPH 
PQI01 Diabetes Short-Term Complications 21 0 4 2 4 31 10,991 11,022 
PQI03 Diabetes Long-Term Complications 76 1 10 4 21 112 21,243 21,355 
PQI05 COPD or Asthma in Older Adults 42 0 10 11 76 139 41,212 41,351 
PQI07 Hypertension 3 0 2 2 1 8 10,925 10,933 
PQI08 Heart Failure 104 0 24 44 98 270 49,496 49,766 
PQI09 Low Birth Weight 2 0 29 0 5 36 17,904 17,940 
PQI10 Dehydration 36 0 4 11 9 60 20,013 20,073 
PQI11 Bacterial Pneumonia 97 0 26 13 8 144 43,424 43,568 
PQI12 Urinary Tract Infection 96 0 14 17 8 135 34,708 34,843 
PQI13 Angina without Procedure 1 0 0 0 0 1 1,954 1,955 
PQI14 Uncontrolled Diabetes 2 0 0 0 0 2 3,030 3,032 
PQI15 Asthma in Younger Adults 1 0 0 1 2 4 2,423 2,427 
PQI16 Lower-Extremity Amputation among 
diabetes patients 46 0 4 4 23 77 3,620 3,697 
PDI14 Asthma admission for under 18 1 0 1 0 0 2 7,560 7,562 
PDI15 Diabetes  (under 18) 0 0 0 0 0 0 1,275 1,275 
PDI16 Gastroenteritis (under 18) 0 0 5 0 1 6 5,402 5,408 
PDI18 Urinary Tract Infection (Under 18) 2 0 0 0 2 4 3,556 3,560 
Subtotal  530 1 133 109 258 965 278,736 279,767 
HAI with No PQI 6,381 389 1,353 940 4,789 13,454 
  Total HAI 6,911 390 1,486 1,049 5,047 14,419     
Source: Texas Healthcare Information Collection Inpatient Public Use Data File, 2011 and AHRQ Quality 
Indicator programs 
 
 
The HAI with the highest incidence in 2011 was CDI in both the PPH population 
and the overall inpatient population with 530 and 6,911 cases, respectively (Table 3). 
VAP demonstrated the second highest incidence at 258 and 5,047 cases for the PPH and 
overall inpatient populations, respectively (Table 3). Conversely, identification of SSI 
and CAUTI were limited due to inability to track the surgical population over a 90 day 
period, and lack of specificity in ICD-9-CM diagnosis codes for CAUTI. The inability to 
identify all cases of SSI translated to an inability to draw statistically meaningful 
individualized conclusions from analyses for SSI. However, where analyses aggregated 
to an all HAI level, cases of SSI were included. 
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Multiple PQI or HAI for one discharge 
 Because the methods for identifying PPH admissions and acquisition of HAI do 
not consider the presence of other PPH or HAIs, it was necessary to identify discharges 
with multiple PPH or HAI assignments. For the PPH, all 1,826 discharges identified 
with more than one PPH, identified PPH for diabetes related lower extremity amputation 
as one of the PPH. The secondary PPH was diabetes related for 1,814 of the 1,826 
discharges. For the remaining discharges with multiple PPH assignments, the secondary 
PPH included heart failure (13), dehydration (2), urinary tract infection (2), and bacterial 
pneumonia (1). Because some analysis required mutually exclusive categories of PPH, 
the 1,814 PPH admissions with less severe forms of diabetic complications as a 
secondary PPH were assigned to diabetes related lower extremity amputation. For the 
remaining discharges, an unadjusted mean cost per discharge was used as a proxy for 
intensity of utilization. Since the unadjusted mean cost per discharge was highest for 
diabetes related lower extremity amputation, the remaining individuals with multiple 
PPH were also assigned to the diabetes related lower extremity amputation PPH for 
analyses requiring a mutually exclusive category.  
 For the HAIs, 496 discharges included multiple HAI. Of the 496 discharges with 
multiple HAIs, 235 were cases of both CDI and VAP, 82 cases with both VAP and 
CLABSI, 55 cases with both CDI and CAUTI, 57 cases with CDI and CAUTI, 40 cases 
of CAUTI and VAP, and 14 cases with CAUTI and CLABSI. Using unadjusted mean 
cost per discharge as a proxy for intensity of utilization, all discharges with multiple HAI 
were assigned to the highest intensity category of identified HAI for analyses that 
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required mutually exclusive categories. From highest intensity to lowest, the HAI 
categories were VAP, CLABSI, SSI, CDI and CAUTI. 
BCBSTX  populations 
Datasets 
 Since the 2011 Texas pediatric inpatient population had extremely limited 
number of HAIs in the pediatric PPH population, only claims for patients 18 years of age 
and older were examined from the BCBSTX data. The data pull consisted of four 
populations within the BCBSTX claims data: beneficiaries with a hospital admission in 
2011, beneficiaries with no hospital admission for 2011 with an ACSC, beneficiaries 
with a prenatal care diagnosis, and prescriptions for the included beneficiaries. Due to 
incomplete utilization information for managed care beneficiaries, 30,539 BCBSTX 
beneficiaries’ information was not included. For 1,014,905 beneficiaries participating in 
a preferred provider payment structure, the BCBSTX data included over 38.7 million 
claim lines representing all types of utilization for individuals with a hospitalization in 
2011. For beneficiaries with no hospitalization in 2011, 70.2 million claim lines 
represented all types of utilization for 788,091 beneficiaries with a potential ACSC. For 
beneficiaries with prescription drug coverage, approximately 23.2 million claim lines 
represented 327 thousand prescriptions for 574 thousand beneficiaries. Finally, nearly 
8.5 million claim lines represented utilization for more than 735 thousand women with 
prenatal care. 
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BCBSTX inpatient PPH and HAI identification 
For the beneficiaries that generated 156,296 inpatient stays in 2011, the AHRQ 
PQI software identified 9,783 inpatient discharges for 7,982 beneficiaries (Table 4). For 
the purposes of comparability to the PUDF, the BCBSTX demographic summary of 
inpatient stays is reported by number of discharges. Since all evaluation variables were 
populated with valid values, the only exclusions for the data centered on outlier length of 
stay where 8 inpatient stays exceeded 180 days.  
Relative to the general BCBSTX inpatient population, individuals with a PPH 
were more likely to be female and slightly older (Table 4). When examined by HAI, 
individuals were more likely to be females aged 45 to 64 years than the general 
BCBSTX population (Table 4). We observed the same trend of slightly older females 
when comparing individuals admitted for a PPH with an HAI to the general BCBSTX 
inpatient population (Table 4). Consistently, approximately 90% of inpatient discharges 
where associated with the BCBS PPO plan verses the PPO+ plan (Table 4). 
Compared to the THCIC PUDF Texas inpatient population, the BCBSTX 
inpatient population exhibited a slightly larger proportion of females (64.8%) with the 
bulk of beneficiaries (84.4%) between 25 and 64 years of age (Table 4). Although the 
BCBSTX proportion of females was larger, the Texas PUDF inpatient population by 
gender was comparable where 61% of discharges were female. However, the distribution 
by age was flatter in the THCIC PUDF, with approximately 41% of the general inpatient 
population between 25 and 64 years of age (Table 4). 
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Table 4. BCBSTX population by PPH, HAI, PPH with HAI and general inpatient population for 2011.  
  With PQI   With HAI   With Both   Total Discharges 
N= 9,783 % of total 
discharges 
N= 1,326 % of total 
discharges 
N= 67 % of total 
discharges 
N= 156,295  
n % 
 
n % 
 
n % 
 
n % 
Gender 
              
male 4,292 43.9% 2.75% 
 
703 53.0% 0.45% 
 
33 49.3% 0.02% 
 
55,003 35.19% 
Age Group 
          
18-24 Years 528 5.4% 0.34% 
 
63 4.8% 0.04% 
 
2 3.0% 0.00% 
 
14,109 9.03% 
25-44 Years 2,267 23.2% 1.45% 
 
263 19.8% 0.17% 
 
12 17.9% 0.01% 
 
62,474 39.97% 
45-64 Years 5,694 58.2% 3.64% 
 
792 59.7% 0.51% 
 
38 56.7% 0.02% 
 
68,836 44.04% 
65-74 Years 764 7.8% 0.49% 
 
123 9.3% 0.08% 
 
7 10.4% 0.00% 
 
7,575 4.85% 
75-84 Years 442 4.5% 0.28% 
 
73 5.5% 0.05% 
 
7 10.4% 0.00% 
 
2,900 1.86% 
85+ Years 88 0.9% 0.06% 
 
12 0.9% 0.01% 
 
1 1.5% 0.00% 
 
401 0.26% 
Program Type 
          
PPO 8,776 89.7% 5.61% 
 
1,208 91.1% 0.77% 
 
58 86.6% 0.04% 
 
140,969 90.19% 
PPO+ 1,007 10.3% 0.64%   118 8.9% 0.08%   9 13.4% 0.01%   15,326 9.81% 
Source: Blue Cross/Blue Shield of Texas Claims data, 2011 and AHRQ Quality Indicator programs 
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Distribution of PPH with HAI within the BCBSTX population 
 To understand the effect of insurance on individuals admitted with a PPH, HAI, 
or PPH with HAI, I examined the distribution of admissions with HAI by type of PPH 
(Table 5). Overall, the BCBSTX population had fewer PPH admissions at 6.3% of total 
inpatient admissions verses the general Texas inpatient population at 9.5% of total 
admissions. For the BCBSTX population, bacterial pneumonia, hypertension, and 
dehydration were the most likely reasons for a PPH (Table 5). Like the THCIC PUDF 
Texas inpatient population, the methods used for identification for SSI  demonstrated our 
limited ability to identify all SSI from unlinked discharge data and diagnosis codes 
(Table 5). Also important to note, due to lack of present on admission and procedure 
date information, modifications to the methods for identifying CDI and VAP likely 
overestimated the occurrence of these HAI events.  
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Table 5. Frequency of HAIs in the BCBSTX population with PPH, 2011 
PPH Type CDI SSI CLABSI CAUTI VAP 
PPH 
with 
HAI 
PPH 
with No 
HAI Total PPH 
PQI01 Diabetes Short-Term Complications 1 0 0 1 2 4 661 665 
PQI03 Diabetes Long-Term Complications 5 0 1 1 1 8 966 974 
PQI05 COPD or Asthma in Older Adults 5 0 0 0 9 14 1,346 1,360 
PQI07 Hypertension 0 0 0 0 1 1 613 614 
PQI08 Heart Failure 5 0 0 0 4 9 1,078 1,087 
PQI10 Dehydration 3 0 0 2 2 7 1,276 1,283 
PQI11 Bacterial Pneumonia 6 0 0 4 6 16 1,923 1,939 
PQI12 Urinary Tract Infection 6 0 1 0 0 7 1,249 1,256 
PQI13 Angina without Procedure 0 0 0 0 0 0 167 167 
PQI14 Uncontrolled Diabetes 1 0 0 0 0 1 165 166 
PQI15 Asthma in Younger Adults 0 0 0 0 0 0 194 194 
PQI16 Lower-Extremity Amputation among 
diabetes patients 0 0 0 0 0 0 78 78 
Subtotal  32 0 2 8 25 67 9,718 9,783 
HAI with No PQI 438 41 46 100 633 1,258 
  Total HAI 470 41 48 108 658 1,325     
Source: Blue Cross/Blue Shield of Texas Claims data, 2011 and AHRQ Quality Indicator programs 
 
 
BCBSTX ambulatory care sensitive condition population, 2011 
Of the 788,091 beneficiaries in the non-hospitalized data, 606,138 experienced 
utilization for an ACSC in 2011. The ACSC population followed similar demographic 
patterns to the hospitalized patient population for BCBSTX beneficiaries (Table 6). Of 
the 606,138 beneficiaries identified with an ACSC in 2011, the most prevalent 
conditions were hypertension, diabetes and urinary tract infection with 64.2%, 24.1%, 
and 19.5% of the ACSC population respectively. Just over 172 thousand beneficiaries 
experienced more than one ACSC in 2011. During analyses, other ACSC were treated as 
comorbid conditions. 
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Table 6. ACSC population demographics and ACSC, 2011 
  n = 606,138 
 
n % 
Gender 
  male 247,700 40.9% 
Age Group 
  18-24 Years 30,858 5.1% 
25-44 Years 193,508 31.9% 
45-64 Years 344,795 56.9% 
65-74 Years 29,340 4.8% 
75-84 Years 6,845 1.1% 
85+ Years 792 0.1% 
Program Type 
  PPO 8,776 1.4% 
PPO+ 1,007 0.2% 
ACSC 
  Diabetes 146,191 24.1% 
COPD 40,728 6.7% 
Hypertension 389,409 64.2% 
Congestive Heart Failure 8,034 1.3% 
Prenatal Care 50,198 8.3% 
Dehydration 22,529 3.7% 
Bacterial Pneumonia 11,872 2.0% 
UTI 118,092 19.5% 
Asthma 14,057 2.3% 
Angina 9,967 1.6% 
Source: Blue Cross/Blue Shield of Texas Claims data, 2011 
 
 
 
For the 606,138 ACSC beneficiaries not hospitalized in 2011, utilization 
included nearly 7.3 million office visits, over 10 thousand home health visits, over 738 
thousand outpatient visits, 197 emergency room visits, and more than 6.4 million 
prescriptions (Table 7). More than half of BCBSTX ACSC population included 
individuals with hypertension, multiple ACSC, and UTI (Table 7). However, prenatal 
care exhibited the highest mean number of office visits followed by individuals with 
multiple ACSC and CHF with 16.4, 14.9, and 14.1 office visits per year, respectively. 
Congestive Heart Failure led mean home healthcare services utilization with 22.3 home 
visits per year, followed by beneficiaries with dehydration and asthma using 16.1 and 
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Table 7. Utilization of healthcare services by ACSC population, 2011 
  Office visits Home Health Visits Outpatient Care 
Emergency Room 
visits Prescriptions 
 
n Mean S.D. n Mean S.D. n Mean S.D. n Mean S.D. n Mean S.D. 
ACSC 
               Diabetes 38,937 9.3 9.6 47 9.4 12.2 15,238 2.2 2.4 4 1.0 0.0 20,960 18.9 18.4 
COPD 18,298 10.3 11.2 19 10.7 11.6 8,604 2.3 2.3 3 2.0 1.7 10,939 15.3 17.2 
Hypertension 240,618 10.0 10.3 263 8.6 14.1 107,245 2.3 2.4 59 1.3 0.7 129,575 19.8 18.1 
Congestive Heart Failure 1,074 14.1 13.7 3 22.3 30.9 645 3.1 4.4 0 - - 578 25.8 23.5 
Prenatal Care 50,198 16.4 9.6 182 7.2 7.7 28,971 2.8 2.9 0 - - 26,751 13.1 13.8 
Dehydration 12,197 10.7 13.3 16 16.1 28.3 6,570 2.2 2.4 3 1.3 0.6 6,960 11.9 14.5 
Bacterial Pneumonia 5,488 10.1 10.4 10 9.3 8.6 2,627 2.3 3.0 1 1.0 
 
3,180 12.8 14.5 
UTI 70,195 11.7 11.2 55 12.7 25.5 34,002 2.2 2.1 5 1.4 0.9 39,696 13.7 14.8 
Asthma 7,195 11.3 12.8 3 13.3 19.7 3,118 2.1 2.3 0 - - 4,054 16.3 17.1 
Angina 1,837 13.0 11.7 0 - - 1,229 2.5 2.4 0 - - 970 16.4 17.9 
Multiple ACSC 160,101 14.9 13.6 388 12.3 22.3 89,344 2.8 3.3 66 1.5 0.8 83,086 30.2 25.2 
Source: Blue Cross/Blue Shield of Texas Claims data, 2011 
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13.3 home visits per year, respectively (Table 7). Beneficiaries with CHF also led 
outpatient services mean utilization with 3.1 visits per year (Table 7). The BCBSTX 
ACSC population also exhibited minimal use of emergency room services (Table 7). Not 
unexpected, beneficiaries with multiple ACSC utilized prescription services a mean of 
30.2 times per year, followed by beneficiaries with CHF at 25.8 prescription claims per 
year (Table7).  
Bivariate and multivariate analyses 
 In this section of the results, I report the results of necessary bivariate analysis 
that support the proposed multivariate analyses. Also reported here are the odds ratios 
that conclude the analyses to fulfill the goals of specific aim one. The odds ratio analysis 
also includes the odds of acquiring an HAI by payer. These comparisons are included in 
partial fulfillment of the goals for specific aim four.  
Texas inpatient population, 2011 
Bivariate 
 To determine whether correlations existed between analyses variables, I 
examined a SAS® generated correlation matrix populated with Pearson correlation 
coefficients. The correlation p-values demonstrated that most associations were 
significant at a p<.05 level. Defining mildly correlated as a Pearson correlation 
coefficient with an absolute value between 0 and 0.3, and a moderate correlation as an 
absolute value between 0.31 and 0.7, only seven correlation coefficients were significant 
and large enough to be considered moderately strong. Four of the variables with 
moderately strong coefficients’ were correlated with age, specifically room type (private, 
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semi-private or ward), primary payer, hypertension, and health status measured as the 
number of comorbid conditions (Pearson correlation coefficients -0.38, -0.43, 0.54, and 
0.56, respectively). The other moderately strong associations were between primary 
payer and health status (-0.31), hypertension and diabetes mellitus (0.35), and 
hypertension and renal failure (0.31). No coefficients presented a strong association. 
After evaluating the cost data for the presence of zero costs, generalized linear 
modeling quantified the effects of evaluation variables on cost of healthcare. All models 
demonstrated significant ability to measure variation in cost based upon the independent 
variable as measured by the F-statistic (p<.001). Of the PPH and comorbid conditions 
evaluated, all demonstrated significant relationships (p<.05) with cost except the 
diabetes-related lower extremity amputation PPH and several comorbid conditions. 
Comorbid conditions not significantly related to cost included valvular disease, 
pulmonary circulation disorders, renal failure, chronic peptic ulcer disease, lymphoma, 
metastatic cancer, solid tumor with metastases, and fluid and electrolyte disorders.  
Using a similar approach, I used logistic regression to measure the association 
between the probability of acquiring an HAI and independent variables. All models 
converged, and I assessed multiple measures of model fit to understand the reliability of 
reported associations. While all models converged and most relationships were 
significant, there were several notable exceptions. For example, when comparing 
variables to reflect size of hospital, average daily census was significant while number of 
beds was not. Therefore, I selected average daily census as the best reflection of hospital 
size. In examining room type, a semi-private room was significantly different from a 
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ward, but a private room was not. For types of PPH, only long-term diabetes was not 
significantly associated with the probability of an HAI. For comorbid conditions, chronic 
peptic ulcer disease and depression did not demonstrate significant associations. 
Odds of PPH with HAI 
 To achieve a better understanding of the associations between PPH and HAI, I 
examined whether individuals with a PPH were more likely than the general inpatient 
population to acquire an HAI during their hospital stay through odds ratios. Adjusted 
odds ratios reflect considerations for demographic characteristics, health status, hospital 
characteristics, and community characteristics as described in Chapter IV-Methods. 
Regression models evaluating the THIC PUDF data included 51 covariates. This left at 
least 1,854,861 degrees of freedom in each model. 
With the exception of short-term diabetes, long-term diabetes and diabetes 
associated lower extremity amputation; individuals were significantly less likely to 
acquire CDI than the rest of the general inpatient population (Table 8). When compared 
to the overall PPH population, the odds of acquiring CDI by the general inpatient 
population was nearly 2 times the odds of the PPH population acquiring CDI (OR: .54, 
CI95% .49, .59). While the short-term and long-term diabetes PPH did not demonstrate 
significant odds ratios for acquiring a CDI, the diabetes associated lower extremity 
amputation did (Table 8). In fact, the odds ratios reflect an effect of that individuals 
admitted with a diabetes related lower extremity amputation PPH had nearly three times   
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Table 8.  Odds ratios of acquiring CDI by PPH type and payer, adjusted for 
demographic, health status, hospital, and community characteristics. 
 
PPH 
Denominator 
Population 
CDI within 
Denominator 
Population 
PPH 
with 
HAI 
Odds 
Ratio LCL UCL 
For all PPH 2,642,681 6,617 530 0.54 0.49 0.59 
by PPH 
      PQI01 Diabetes Short-Term Complications 1,862,070 5,919 21 1.12 0.73 1.73 
PQI03 Diabetes Long-Term Complications 1,872,221 5,970 76 0.97 0.76 1.22 
PQI05 COPD or Asthma in Older Adults 1,891,645 5,939 42 0.24 0.18 0.33 
PQI08 Heart Failure 1,899,828 5,997 104 0.50 0.41 0.61 
PQI10 Dehydration 1,870,759 5,933 36 0.50 0.36 0.70 
PQI11 Bacterial Pneumonia 1,893,646 5,994 97 0.57 0.46 0.70 
PQI12 Urinary Tract Infection 1,885,483 5,992 96 0.61 0.49 0.74 
PQI16 Lower-Extremity Amputation 
among diabetes patients 1,854,910 5,945 46 2.90 2.16 3.91 
All PPH by payer 
      Medicare 2,642,681 6,617 530 Referent 
  Private Insurance 
   
0.56 0.52 0.61 
Medicaid 
   
0.58 0.51 0.66 
Other 
   
0.53 0.43 0.64 
Self-Pay or Charity    0.46 0.40 0.53 
Odds ratios in bold are significant at a p<.05 level 
Source: Texas Healthcare Information Collection Inpatient Public Use Data File, 2011 and AHRQ Quality 
Indicator programs 
Notes: Where not listed, the referent group is the non-PPH adult Texas inpatient population  
 
 
 
the odds of acquiring CDI as the general inpatient population (OR: 2.9, CI95% 2.16, 
3.91)(Table 8). When examined by payer, accounting for the effects of PPH and HAI, 
the odds of the Medicare population acquiring CDI was approximately twice the odds of 
any other payer (Table 8). All payer categories contributed significantly to explain 
variation in the probability of acquiring a CDI infection (Table 8). 
When examining CLABSI and PPH, individuals admitted for a PPH were less 
likely to acquire CLABSI than the general inpatient population, except for the diabetes 
related lower extremity amputation PPH. Effects ranged from an odds ratio of .37 for 
dehydration to 1.65 for diabetes related lower extremity amputation (Table 9). PPH 
considered significant in explaining variation in the probability of acquiring CLABSI   
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Table 9.  Odds ratios of acquiring CLABSI by PPH type and payer, adjusted for 
demographic, health status, hospital, and community characteristics. 
 
PPH 
Denominator 
Population 
CLABSI 
within 
Denominator 
Population 
PPH 
with 
HAI 
Odds 
Ratio LCL UCL 
For all PPH 2,642,681 1,532 133 0.729 0.609 0.874 
by PPH  
     PQI01 Diabetes Short-Term Complications 1,862,070 1120 4 0.683 0.255 1.830 
PQI03 Diabetes Long-Term Complications 1,872,221 1125 10 0.618 0.320 1.196 
PQI05 COPD or Asthma in Older Adults 1,891,645 1127 10 0.387 0.213 0.703 
PQI08 Heart Failure 1,899,828 1141 24 0.847 0.566 1.267 
PQI10 Dehydration 1,870,759 1120 4 0.366 0.137 0.977 
PQI11 Bacterial Pneumonia 1,893,646 1142 26 0.889 0.600 1.317 
PQI12 Urinary Tract Infection 1,885,483 1129 14 0.514 0.296 0.892 
PQI16 Lower-Extremity Amputation among 
diabetes patients 1,854,910 1121 4 1.654 0.679 4.031 
All PPH by payer  
     Medicare 2,642,681 1,532 133 Referent 
  Private Insurance  
  
0.734 0.618 0.872 
Medicaid  
  
1.163 0.953 1.418 
Other  
  
0.892 0.643 1.238 
Self-Pay or Charity  
  
0.742 0.583 0.945 
Odds ratios in bold are significant at a p<.05 level 
Source: Texas Healthcare Information Collection Inpatient Public Use Data File, 2011 and AHRQ Quality 
Indicator programs 
Notes: Where not listed, the referent group is the non-PPH adult Texas inpatient population  
 
 
included dehydration, COPD,  and UTI where odds ratios were .37, .39, and .51 
respectively (Table 9). Additionally, dehydration, COPD, and UTI demonstrated the  
largest effects (Table 9). While differences among payers were significant, the 
measurable effect was considered moderate (Table 9). 
When examining the odds of acquiring CAUTI, we observed the general 
inpatient population had significant odds of acquiring CAUTI that were approximately 
2.5 times the odds of individuals admitted with a COPD/asthma PPH (OR: .40, CI95% 
.23, .71) or individuals admitted for the bacterial pneumonia PPH (OR: .43, CI95% .25, 
.75)(Table 10). The largest adverse odds ratio was for the diabetes related lower 
extremity amputation PPH where patients admitted for diabetes related lower extremity 
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amputation had an odds of acquiring CAUTI that was 2.3 times that of the general 
inpatient population, however the relationship was not considered significant. When we 
compared PPH patients with the general inpatient population, we observed significantly 
lower odds of acquiring CAUTI by the PPH population approximately two thirds that of 
the general inpatient population. We observed a relationship of similar magnitude and 
significance between Medicare and privately insured individuals where Medicare 
beneficiaries odds of acquiring CAUTI were 1.5 times that of privately insured patients. 
 
Table 10.  Odds ratios of acquiring CAUTI by PPH type and payer, adjusted for 
demographic, health status, hospital, and community characteristics. 
 
PPH 
Denominator 
Population 
CAUTI 
within 
Denominator 
Population 
PPH 
with 
HAI 
Odds 
Ratio LCL UCL 
For all PPH 2,636,064 1,118 109 0.677 0.556 0.826 
by PPH 
      PQI01 Diabetes Short-Term Complications 1,862,070 997 2 0.657 0.163 2.640 
PQI03 Diabetes Long-Term Complications 1,872,221 1,000 4 0.438 0.181 1.058 
PQI05 COPD or Asthma in Older Adults 1,891,645 1,007 11 0.402 0.227 0.713 
PQI08 Heart Failure 1,899,828 1,039 44 1.281 0.940 1.747 
PQI10 Dehydration 1,870,759 1,006 11 0.887 0.488 1.610 
PQI11 Bacterial Pneumonia 1,893,646 1,008 13 0.431 0.249 0.748 
PQI12 Urinary Tract Infection 1,885,483 1,012 17 0.622 0.383 1.009 
PQI16 Lower-Extremity Amputation among 
diabetes patients 1,854,910 1,000 4 2.301 0.944 5.606 
All PPH by payer 
      Medicare 2,636,064 1,118 109 Referent 
  Private Insurance 
   
0.666 0.541 0.82 
Medicaid 
   
0.897 0.666 1.208 
Other 
   
0.772 0.494 1.204 
Self-Pay or Charity    0.828 0.614 1.118 
Odds ratios in bold are significant at a p<.05 level 
Source: Texas Healthcare Information Collection Inpatient Public Use Data File, 2011 and AHRQ Quality 
Indicator programs 
Notes: Where not listed, the referent group is the non-PPH adult Texas inpatient population  
 
 
For VAP, associations with all PPH were significant and size of effect was large 
(Table 11). With the exception of lower extremity amputation, all other PPH 
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demonstrated that patients with a PPH were less likely to acquire an HAI with odds 
ratios ranging from .056 to .56 (Table 11). However, the odds of acquiring VAP for 
individuals admitted with diabetes related lower extremity amputation were 1.44 times 
that of the general inpatient population (Table 11). By payer, private insurance and 
Medicaid were significantly different from Medicare, but the size of the effect was small 
(Table 11).  
 
Table 11. Odds ratios of acquiring VAP by PPH type and payer, adjusted for 
demographic, health status, hospital, and community characteristics. 
 
PPH 
Denominator 
Population 
VAP within 
Denominator 
Population 
PPH 
with 
HAI 
Odds 
Ratio LCL UCL 
For all PPH 2,642,681 5,012 258 0.34 0.30 0.38 
by PPH  
     PQI01 Diabetes Short-Term Complications 1,862,070 4492 4 0.20 0.07 0.53 
PQI03 Diabetes Long-Term Complications 1,872,221 4509 21 0.31 0.20 0.48 
PQI05 COPD or Asthma in Older Adults 1,891,645 4560 76 0.56 0.45 0.71 
PQI08 Heart Failure 1,899,828 4580 98 0.56 0.46 0.70 
PQI10 Dehydration 1,870,759 4497 9 0.19 0.10 0.37 
PQI11 Bacterial Pneumonia 1,893,646 4496 8 0.06 0.03 0.11 
PQI12 Urinary Tract Infection 1,885,483 4496 8 0.08 0.04 0.17 
PQI16 Lower-Extremity Amputation 
among diabetes patients 1,854,910 4511 23 1.44 0.95 2.18 
All PPH by payer  
     Medicare 2,642,681 5,012 258 Referent 
  Private Insurance  
  
0.77 0.70 0.84 
Medicaid  
  
1.11 0.99 1.25 
Other  
  
1.06 0.89 1.26 
Self-Pay or Charity     1.00 0.88 1.13 
Odds ratios in bold are significant at a p<.05 level 
Source: Texas Healthcare Information Collection Inpatient Public Use Data File, 2011 and AHRQ Quality 
Indicator programs 
Notes: Where not listed, the referent group is the non-PPH adult Texas inpatient population  
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BCBSTX populations, 2011 
Bivariate 
 To examine associations between evaluation variables in the BCBXTX data, I 
used SAS® 9.3 to generate a correlation matrix, and used Pearson correlation 
coefficients to quantify associations. While approximately half of the variable 
combinations exhibited significant associations, only two exhibited a moderately strong 
association. Similar to the THCIC inpatient population, age was significantly and 
moderately associated with hypertension and health status as measured by the number of 
comorbid conditions. Pearson correlation coefficients were both .44 and significant at a 
p=<.001 level. All other associations reflected a weak association regardless of 
significance. 
 For examining evaluation variables in association with the probability of 
acquiring an HAI during hospitalization, I used logistic regression. All models 
converged, and I assessed multiple measures of model fit to understand the reliability of 
reported associations. Of the evaluation variables, none of the PPH variables were 
significantly associated in predicting the acquisition of an HAI. Variables considered 
significant in bivariate logistic regression of the probability of acquiring an HAI were 
age, gender, and health status as measured by the number of comorbid conditions. 
Individual comorbid conditions considered significant were CHF, pulmonary circulation 
disorders, hypertension, paralysis, neurological disorders, chronic pulmonary lung 
diseases, diabetes without complications, hypothyroidism, renal failure, liver disease, 
lymphoma, metastatic cancers, non-metastatic tumors, coagulation disorders, weight 
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loss, dehydration, alcohol abuse, and depression. All relationships were significant at a 
p<.05 level. 
Odds of PPH with HAI in the BCBSTX hospitalized population 
 To examine associations between PPH and acquisition of an HAI during 
hospitalization for the BCBSTX population, I used SAS® 9.3 to calculate odds ratios 
while adjusting for age, gender, and comorbid conditions. Consistent with the bivariate 
analyses, we observed no significant associations between the PPH and CDI. We 
observed significant associations between VAP and long-term diabetes, bacterial 
pneumonia, and the all PHH variables (Table 12). Additionally, the odds ratios suggest 
that the general BCBSTX inpatient population is more than 14 times as likely to acquire 
an HAI as the long-term diabetes PPH beneficiary, and approximately 2.5 times as likely 
as a pneumonia PPH beneficiary or anyone admitted with a PPH (Table 12). Similar 
effect sizes are exhibited between VAP and the dehydration PPH, VAP and the short-
term diabetes PPH, and the short-term diabetes PPH and CDI, but these associations 
were not significant (Table 12).
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Table 12. Odds ratios of acquiring an HAI by type of PPH in the BCBSTX inpatient population, 2011 
    CDI   VAP 
 
PPH 
Denominator 
Population 
CDI 
Population 
PPH 
with 
CDI 
Odds 
Ratio LCL UCL  
VAP 
Population 
PPH 
with 
VAP 
Odds 
Ratio LCL UCL 
For all PPH 156,287 486 32 0.78 0.54 1.12  658 25 0.41 0.27 0.61 
by PPH             
PQI01 Diabetes Short-Term Complications 147,169 455 1 0.33 0.05 2.35  635 2 0.48 0.12 1.95 
PQI03 Diabetes Long-Term Complications 147,478 459 5 1.09 0.45 2.69  634 1 0.14 0.02 0.98 
PQI05 COPD or Asthma in Older Adults 147,864 459 5 1.04 0.43 2.55  642 9 1.32 0.67 2.60 
PQI08 Heart Failure 147,591 459 5 0.96 0.39 2.37  637 4 0.61 0.23 1.66 
PQI10 Dehydration 147,787 457 3 0.71 0.23 2.21  635 2 0.38 0.09 1.53 
PQI11 Bacterial Pneumonia 148,443 460 6 0.70 0.31 1.59  639 6 0.40 0.17 0.90 
PQI12 Urinary Tract Infection 147,760 460 6 1.08 0.48 2.45  143 0    
PQI16 Lower-Extremity Amputation among 
diabetes patients 146,582 454 0      207 0       
Odds ratios in bold are significant at a p<.05 level 
Source: Blue Cross/Blue Shield of Texas Claims data, 2011 and AHRQ Quality Indicator programs 
Note: Adjusted for age, gender, and comorbid conditions. Where not listed, the referent group is the non-PPH adult BCBSTX inpatient population  
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Cost of care 
 In this final section of the results, I report the multivariate evaluation of costs for 
the THCIC inpatient PUDF and the BCBSTX data. The results of the THCIC inpatient 
PUDF cost analysis fulfills the goals of specific aim two, while the costs of preventive 
care and follow-up generated from the BCBSTX data allows the fulfillment the goals of 
specific aim three, and to generate an answer to the hypothesis question. Included in the 
THCIC inpatient PUDF multivariate analysis of cost and throughout generation of an 
answer to the hypothesis question is an evaluation by payer, fulfilling the goals of 
specific aim four. 
Texas inpatient population, 2011 
 In examining costs, I adjusted for demographic, health status, hospital and 
community characteristics and limited the regression populations to adults. Additionally, 
all cost models were considered significant as measured by the F-statistic (p<.0001). 
Models contained 790 to 792 covariates depending upon the number of DRGs in the 
denominator population, leaving a minimum of 1,854,118 degrees of freedom for any of 
the cost regression models. After adjustment, the differences in mean hospitalization cost 
attributable to PPH were approximately $2,100 less than other hospitalizations (Tables 
13-17). One exception included hospitalizations for heart failure at approximately $425 
more per admission when compared to the mean cost of hospitalization for the remaining 
inpatient population (Tables 13-17). Surprisingly, admissions for diabetes related lower 
extremity amputation were approximately $4,100 per admission less than other inpatient 
stays after adjustment (Tables 13-17). We also observed that when private insurance was 
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listed as primary payer, hospitalizations costs range from $2,050 more per person than 
Medicaid to $3,994 more per person than the uninsured (Tables 13-17). 
 
Table 13. Mean differences in cost of inpatient care for CDI by PPH, 2011 
  n 
Mean 
difference 
due to 
PPH
1 
S.E. 
Mean 
difference 
due to 
HAI
2 
S.E. 
For all PPH 2,642,681 -$2,102 $64 $17,040 $240 
by PPH 
     PQI01 Diabetes Short-Term Complications 1,862,070 -$5,349 $457 $17,028 $272 
PQI03 Diabetes Long-Term Complications 1,872,221 -$2,309 $226 $17,042 $271 
PQI05 COPD or Asthma in Older Adults 1,891,645 -$2,104 $195 $17,071 $270 
PQI08 Heart Failure 1,899,828 $461 $202 $16,931 $268 
PQI10 Dehydration 1,870,759 -$596 $171 $16,968 $271 
PQI11 Bacterial Pneumonia 1,893,646 -$1,867 $208 $16,934 $269 
PQI12 Urinary Tract Infection 1,885,483 -$1,170 $283 $16,880 $269 
PQI16 Lower-Extremity Amputation 
among diabetes patients 1,854,910 -$4,119 $503 $16,985 $272 
      All PPH by payer and adjusting for CDI 
     Private Insurance 2,642,681 Referent
   Medicare 
 
-$2,257 $40
  Medicaid 
 
-$2,052 $37 
  Other Gov't 
 
-$2,964 $74 
  Self-Pay or Charity  -$3,987 $47   
All associations are significant at a p<.01 level. 
Source: Texas Healthcare Information Collection Inpatient Public Use Data File, 2011 and AHRQ Quality 
Indicator programs 
Note: All differences are adjusted for demographic, health status, community and hospital characteristics. 
1. Difference in mean cost between the non-PPH adult Texas inpatient population and the specified PPH 
population 
2. Difference in mean costs between the non-HAI adult Texas inpatient population and the Texas inpatient 
population 
 
  
 When examining the effect of CDI on cost, increased payments per admission 
were estimated at $17 thousand (Table 13). Where an admission was potentially 
preventable and CDI acquired by the patient, the increase in hospitalization costs was 
approximately $14,900 per admission.  
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Table 14. Mean differences in cost of inpatient care for CLABSI by PPH, 2011 
  n 
Mean 
difference 
due to PPH S.E. 
Mean 
difference 
due to HAI S.E. 
For all PPH 2,642,681 -$2,136 $64 $32,408 $498 
by PPH 
     PQI01 Diabetes Short-Term Complications 1,862,070 -$5,436 $458 $22,283 $623
PQI03 Diabetes Long-Term Complications 1,872,221 -$2,352 $226 $22,248 $621 
PQI05 COPD or Asthma in Older Adults 1,891,645 -$2,155 $196 $22,348 $617 
PQI08 Heart Failure 1,899,828 $462 $202 $22,181 $612 
PQI10 Dehydration 1,870,759 -$604 $172 $22,241 $622 
PQI11 Bacterial Pneumonia 1,893,646 -$1,974 $208 $22,215 $613 
PQI12 Urinary Tract Infection 1,885,483 -$1,298 $283 $22,155 $617 
PQI16 Lower-Extremity Amputation 
among diabetes patients 1,854,910 -$4,086 $60 $22,367 $624 
      All PPH by payer adjusting for CLABSI 
     Private Insurance 2,642,681 Referent
   Medicare 
 
-$2,057 $40
  Medicaid 
 
-$2,057 $37 
  Other Gov't 
 
-$2,969 $74 
  Self-Pay or Charity  -$3,990 $47   
All associations are significant at a p<.01 level. 
Source: Texas Healthcare Information Collection Inpatient Public Use Data File, 2011 and AHRQ Quality 
Indicator programs 
Note: All differences are adjusted for demographic, health status, community and hospital characteristics. 
1. Difference in mean cost between the non-PPH adult Texas inpatient population and the specified PPH 
population 
2. Difference in mean costs between the non-HAI adult Texas inpatient population and the Texas inpatient 
population 
 
  
 When examining the effect of CLABSI on cost, we observed a difference in 
mean hospitalization cost of more than $32 thousand per hospitalization (Table 14). We 
also observed that none of the incremental CLABSI cost reported by type of PPH is 
more than $23 thousand dollars. This suggests that the effect of CLABSI in PPH such as 
hypertension, low birth weight babies, or pediatric gastroenteritis generates significant 
utilization driving the mean adjusted cost upward (Table 14). When a PPH admitted 
individual also acquired CLABSI, the incremental increase in the adjusted mean cost 
was approximately $30,100 per admission.  
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Table 15. Mean differences in cost of inpatient care for CAUTI by PPH, 2011 
  n 
Mean 
difference 
due to 
PPH S.E. 
Mean 
difference 
due to 
HAI S.E. 
For all PPH 2,642,681 -$2,132 $64 $13,118 $582 
by PPH 
     PQI01 Diabetes Short-Term Complications 1,862,070 -$5,438 $458 $13,300 $659
PQI03 Diabetes Long-Term Complications 1,872,221 -$2,350 $226 $13,414 $657 
PQI05 COPD or Asthma in Older Adults 1,891,645 -$2,161 $196 $13,307 $651 
PQI08 Heart Failure 1,899,828 $455 $202 $13,340 $640 
PQI09 Low Birth Weight 
     PQI11 Bacterial Pneumonia 1,893,646 -$1,953 $208 $13,272 $651
PQI12 Urinary Tract Infection 1,885,483 -$1,282 $283 $13,101 $651 
PQI16 Lower-Extremity Amputation among 
diabetes patients 1,854,910 -$4,119 $503 $13,361 $660 
      All PQI by payer adjusting for CAUTI 
    Private Insurance 2,642,681 Referent
   Medicare 
 
-$2,239 $41
  Medicaid 
 
-$2,050 $37 
  Other Gov't 
 
-$2,968 $74 
  Self-Pay or Charity  -$3,994 $47   
All associations are significant at a p<.01 level. 
Source: Texas Healthcare Information Collection Inpatient Public Use Data File, 2011 and AHRQ Quality 
Indicator programs 
Note: All differences are adjusted for demographic, health status, community and hospital characteristics. 
1. Difference in mean cost between the non-PPH adult Texas inpatient population and the specified PPH 
population 
2. Difference in mean costs between the non-HAI adult Texas inpatient population and the Texas inpatient 
population 
 
  
For CAUTI , we observed a mean increase of over $13 thousand per admission 
(Table 15). Depending on the type of PPH, the increased cost was offset by the mean 
difference related to a PPH admission. On average, the mean cost of CAUTI during a 
PPH admission was $11,000 more than the mean cost of the hospitalization for the non-
PPH inpatient population in Texas. 
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Table 16. Mean differences in cost of inpatient care for VAP by PPH, 2011 
  n 
Mean 
difference 
due to PPH S.E. 
Mean 
difference 
due to HAI S.E. 
For all PPH 2,642,681 -$2,119 $64 $32,541 $286 
by PPH 
     PQI01 Diabetes Short-Term Complications 1,862,070 -$5,418 $457 $29,609 $325
PQI03 Diabetes Long-Term Complications 1,872,221 -$2,354 $226 $29,615 $324 
PQI05 COPD or Asthma in Older Adults 1,891,645 -$2,245 $195 $29,360 $320 
PQI08 Heart Failure 1,899,828 $395 $202 $29,519 $319 
PQI10 Dehydration 1,870,759 -$601 $171 $29,584 $324 
PQI11 Bacterial Pneumonia 1,893,646 -$1,818 $208 $29,610 $322 
PQI12 Urinary Tract Infection 1,885,483 -$1,262 $283 $29,592 $323 
PQI16 Lower-Extremity Amputation 
among diabetes patients 1,854,910 -$4,073 $325 $29,691 $325 
      All PPH by payer adjusting for VAP 
     Private Insurance 2,642,681 Referent
   Medicare 
 
-$2,237 $40
  Medicaid 
 
-$2,057 $37 
  Other Gov't 
 
-$2,974 $74 
  Self-Pay or Charity  -$3,994 $47   
All associations are significant at a p<.01 level. 
Source: Texas Healthcare Information Collection Inpatient Public Use Data File, 2011 and AHRQ Quality 
Indicator programs 
Note: All differences are adjusted for demographic, health status, community and hospital characteristics. 
1. Difference in mean cost between the non-PPH adult Texas inpatient population and the specified PPH 
population 
2. Difference in mean costs between the non-HAI adult Texas inpatient population and the Texas inpatient 
population 
 
  
VAP exhibited the largest incremental increase in hospitalization cost at 
approximately $32,500 for all PPH (Table 16). Like the incremental cost of HAI for 
CLABSI, VAP incremental cost of HAI is larger for all PPH than for estimates limited 
to an individual PPH. Suggesting other PPH with VAP such a low birth weight babies, 
hypertension, asthma, or any of the pediatric PPH may generate substantial utilization 
and associated costs (Table 16). 
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Table 17. Mean differences in cost of inpatient care for all HAI by PPH, 2011 
  n 
Mean 
difference 
due to PPH S.E. 
Mean 
difference 
due to HAI S.E. 
For all PPH 2,642,681 -$2,082 $64 $23,559 $170 
by PPH 
     PQI01 Diabetes Short-Term Complications 1,862,070 -$5,305 $456 $21,266 $195
PQI03 Diabetes Long-Term Complications 1,872,221 -$2,289 $225 $21,268 $194 
PQI05 COPD or Asthma in Older Adults 1,891,645 -$2,154 $195 $21,241 $193 
PQI08 Heart Failure 1,899,828 $402 $202 $21,196 $192 
PQI10 Dehydration 1,870,759 -$587 $171 $21,215 $195 
PQI11 Bacterial Pneumonia 1,893,646 -$1,749 $207 $21,188 $193 
PQI12 Urinary Tract Infection 1,885,483 -$1,120 $282 $21,145 $193 
PQI16 Lower-Extremity Amputation among 
diabetes patients 1,854,910 -$4,061 $502 $21,279 $195 
      All PPH by payer adjusting for HAI 
     Private Insurance 2,642,681 Referent
   Medicare 
 
-$2,266 $40
  Medicaid 
 
-$2,065 $40 
  Other Gov't 
 
-$2,967 $74 
  Self-Pay or Charity   -$3,982 $47   
All associations are significant at a p<.01 level. 
Source: Texas Healthcare Information Collection Inpatient Public Use Data File, 2011 and AHRQ Quality 
Indicator programs 
Note: All differences are adjusted for demographic, health status, community and hospital characteristics. 
1. Difference in mean cost between the non-PPH adult Texas inpatient population and the specified PPH 
population 
2. Difference in mean costs between the non-HAI adult Texas inpatient population and the Texas inpatient 
population 
 
  
Across all PPH and all HAI, the mean adjusted incremental cost of a PPH is less 
than other hospitalizations by approximately $2,000 (Table 17). However, when an HAI 
is acquired, the mean adjusted incremental cost of hospitalization increased by 
approximately $23,500 in 2011(Table 17). When a PPH and HAI occur during the same 
admission, the mean adjusted cost per hospitalization is approximately $21,500 more 
than the mean adjusted cost of other hospitalizations per hospitalization (Table 17). 
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BCBSTX cost of healthcare for beneficiaries with a PPH admission in 2011 
 To aggregate healthcare utilization for BCBSTX beneficiaries with a PPH during 
2011, I used the PPH discharge date to assign other utilization as either pre or post PPH 
utilization. After adjusting for gender, age, and comorbid conditions, I elected to report 
findings by plan type since the foundation of my analyses is pinned to access through 
insurance. Differences in mean pre-PPH utilization costs by plan type were not found to 
be significant. Estimates for aggregated mean healthcare utilization occurring in the year 
prior to the PPH ranged from $29 thousand for heart failure to $288 thousand for 
diabetes related lower extremity amputation (Table 18). For the six months after the 
PPH, aggregated and adjusted healthcare utilization ranged from $27 thousand for heart 
failure beneficiaries to $291 thousand for diabetes related lower extremity amputation 
patients (Table 18). When examining post PPH healthcare costs, six-month follow-up 
costs were similar in magnitude to costs reported for annual pre-PPH utilization. 
Although differences in mean payment by plan type were not significant, the models 
estimating cost were considered significant at a p<.001 level as measured by the F-
statistic. Regression models included 20 to 29 covariates to adjust for demographic and 
health status and varied depending upon the presence of comorbid conditions in the PPH 
population being measured.  
When examining the effect of acquiring an HAI during a PPH on utilization of 
healthcare services after a PPH, significant increases in mean healthcare utilization 
attributable to HAI were associated with COPD or long-term complications of diabetes 
with increases of over $36 thousand and nearly $48 thousand, respectively. While post-  
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Table 18. Preventive care cost for BCBSTX beneficiaries before and after a PPH 
  Pre-hospitalization   Post PPH   Post PPH with HAI 
 n 
PPO 
Mean 
payment 
PPO+ 
Mean 
payment S.E.  n 
PPO 
Mean 
payment 
PPO+ 
Mean 
payment S.E.  n 
Mean HAI 
effect1 on 
payment S.E. 
For all PPH           8,099 $15,035 $4,422 
by PPH              
PQI01 Diabetes Short-Term Complications 477 $40,847 $38,134 $1,943  477 $42,797 $39,870 $1,912  477   
PQI03 Diabetes Long-Term Complications 742 $51,166 $58,852 $4,428  742 $42,440 $49,801 $4,417  742 $47,952 $15,226 
PQI05 COPD or Asthma in Older Adults 1,106 $67,415 $68,905 $1,798  1,106 $63,140 $64,875 $1,760  1,106 $36,264 $7,967 
PQI08 Heart Failure 829 $29,325 $26,685 $3,289  829 $27,079 $24,594 $3,269  829 $6,432 $12,375 
PQI10 Dehydration 1,104 $78,338 $79,163 $2,905  1,104 $73,648 $74,245 $2,902  1,104 -$9,526 $13,644 
PQI11 Bacterial Pneumonia 1,708 $85,935 $82,229 $2,605  1,708 $80,818 $77,363 $2,613  1,708 -$4,177 $10,161 
PQI12 Urinary Tract Infection 1,088 $58,293 $57,286 $1,851  1,088 $56,707 $56,231 $1,833  1,088 $31,271 $10,765 
PQI16 Lower-Extremity Amputation among 
diabetes patients 49 $288,150 $276,420 $37,270   49 $291,429 $277,744 $37,353   49     
Mean effects in bold are significant at a p<.001 for HAI  
Source: Blue Cross/Blue Shield of Texas Claims data, 2011 
NOTE: All estimates are adjusted for demographic characteristics and health status. Population includes adults from the BCBSTX with the described 
PPH in 2011. 
1. Referent group are individuals with no HAI within the described PPH population. 
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PPH with HAI utilization for dehydration and bacterial pneumonia were on average 
$9,500 and $4,200 less than PPH individuals with no HAI, these differences were not 
considered significant. Additionally, although other PPH specific differences in mean 
post-PPH utilizations were not significant, the mean effect of HAI on post-PPH 
healthcare utilization was significant and increased post-PPH utilization costs by $15 
thousand (Table 18).  
BCBSTX ambulatory care sensitive condition population, 2011 
 For beneficiaries with no PPH and evidence of healthcare for an ACSC in 2011, 
aggregated healthcare utilization costs estimated annual utilization for each ACSC. After 
adjusting for age, gender and health status, all differences between payment plans were 
significant. Additionally, all models were deemed significant at a p<.001 level as 
measured by the F-statistic. All models contained 31 or 32 covariates depending upon 
the presence of comorbid conditions. 
Mean adjusted annual payment for healthcare associated with an ACSC was 
highest for bacterial pneumonia followed by dehydration (Table 19). However, bacterial 
pneumonia accounted for less than 2% of individuals and dehydration accounted for less 
than 3%. Conversely, hypertension affected the most individuals in the BCBSTX 
population with nearly 390 thousand individuals (Table 19). While diabetes was the 
second most frequently occurring condition among the BCBSTX population, it 
accounted for 18% of the population at a mean annual cost of just over $110 thousand in 
preventive care. 
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Table 19. Mean annual payment for preventive care by ACSC  
ACSC n 
PPO Mean 
payment 
PPO+ Mean 
payment S.E. 
Diabetes 145,210 $110,139 $109,218 $205 
COPD 40,418 $117,346 $113,521 $501 
Hypertension 386,300 $112,752 $110,760 $141 
Congestive Heart Failure 7,950 $112,548 $106,668 $1,270 
Low Birth Weight/ Pre-Natal Care 50,198 $80,530 $81,361 $117 
Dehydration 21,569 $142,056 $137,886 $1,414 
Bacterial Pneumonia 11,739 $145,974 $143,407 $1,127 
UTI 109,611 $124,073 $122,164 $339 
Asthma 13,808 $76,795 $74,149 $799 
Angina 9,949 $126,940 $120,184 $1,375 
All difference are significant at a p<.05 for HAI  
Source: Blue Cross/Blue Shield of Texas Claims data, 2011 
NOTE: All estimates are adjusted for demographic characteristics and health status. 
  
 
 
Calculation of statewide costs 
 Let us restate the hypothesis question here to remind us how the previously 
generated cost estimates were intended to be applied to answer the question. Hypothesis 
question: Following the full implementation of ACA, will the increase in preventive care 
cost attributable to improved insurance coverage for individuals with ACSCs be offset 
by reductions in costs associated a reduced rate of HAI during a PPH? 
 Hence, we must estimate the cost of preventive care for the uninsured ACSC 
population before and after attaining insurance to measure the increase in preventive 
care utilization. Then we must estimate the total incremental effect an HAI has on the 
PPH population during and after hospitalization by estimating the difference in costs 
between individuals with a PPH and individuals with a PPH with HAI. 
Calculation of statewide preventive care cost 
To estimate the preventive care costs for the ACSC population, we must estimate 
the number of the uninsured with ACSCs. Using prevalence rates reported by the Texas 
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Department of State Health Services or reported by the CDC for the seven ACSC 
remaining in the analyses, I estimated the number of uninsured with each ACSC.  In 
combination with adjusted mean cost estimates generated previously (Table 18 and 19), I 
estimated annual costs for individuals using preventive care without a PPH and annual 
cost for individuals with a PPH (Table 20). Diabetes accounted for the most frequently 
occurring condition, while bacterial pneumonia accounted for the most expensive annual 
preventive care (Table 20). Bacterial pneumonia also generated the most cost for the 
PPH population per person with the largest per person differences between preventive 
care for heart failure and PPH care for heart failure. Additionally, only asthma is less 
expensive for preventive care than for PPH and follow-up care at the per person level 
(Table 20). 
When aggregated to the state level, I observed that diabetes contributed the most 
to the aggregated difference between cost for preventive verses PPH patterns of 
utilization while bacterial pneumonia contributed the least. Estimated cost of healthcare 
for the PPH population accounted for the likelihood of a “non-preventable” PPH and the 
likelihood of acquiring an HAI (Table 20). The net increase in expenditures is estimated 
at $66.9 billion for approximately 1.3 million uninsured individuals (Table 20). If the net 
cost were dispersed across the entire uninsured population, the additional cost per person 
equates to approximately $11,100 per year per uninsured person for the ACSC included 
in Table 20.
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Table 20. Calculations for increase in preventive healthcare costs for Texas 
ACSC 
Estimated 
number of 
uninsured 
with ACSC 
Annual cost 
per person 
of 
preventive 
care for 
ACSC 
Annual cost 
of preventive 
care in the 
BCBSTX 
population 
with a PPH 
Six-month 
follow-up 
cost of 
healthcare 
after PPH 
Cost of 
PPH   
Total Annual 
Preventive Care 
Cost 
Current annual 
cost of care for 
Uninsured with 
ACSC 
Net Annual Increase 
to insure the 
Uninsured 
Diabetes 425,552 $110,139 $52,196 $56,442 $12,921 
 
$46,870,043,560 $22,224,523,443 $24,645,520,117 
COPD 245,680 $117,346 $63,140 $68,905 $14,203 
 
$28,829,525,756 $15,515,853,653 $13,313,672,103 
Congestive Heart Failure 175,485 $112,548 $27,079 $29,325 $16,833 
 
$19,750,595,243 $4,755,848,085 $14,994,747,158 
Dehydration 88,280 $142,056 $78,338 $73,648 $15,627 
 
$12,540,721,584 $6,922,130,495 $5,618,591,090 
Bacterial Pneumonia 15,443 $145,974 $80,818 $60,325 $14,341 
 
$2,254,236,909 $1,254,920,736 $999,316,174 
UTI 43,871 $124,073 $56,707 $58,293 $14,971 
 
$5,443,252,297 $2,493,666,413 $2,949,585,884 
Asthma 320,261 $76,795 $63,140 $67,415 $14,203 
 
$24,594,458,656 $20,224,825,240 $4,369,633,415 
                Total Increase $66,891,065,940 
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Calculation of statewide incremental HAI cost 
 From the THCIC inpatient discharge, I identified the number of PPH with HAI 
by type of HAI (Table 21). Using the incremental hospitalization cost associated with 
each HAI and the six month follow-up cost estimated to be attributable to each type of 
HAI, the total incremental cost of HAI in Texas during 2011 was estimated to be over 
$31 million. CDI contributed the most cost due to the higher prevalence in the THCIC 
discharge data. While the incremental cost of VAP was nearly double the incremental 
cost of CDI during hospitalization, the follow-up cost for CDI was nearly 5 times that of 
VAP. The estimated total incremental cost of HAI would likely be much greater if the 
limitations for identifying SSI and CAUTI from discharge data could be overcome. 
 
Table 21. Incremental cost of HAI by HAI in Texas 
  
PPH 
with 
HAI 
Incremental 
HAI 
hospitalization 
cost
1 
Incremental 
HAI follow-
up cost
2 
Total 
Incremental HAI 
cost 
CDI 530 $17,040 $11,467 $15,108,846 
CLABSI 133 $32,408 -$1,716 $4,082,157 
CAUTI 109 $13,118 $17,578 $3,345,909 
VAP  258 $32,541 $1,977 $8,905,714 
        $31,442,627 
1. All estimates are adjusted for demographic, health status, community and hospital characteristics 
2. All estimates are adjusted for demographic characteristics and health status 
 
 
 
 To identify the incremental cost of HAI associated with the uninsured, I used the 
distribution of the PPH with HAI population by payer identified in the descriptive 
analyses (Table 22). The bulk of incremental HAI costs are paid by Medicare, private 
insurers and Medicaid at $20.7 million, $4.7 million, and $3.4 million, respectively 
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(Table 22). The uninsured accounted for 7% of incremental HAI costs at $2.1 million 
(Table 22). 
 
Table 22. Incremental cost of HAI by payer 
Primary Payer 
% of PPH with 
HAI 
Population 
Total 
Incremental 
HAI Costs 
Private payer 15% $4,727,068 
Medicare 66% $20,707,608 
Medicaid 11% $3,385,191 
Other Gov't 2% $518,453 
Self-pay or Charity 7% $2,104,308 
 
 
Sensitivity to changes of insurance rates 
 It is unrealistic to assume 100% participation of the uninsured in newly available 
insurance options and that 100% of PPH are preventable through access to preventive 
care. Additionally, uncertainty and variation in estimates of participation in the new 
insurance marketplaces exists. Another factor influencing hospitalization is the quality of 
care available. To account for these uncertainties, I created a table that tracks changes in 
rates of the uninsured and the percent of the PPH with HAI that is uninsured. The 
incremental analysis reflects sensitivity to take-up rates of new insurance options and the 
whether the care the uninsured receives for ACSC is sufficient to avoid a PPH. 
 From the sensitivity analysis, we observed the greatest effect on the difference in 
preventive care and incremental HAI costs from the transition of individuals from 
uninsured to insured, accounting for decreases of approximately $14 billion for a 5% 
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decrease in the uninsured rate (Table 23). Since transition from uninsured to insured 
does not assure receipt of quality preventive healthcare, I changed the percentage of 
uninsured for the PPH with HAI population to reflect reductions in PPH due to receipt of 
quality healthcare. For each percent decrease of the uninsured in the PPH with HAI 
population, we observed an estimated decrease in incremental costs of $0.3 million 
(Table 23). 
 
Table 23. Sensitivity of incremental costs to state uninsurance rate and percent of 
uninsured PPH with HAI 
 
% of Texas 
population that 
is Uninsured 24% 20% 15% 10% 5% 3% 1% 
% of PPH with 
HAI population 
in Texas hospitals 
that is uninsured 
 
In Millions of dollars 
7% 
Preventive care 66,891.1 55,668.6 41,738.5 27,808.5 13,878.4 8,306.4 2,734.4 
Incremental HAI 2.1 2.1 2.1 2.1 2.1 2.1 2.1 
Preventive-HAI 66,889.0 55,666.5 41,736.4 27,806.4 13,876.3 8,304.3 2,732.3 
6% 
Preventive care 66,891.1 55,668.6 41,738.5 27,808.5 13,878.4 8,306.4 2,734.4 
Incremental HAI 1.9 1.9 1.9 1.9 1.9 1.9 1.9 
Preventive-HAI 66,889.2 55,666.7 41,736.6 27,806.6 13,876.5 8,304.5 2,732.5 
5% 
Preventive care 66,891.1 55,668.6 41,738.5 27,808.5 13,878.4 8,306.4 2,734.4 
Incremental HAI 1.6 1.6 1.6 1.6 1.6 1.6 1.6 
Preventive-HAI 66,889.5 55,667.0 41,737.0 27,806.9 13,876.8 8,304.8 2,732.8 
4% 
Preventive care 66,891.1 55,668.6 41,738.5 27,808.5 13,878.4 8,306.4 2,734.4 
Incremental HAI 1.3 1.3 1.3 1.3 1.3 1.3 1.3 
Preventive-HAI 66,889.8 55,667.3 41,737.3 27,807.2 13,877.2 8,305.1 2,733.1 
3% 
Preventive care 66,891.1 55,668.6 41,738.5 27,808.5 13,878.4 8,306.4 2,734.4 
Incremental HAI 0.9 0.9 0.9 0.9 0.9 0.9 0.9 
Preventive-HAI 66,890.1 55,667.7 41,737.6 27,807.5 13,877.5 8,305.4 2,733.4 
2% 
Preventive care 66,891.1 55,668.6 41,738.5 27,808.5 13,878.4 8,306.4 2,734.4 
Incremental HAI 0.6 0.6 0.6 0.6 0.6 0.6 0.6 
Preventive-HAI 66,890.4 55,668.0 41,737.9 27,807.8 13,877.8 8,305.8 2,733.7 
1% 
Preventive care 66,891.1 55,668.6 41,738.5 27,808.5 13,878.4 8,306.4 2,734.4 
Incremental HAI 0.3 0.3 0.3 0.3 0.3 0.3 0.3 
Preventive-HAI 66,890.8 55,668.3 41,738.2 27,808.2 13,878.1 8,306.1 2,734.1 
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Limitations 
THCIC data 
 Limitations in the THCIC inpatient PUDF centered on the inability to identify 
SSI and CAUTI. For SSI, the inability to link a patient across time prohibited 
identification of SSI beyond the initial surgical procedure. As CAUTI has been 
identified by the CDC as the most common HAI, limitations of administrative coding 
practices for CAUTI  resulted in limited ability evaluate the total effects of CAUTI on 
cost and utilization in this study. Finally, limitations extended to accounting for effects 
related to the comorbid conditions for AIDS, alcohol abuse, and drug abuse. The 
limitations center on suppressed diagnosis codes and age for patients with these 
conditions in the THCIC inpatient PUDF. 
BCBSTX data 
While appropriately populated variables included age, gender, principal 
diagnosis and date of service, other evaluation variables such as race, present on 
admission, and facility specific data did not exist in the data. Unavailable present on 
admission information limited my ability to assuredly identify HAI over community 
acquired CDI, and missing procedure date limited my ability to identify duration of 
ventilation when evaluating VAP. Additionally, since no geographic identifier existed in 
the data, and facility specific identifiers could not be linked to hospital survey 
information, community factors such as rurality, availability of public benefits, or other 
facility specific information could not be included in regression analysis. The inability to 
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assign variation in cost and utilization by these variables should be considered when 
comparing costs and utilization between the THCIC and BCBSTX data. 
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CHAPTER VI 
DISCUSSION 
The PPH, HAI, PPH with HAI, and general inpatient populations 
 Individuals with a PPH are more likely to be older, white, females when 
compared to the general inpatient population. Although the 45-64 years of age 
population appears to be the largest single age group, when I combined the 65 and over 
categories, we observe that 65 and over accounts for nearly half of the PPH population. 
This is consistent with the fact that approximately 54% of PPH patients specified 
Medicare as their primary payer. The proportion of the uninsured was slightly greater in 
the PPH population than the general inpatient population, accounting for 10% of the 
PPH population and only 9% of the general inpatient population. The increased 
proportion in the Medicare payer group was offset by decreases in the proportion of 
individuals specifying private insurance or Medicaid as their primary payer. 
 For the HAI population, we observed a similar demographic composition as the 
PPH population. However, for the HAI population, 56% of patients were 65 and over. 
The increased proportion of 65 and over in the HAI population was reflected in the 
proportion of individuals that specified Medicare as their primary payer (62%). As the 
proportion of Medicare beneficiaries grows, we observed major decreases in the 
proportion of private (11%-17% decreases) and Medicaid (8%-12% decreases) payer 
groups while the uninsured decreased in proportion for HAI (6%), but maintained the 
proportion of admissions for PPH with HAI (7%). 
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 When we consider these changes in population composition in isolation, the 
changes suggest three things. First, that the Medicare population is at greater risk than 
other groups for a PPH, HAI, and a PPH with HAI. Second, that private payers and 
Medicaid beneficiaries are at less risk for PPH, HAI, and PPH with HAI, Third, the 
uninsured’s risk is minimal for PPH and slightly decreased for HAI and PPH with HAI. 
However, when we consider that Medicare beneficiaries are mostly 65 and over, that 
Medicaid primarily covers children, that private insurance primarily covers members of 
a family with a healthy working individual, and the uninsured avoid utilization unless 
absolutely necessary, the proportional changes in demographic composition of the 
populations are not surprising. The demographic descriptive analysis does illuminate the 
need for additional research regarding the effects of PPH and HAI on the Medicare 
population, since they are the majority population of those affected with PPH, HAI, and 
PPH with HAI.  
The ability to identify HAI from administrative data 
Identified issues  
The ability to identify HAI from administrative data using cross-sectional 
methods allows researchers to analyze and identify associations between HAI and other 
factors such as PPH. However, the cross-sectional methods were limited by specificity in 
ICD-9-CM codes and administrative coding practices. For example, where multiple 
ICD-9-CM codes are required to capture a single event, there is no method for 
researchers to link the information together without review of the clinical record. Aside 
from the principal diagnosis, ICD-9-CM codes are usually listed according to level of 
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compensation rather than clinical importance or date of occurrence. While procedures 
include date of procedure in the THCIC inpatient PUDF, it is impossible to tell whether 
an infection diagnosis is a result of a procedure, the reason for the procedure or 
unrelated. The inclusion of present on admission information for each diagnosis has 
improved researchers’ abilities to make chronologically valid assumptions, but it is not 
infallible. 
 One example is the under identification of CAUTI, the most common HAI. 
There are numerous UTI diagnosis codes including a code for CAUTI (ICD-9-CM code 
996.64). Other researchers have also found CAUTI under identified with the ICD-9-CM 
code 996.64. An option for researchers is to use the other UTI diagnosis codes, present 
on admission information, and evidence of urinary catheterization to identify infection 
that started after admission. However, it is difficult for researchers to reliably link the 
UTI diagnosis with urinary catheterization. For some reason, information about CAUTI 
is either not captured in the clinical record or it is not translated in a consistent way to 
the administrative discharge abstract. 
For VAP, cross-sectional methods were more successful in identifying cases of 
VAP, but the method faces similar challenges as CAUTI. Similarities are related to the 
ability to identify pneumonia, ventilation, and present on admission information for 
pneumonia, but our ability to reliably link the three things together for a VAP diagnosis 
could create both under, over, and misidentification. 
 For identifying SSI, ICD-9-CM codes specify surgical procedures and infections 
associated with bodily location. When surgery codes and infection codes are combined 
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with present on admission information, we can identify SSI during the initial 
hospitalization. However, SSI may take up to 90 days after surgery to manifest 
sufficiently for diagnosis by a physician. Therefore, infection identification may not 
occur during the same hospitalization as the surgery. Additionally, treatment of SSI may 
or may not involve additional hospitalization. Where additional hospitalization occurs, 
and if hospitalizations for an individual were linked across time and facilities, SSI might 
be more reliably identified through the inpatient discharge abstract. Given the course of 
disease and the identification process, claims data may be a more reliable source for 
identifying SSI and SSI costs. However, the use of claims data limits identification to 
single payers limiting our ability to compare multiple groups especially the uninsured.  
 For CDI, cross-sectional methods of identification appeared to identify CDI 
sufficiently. The primary issue with CDI identification is related to differentiating 
between community and hospital acquired CDI. The present on admission information 
can rule out some of the community acquired CDI individuals. Length of stay can also 
be used to eliminate community acquired, but only for individuals with inpatient stays 
less than three days, as CDI requires 2 to 3 days to manifest symptoms.  
Another important explanatory factor for CDI is antibiotic use during 
hospitalization. Since the THCIC inpatient PUDF does not contain pharmaceutical 
information, this limits the ability to chronologically determine when antibiotics where 
given relative to symptomatic CDI being diagnosed. The reason this relationship is 
important is that it may differentiate some individuals as community acquired rather that 
hospital acquired.  
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Another consideration for CDI includes previous hospitalization within 3 to 6 
months. As CDI is a long living spore, a post-discharge need for antibiotics may result in 
CDI being identified as community acquired rather than as the subsequent episode of 
healthcare associated CDI. As strategies to reduce other HAIs have met with measurable 
success, CDI has proven difficult to restrain. While healthcare quality strategies have 
mostly contained CDI, our inability to reduce occurrence requires continued research to 
understand the transmission of CDI. 
 Finally, consistent with recently published rates of CLABSI, we see in 2011 
lower than expected rates of CLABSI suggesting a ramp up effect of quality or patient 
safety initiatives targeted at reducing the occurrence of CLABSI in response to 
implementation of non-payment strategies by CMS. Since the methodologies for 
identifying CLABSI are validated by AHRQ, CMS, and NQF, the lower than expected 
identification of CLABSI is likely due to hospitals’ response to non-payment of HAI. 
Another contributing factor is possible changes in administrative coding practices. Since 
CMS annually publishes conditions for non-payment and the ICD-9-CM codes 
associated with those conditions, hospitals may also respond by changing coding 
strategies that contribute to the reduced identification of CLABSI. However, given the 
focus on reduction of HAI, the effects we observe in the data are consistent with other 
surveillance initiatives (U.S. Department of Health and Human Services, 2014). 
Potential solutions 
 Since the bulk of issues for identifying HAI from administrative data are related 
to coding practices, I have generated a potential solution that should not create 
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substantial additional reporting burden, and would greatly enhance our ability to assign 
diagnosis codes to relevant groups of healthcare provision. Append diagnoses codes with 
one letter for each group of codes that describe a single event. For example, all diagnosis 
fields would start with a letter. Principal diagnosis would start with the letter “A”. In 
secondary diagnosis fields, if the diagnosis code started with “A”, it would further 
describe the primary reason for hospitalization. Each subsequent diagnosis would start 
with a different letter for each “grouping” of diagnosis codes. This allows diagnosis for 
pathogens to be linked to the diagnosis for infection site. For the state of Texas, only 25 
diagnosis codes are recorded, so if all 25 diagnosis fields were independent and used, a 
letter could be used for each field without duplication. In consideration for other states 
that report up to 30 diagnosis codes per admission, an alternative would be no letter at 
the beginning of a diagnosis code or a blank for stand-alone diagnosis. Either strategy 
would provide researchers and potentially payers with easily disseminated information 
about a healthcare event. This method could also be extended to include procedure 
codes. 
The potential down side to this strategy is the time and resources for additional 
training required for providers and coders. For example, providers may be required to 
include more information when charting patient information to allow administrative 
coders to appropriately apply the new scheme. Other resource concerns may involve the 
additional time coders’ need to assure they capture the relevant information in the 
clinical record. Another consideration is the transition from ICD-9-CM to ICD-10 codes. 
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Since ICD-10 codes include substantially increased specificity, additional research with 
ICD-10 codes would illuminate whether this strategy is relevant or practical. 
Odds of PPH with HAI  
 Because PPH with HAI is a rare event, 37 in every 100,000 admissions, and the 
large sample size was likely to detect the smallest changes as significant, I decided that 
large effects that were statistically significant would provide the most information about 
PPH with HAI. For the odds ratio analysis, I defined a large effect to be an odds ratio 
less than .5 or greater than two. While many effects were large or near large, only a few 
were significant.  
Perhaps counter-intuitive, for most individuals with a PPH, the odds of acquiring 
an HAI was less than the odds of the general inpatient population acquiring an HAI 
during hospitalization. What I anticipated as reduced health status that placed PPH 
patients at greater risk for an HAI, turned out to be less acute disease when compared to 
other inpatients. The possible explanations for lower odds of HAI included non-PPH 
individuals with health issues more frequently requiring central lines, urinary catheters, 
mechanical ventilation, or surgery than PPH patients.   
Overall, individuals with a PPH had odds of acquiring CDI that was 
approximately half of the non-PPH population, and the odds of acquiring VAP was a 
third of the odds when compared to the non-PPH population. Other significant effects 
reported odds ratios of  0.6 or less except for diabetes related lower extremity 
amputation. Diabetes related lower extremity amputation was the only PPH that 
demonstrated an odds ratio greater than 1 for all four types of HAI evaluated. The largest 
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effect between CDI and diabetes related lower extremity amputation was significant and 
measured PPH patients’ odds of acquiring CDI as 2.9 times that of non-PPH patients. 
Also significant for diabetes related lower extremity amputation was VAP where the 
odds of PPH patients acquiring VAP were 1.44 times the non-PPH population. 
At the other extreme of large effects, we observed patients admitted for bacterial 
pneumonia or urinary tract infection had odds ratios below 0.1 for VAP. This translates 
to the general inpatient population odds of acquiring VAP at more than ten times the 
PPH patients. These significantly lower odds of acquiring HAIs beg us to ask how else 
the PPH patients might be different. 
When we examined the odds of acquiring HAI by payer, we observed Medicare 
beneficiaries odds for acquiring CDI was nearly twice that of other payer groups. For 
other types of HAI, effects were not as large and varied in regards to significance. With 
the payer variable significant in the logistic regression models for predicting HAI, two 
possible and likely explanations exist for differences between payer types. First are the 
age and health status of the beneficiaries represented by each payer. A second 
consideration is government verses non-government payers. Since the different payer 
types represent the elderly (Medicare), the working healthy (Private Insurance), children 
(Medicaid), special needs or military (Other government), and the poor (Charity or self-
pay), it is plausible that each group in addition to variation captured by age, will have 
unique and specific needs and utilization. Regarding government verses non-
government, it is plausible that due to the government being held to different standards 
of accountability, transparency, and performance, differences in care delivery as dictated 
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by payer are absorbed by the payer variable. Either way, additional research to tease out 
these differences would be beneficial. 
Costs  
Analysis of costs 
The cost models accounted for variation in cost by adjusting for approximately 
790 other variables. These variables accounted for significant variation associated with 
gender, age, race, hospital ownership, type of room, comorbid conditions and primary 
diagnosis as represented by DRG. While not all categories were significant, DRG 
absorbed the most variation, since DRG is a reflection of mean cost of consumed 
services for a given diagnosis. In determining whether to include DRG, the primary 
analytic concern was sample size and over specification. To assure sufficient sample size 
was available, a variable inflation factor was used when estimating required sample sizes 
(Hsieh, Bloch, & Larsen, 1998). Since PPH with HAI is a rare event that has not been 
previously studied, a large effect was determined to be the best choice and guided 
sample size calculations. Additionally, since there were very few pediatric PPH with 
HAI, all cost analysis were limited to the adult population. With these considerations, 
sample size calculations revealed that there was a sufficient number of observations to 
use DRGs and still detect large effects related to PPH and HAI. 
Cost associated with hospitalizations 
 In addition to the reduced odds of acquiring HAI in the PPH population, the 
mean hospitalization cost was less for PPH patients when adjusted for demographic, 
health status, hospital, and community characteristics. On average, PPH hospitalizations 
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were approximately $2,100 less than the mean cost of other hospitalizations. Consistent 
across the different types of HAI, the PPH for heart failure cost slightly more than other 
hospitalizations between $400 and $500, while the remaining PPH mean costs were from 
$1,100 to $4,000 less than the general inpatient population. Again, the effects were 
significant at a p<.05 level. 
 Like the odds ratio analysis, we may have anticipated costs per hospitalization to 
be greater due to the reduced health status of PPH individuals. However, what we 
observed was ACSC related hospitalization required fewer resources to stabilize, with 
the exception of individuals with heart failure, leading to lower on average cost per 
hospitalization when compared to the non-PPH population. While this may seem counter 
intuitive, when we reflect on the need for surgery and other high intensity services to 
stabilize a PPH patient, with the exception of diabetes related lower extremity 
amputation, it seems plausible that mean PPH cost less than the general inpatient 
population. 
 When we examined mean costs by payer, we observed that patients with private 
insurance consistently had a higher mean cost by more than $2,000 when compared to 
Medicare and Medicaid, and nearly $4,000 more when compared to the uninsured. These 
cost differences are adjusted for demographics, health status, hospital and community 
characteristics as well as DRG diagnosis. This causes us to question whether there are 
differences in services provided to privately insured patients, or whether private insurers 
are paying more for similar services. While we know providers are required to assess 
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and stabilize the uninsured, the question remains why there are such large differences in 
cost for the privately insured, the governmentally insured, and the uninsured. 
Preventive and follow-up care costs for the PPH population 
 For individuals with a PPH, we observed costs of preventive care before 
hospitalization that were noticeably less than the annual cost of preventive care for the 
corresponding ACSC condition with the exception of lower extremity amputation. 
Preventive care costs for the PPH population were approximately half of the 
corresponding ACSC population with the exception of diabetes related lower extremity 
amputation where mean annual preventive care was more than two and half times 
diabetes ACSC annual preventive care costs. After hospitalization, we observed that the 
six-month follow-up cost of preventive care was nearly equivalent to a full year of 
preventive care by the same individuals in the year prior to the PPH admission.  
The differences in preventive care costs before and after a PPH suggest changes 
in utilization patterns for the PPH population. It appears insured individuals who 
underutilize preventive care in managing an ACSC, increase utilization to near “normal” 
levels after a hospitalization. 
For the purposes of answering the research question, I assumed that the 
uninsured used healthcare prior to a PPH in a similar way as the BCBSTX PPH 
population. I used these preventive care costs as a proxy for the uninsured, because 
although previous research estimates that the uninsured use preventive care less than 
insured individuals, it also shows the uninsured access care through more expensive 
channels such as the emergency room (Bradley, Gandhi, Neumark, Garland, & Retchin, 
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2012). While utilization may be similar, given the significant differences in 
hospitalization cost by payer type, I also assume that using the BCBSTX preventive care 
costs overestimates the cost of utilization. By using the BCBSTX preventive care 
estimates, we account for the maximum cost to transition the uninsured to insured. 
Costs associated with HAI 
 As expected, the mean effect of HAI on hospitalization costs was significant and 
substantial. Additional mean cost during hospitalization was approximately $13,100, 
$17,000, $32,400, and $32,500 for CAUTI, CDI, CLABSI, and VAP respectively. Even 
with the mean decrease in hospitalization costs associated with a PPH, the mean increase 
in hospitalization costs associated with HAI clearly added substantial financial burden to 
patients who acquired an HAI during hospitalization. 
 Unfortunately, for individuals who acquire an HAI during hospitalization, there 
are additional costs associated with post-hospitalization care. Although CLABSI 
incremental hospitalization costs were the second highest, the incremental cost in 
follow-up care was approximately $1,700 less than other PPH patients with no CLABSI. 
For VAP, the most expensive HAI, follow-up costs added to the financial burden with 
nearly $2,000 more of follow-up care for individuals with VAP during a PPH. For CDI 
and CAUTI, incremental cost of follow-up care were approximately $11,500 and 
$17,600 respectively. This makes the total incremental cost of HAI range from $28 
thousand to nearly $35 thousand per person. This translates to over $31 million of 
healthcare expenditures attributable to HAI in the adult PPH population.  
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 To answer the research question, I needed an estimate of incremental cost of HAI 
for the uninsured with a PPH. By multiplying the total incremental cost of HAI in the 
PPH population by the proportion of uninsured in the PPH with HAI population (7%), I 
estimated that the uninsured accounted for $2.1 million in healthcare expenditures 
attributable to HAI in the PPH population. This estimate is likely an underestimation due 
to the under identification of CAUTI and SSI. Since the $2.1 million is attributable to 69 
individuals, and SSI has been identified as the most expensive HAI, identification of SSI 
in the uninsured population may substantially change the estimate. While the cost of care 
for CAUTI was similar to the other HAI, if we raised the number of individuals in the 
PPH with CAUTI to match the CDI levels, the costs attributed to HAI in the uninsured 
PPH population increased by nearly thirteen million dollars.  
Costs associated with preventive care for ACSC  
 The other cost estimate required to answer the research question was the increase 
in healthcare cost to provide preventive health care to the uninsured ACSC population in 
Texas. Using the proportion of individuals with each ACSC as estimated by the Texas 
DSHS or by the CDC and estimates of preventive and follow-up care cost from the 
BCBSTX population, I estimated costs for existing utilization by the uninsured, and 
estimated utilization if all uninsured ACSC individuals became insured. To provide a 
genesis for testing changes in uninsurance rates and the proportion of the uninsured in 
the PPH with HAI population, I made three additional assumptions to facilitate a 
maximum estimation. First, I assumed that the entire uninsured ACSC population would 
participate fully in preventive healthcare once insured. Second, I assumed that all PPH 
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were preventable. Third, I assumed the proportion of the inpatient population with PPH 
and HAI would not change. While the first two assumptions are not reasonable to 
expect, they provide a starting point for sensitivity analyses regarding uninsurance rates, 
and the effect access to preventive care is hypothesized to have on PPH. 
 With the exception of asthma and congestive heart failure, preventive healthcare 
costs per person in the ACSC population were nearly double the total annual 
expenditures by the PPH population. For the uninsured with asthma, annual healthcare 
expenditures would increase by approximately 20%, and for the uninsured with heart 
failure, annual expenditures would increase three fold. When aggregated across all 
ACSC, the increase in healthcare spending was estimated at $66.8 billion. 
  With analysis limited to the PPH conditions that also experienced measurable 
HAI, the estimate likely understates the increase in healthcare expenditures for moving 
the uninsured to being insured. Other phenomena likely to play a role in the consumption 
of healthcare services for the uninsured include pent-up demand creating spikes in 
utilization, continued misuse of preventive services, and limitations in participation due 
to immigration status. The effects of pent-up demand may lead to increases in PPH such 
as those seen when Oregon expanded Medicaid (Saha, Solotaroff, Oster, & Bindman, 
2007). Continued misuse of services may be curbed through spill-over effects as 
Medicare and Medicaid penetrate markets with their managed care products (Baicker, 
Chernew, & Robbins, 2013). Finally, immigrants not eligible to participate in the health 
insurance marketplace, may continue to under use healthcare as immigrants account for 
up to 22% of the uninsured in Texas (Hoffman, Schwartz, Tolbert, Cook, & Williams, 
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2007; Lorden, 2008). These effects should be considered when discussing policy to 
increase access to preventive care and reduce PPH. 
The role of insurance 
 In addition to the increased cost associated with private insurance, we observed 
no cases of HAI in the diabetes related lower extremity amputation PPH for the 
BCBSTX population. This is interesting as the general inpatient population of diabetes 
related lower extremity amputation patients were the most likely to acquire an HAI. This 
may be attributable to the overall younger BCBSTX population, or the substantial 
preventive care received by the diabetes related lower extremity amputation BCBSTX 
beneficiaries both before and after hospitalization. This finding also highlights the fact 
that not all PPH are preventable. Additionally interesting, none of the BCBSTX diabetes 
related lower extremity amputation patients acquired an HAI despite being in the most 
likely group. This brings into question whether privately insured individuals are treated 
differently during hospitalization or whether privately insured individuals systematically 
seek out providers and facilities with higher quality practices.  
 Since Medicare beneficiaries are disproportionately admitted for PPH and 
disproportionately acquire HAI during hospitalization, additional research is needed to 
discover whether Medicare beneficiaries are different simply due to age or if other 
definable attributes exist. Other potential reasons that may explain increased risk of PPH 
or HAI may include community verses institutional living, presence of an active patient 
advocate, ACSC as a comorbid condition to diseases that create an 
immunocompromised state, or beneficiary within a year of death. With the Medicare 
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population accounting for over $20 million in healthcare expenditures related to PPH 
with HAI in Texas, any insight may reduce spending and improve the quality of 
remaining life for elders. 
Sensitivity to uptake and use of preventive care 
 Once costs for preventive healthcare and incremental cost of HAI were 
calculated, I changed rates of uninsurance and the percentage of uninsured in the PPH 
with HAI population to estimate the effect of newly available insurance options. A 1% 
decrease in the uninsurance rate translated to approximately a $2.8 billion decrease in 
the estimated total cost to insure the uninsured ACSC population. To date, just over 12% 
of the uninsured in Texas have enrolled into health insurance plans through the federal 
insurance exchange. The enrollment should translate into a decrease in the estimated 
total cost to insure the uninsured ACSC population by approximately $8 billion. If there 
is initial adverse selection, a higher proportion of the newly enrolled uninsured 
individuals will have an ACSC than compared to the state prevalence levels. While 
enrollment will translate to reductions in the cost estimate, it may also provide 
researchers with the ability to track the effects of pent-up demand for the newly insured.   
Limitations  
 There were three limitations within this study. First, administrative inpatient 
discharge data was limited through issues of coding specificity and the ability to link 
infections with procedures with certainty leading to under identification of CAUTI and 
potentially VAP. Identification of SSI was limited due to inability to link infection to 
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past surgical admissions or with non-hospital utilization. The under or potentially mis-
identification of HAI translates to unidentified costs and effects of HAI. 
Second, preventive care cost estimations are based upon private insurance claims 
data. Since private insurance is associated with more expensive utilization, the BCBSTX 
preventive care costs may over estimate the cost of preventive care services used by the 
uninsured and individuals with other payers. As the uninsured move to insured status, 
they are likely to choose health insurance plans similar to Medicaid or Medicare in cost, 
because they are accessing insurance through the health insurance exchange or 
Medicaid. 
Finally, pre and post PPH utilization for the BCBSTX PPH population are likely 
to overestimate current utilization by the uninsured. Since most uninsured are assumed 
to have financial barriers to insurance, individuals with insurance will not have the same 
financial barriers when accessing healthcare as the uninsured. The differences between 
utilization misuse of preventive services and under-use due to insurance barriers may be 
very different from one another. 
While study results are generalizable, these three limitations suggest that context 
is necessary when interpreting the results. 
Policy implications and future research 
To provide preventive care for individuals with ACSC equates to an average 
increase of between $11,000 and $15,000 per uninsured individual in Texas. If the 
decision to expand insurance options were based solely on cost savings related to PPH 
with HAI, there is no compelling evidence. However, at $2.1 million of potentially 
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avoidable cost, the cost of HAI in the PPH population should be part of the preventive 
care and HAI discussions.   
Another consideration for the policy discussion regarding expansion of insurance 
for preventive care is the existence of other unidentified or under quantified rare events 
within the ACSC population. For PPH with HAI, 69 individuals accounted for $2.1 
million of potentially avoidable healthcare costs. If other similar groups exist within the 
uninsured ACSC population, and preventive care provides a direct or theoretical solution 
to the issue, the financial argument for not expanding insurance options becomes less 
compelling. 
Is it really about access in preventive care? 
 With the majority of PPH admissions designated as insured individuals, I 
speculate that three things are occurring simultaneously. First, individuals with a PPH 
are not accessing preventive care in a timely manner. Second, since the PPH population 
is primarily composed of Medicare beneficiaries, I suspect lack of a patient advocate or 
institutional living may play a significant role in timely access to care. Finally, for the 
entire PPH population, the question remains as to the quality of preventive care received. 
Claims analyses focused on providers with PPH patients may illuminate care settings, 
living situations or quality metrics associated with PPH. 
Is it about age? 
 Since the majority of individuals in the PPH, HAI and PPH with HAI are 
Medicare beneficiaries, and the majority of Medicare beneficiaries qualify for Medicare 
due to age, is it about age or nearness to death rather than access. Exploring the 
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Medicare PPH population utilization characteristics and mortality may explain the 
disproportionate share of Medicare beneficiaries in the PPH population. 
Is it about quality of preventive care? 
Since over 90% of individuals with a PPH have insurance, we must ask if it is the 
quality of care. As suggested for the Medicare population, claims analyses focused on 
providers with PPH patients may illuminate care settings, living situations or quality 
metrics associated with PPH. 
Is it about patterns in utilization? 
 Since we observed different preventive care cost patterns between the BCBSTX 
PPH and ACSC populations, I speculate that individuals with a PPH and insurance either 
do not access preventive care in a timely manner or they are non-compliant with 
provider recommendations for self-care. Claims analysis examining first diagnosis of an 
ACSC in relation to a PPH would illuminate whether individuals are non-compliant or 
are unaware that they have an ACSC. Another approach would be a longitudinal look at 
preventive care by six-month intervals for one year prior to PPH and two years post 
PPH. 
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CHAPTER VII 
CONCLUSIONS 
 For Texas, the estimated increase in healthcare spending to provide preventive 
healthcare through insurance for uninsured adults with an ACSC was $66.8 billion. 
When spread across the uninsured population, the cost equates to an $11 thousand per 
person increase in healthcare spending. For the PPH population, if preventive care 
translated to avoiding hospitalization, the spending for preventive care would less than 
the hospitalization costs that range from $12 to $15 thousand for a PPH. For individuals 
who acquire an HAI during a PPH hospitalization, an addition $15 thousand of 
hospitalization cost and $15 thousand of follow-up care could also be avoided. However, 
only a small portion of the Texas uninsured admitted for a PPH acquired an HAI, 
therefore the incremental HAI costs of approximately $2.1 million does not produce 
sufficient justification for the expansion of insurance options. 
 Regardless of this conclusion, this study has illuminated two important issues. 
First, $31 million in additional healthcare expenditures were attributed to the effects of 
HAI on approximately one thousand patients with PPH in Texas during 2011. The 
additional healthcare expenditures merit investigation into methods to reduce the 
ultimate source, HAI. This is especially true, since the estimated $31 million is likely an 
underestimation of HAI in the PPH population due to the limitations in administrative 
discharge data to identify HAI, especially CAUTI and SSI. Second, 90%, 94%, and 93% 
of the PPH, HAI, and PPH with HAI populations were insured. Given that insurance 
related access to preventive healthcare services should theoretically translate to lower 
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rates of PPH, we must ask what other changeable factors besides insurance related 
access would reduce PPH. 
HAI in the Texas PPH population 
 An HAI is an unfortunate outcome when individuals have an encounter with the 
healthcare system. Since identifiable CDI, CLABSI, VAP, and CAUTI accounted for an 
estimated $31 million of additional healthcare expenditures for 1,031 of the nearly 
15,000 individuals with an HAI during hospitalization, any method to reduce HAI 
occurrence is worth considering.  The outcome of this study supports HAI focused 
initiatives as more productive in reducing HAI than initiatives that reduce exposure to 
risk such as initiatives that reduce PPH. Although most PPH patients were less likely to 
acquire an HAI compared to the general inpatient population, individuals admitted with 
diabetes related lower extremity amputation experienced odds of acquiring CDI 2.9 
times that of the general inpatient population, and their odds of acquiring any HAI was 
1.4 times that of the general inpatient population. Because of the increased odds of 
acquiring an HAI, it may be beneficial for the diabetes related lower extremity 
amputation population to be the focus of both additional preventive healthcare strategies 
and in-hospital strategies to reduce acquisition of HAI. Another group identified in this 
study at potentially higher risk of an HAI during a PPH were Medicare beneficiaries as 
their odds of acquiring an HAI were twice that of any other payer group. Research that 
answers why Medicare beneficiaries are disproportionately hospitalized for ACSC, and 
why Medicare beneficiaries acquire HAI more frequently than any other payer group 
 133 
 
may prove beneficial in generating strategies for reducing PPH, HAI, and PPH with 
HAI.   
Since CAUTI and SSI were under identified in this study, the conclusions I make 
here are speculative. However, since most PPH do not require surgical intervention, SSI 
is likely to maintain low levels in the PPH population. Despite that fact, we still must 
take the few cases that occur into account as other studies identified SSI as the most 
expensive form of HAI (Vinyard, 2013; Zimlichman et al., 2013). As such, better 
methods of identification may pinpoint whether PPH play any role in identifying an at 
risk population. 
 More concerning is the effect CAUTI may have on the PPH population. The 
CDC identified CAUTI as the most frequently occurring HAI (Center for Disease 
Control and Prevention, National Center for Emerging and Zoonotic Infectious Diseases, 
& Division of Healthcare Quality Promotion, 2012a; Saint et al., 2006). Yet, only SSI 
was identified less often for the inpatient population using the methods specified. With a 
mean incremental hospitalization cost of $13 thousand, and an estimated mean 
incremental follow-up cost of $17 thousand, the additional $30 thousand per person 
could translate to tens of millions of dollars in under identified cost for CAUTI. Better 
identification of CAUTI would allow for more accurate cost estimates and provide 
insight into which are the most vulnerable populations regarding CAUTI. 
Finally, given the financial and physical costs associated with HAI, reduction of 
HAIs has been the focus of multiple quality initiatives combining the expertise of a 
variety of stakeholders. In a preliminary report examining the effect of such initiatives 
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on HAI rates between 2010 and 2012, substantial reductions occurred for CLABSI, 
CAUTI, SSI, and VAP in participating Hospital Engagement Networks (U.S. 
Department of Health and Human Services, 2014). With some reductions as high as 
43%, the translation to improved health outcomes and cost savings will be substantial. 
Cause and effect of insurance on PPH 
 While insurance plays a vital role in reducing barriers in access to healthcare, 
especially preventive healthcare services, the majority of individuals with a PPH in 2011 
in Texas had insurance at the time of hospitalization. This is not surprising when viewed 
in the light of previous research where the Medicaid expansion in Oregon preceded 
increases in the number of PPH in the newly insured (Baicker et al., 2013; Saha, 
Solotaroff, Oster, & Bindman, 2007). While the increase in PPH in Oregon was 
attributed to pent-up demand in the Medicaid population, 75% of the PPH in Texas 
during 2011 was attributed to patients with Medicare or private insurance suggesting that 
most were not newly insured.  
Additionally, if preventive care is the key to reducing PPHs, and the majority of 
the PPH population in Texas is insured, other barriers may exist to preventive care. 
Possible barriers include gaps in patient knowledge about how to manage ACSC through 
preventive healthcare or how to effectively interact with the healthcare system. Another 
potentially important barrier may be that access through insurance does not translate to 
access of quality preventive care. The analysis of cost in the PPH BCBSTX population 
suggests the PPH population utilizes preventive care services differently than ACSC 
counterparts without a PPH. While annual utilization costs by PPH individuals is 
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approximately half when compared to the annual ACSC without PPH population costs, 
we observed increased utilization costs by the PPH population after hospitalization up to 
a similar level as the ACSC population. It is likely due to follow-up care associated with 
the PPH, however, it is also possible the PPH may work as an expensive educational 
experience for insured individuals in how to manage an ACSC through preventive care 
services. 
Future research 
 From the results of this study, I have identified three areas where additional 
research would fill gaps in our knowledge. 
PPH and the Medicare population 
 With such a large proportion of the PPH, HAI, and PPH with HAI population 
listing Medicare as their primary insurer, identifying individuals at risk of a PPH in a 
timely manner could substantially reduce expenditures by Medicare, while 
simultaneously improving quality of life of Medicare beneficiaries, and others through 
spillover effects. While continuity of care, comorbid conditions, and dual-eligibility are 
previously identified associations, other areas of research may include community 
dwelling verses institutional living, presence and type of care advocate, or age of onset 
and ACSC self-care and management education.   
Changes in utilization surrounding a PPH event 
 The change in utilization cost before and after a PPH demonstrated by the 
BCBSTX PPH individuals provides us with an opportunity to understand how insured 
individuals with a PPH use healthcare. Since insurance status has been linked to better 
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health and improved outcomes, understanding utilization of services by individuals with 
an ACSC that underutilize healthcare despite access through insurance may illuminate 
our theoretical understanding of healthcare utilization. Additionally, the BCBSTX PPH 
population had increased utilization costs after the PPH event suggesting either follow-
up care was necessary or there was a change in utilization patterns. Since costs increased 
after the PPH, a longitudinal approach to analyze healthcare utilization by insured PPH 
individuals should answer whether changes were permanent. We should also consider or 
validate whether geographic availability of services was cause of underutilization prior 
to the PPH. 
Identification methods for CAUTI and SSI 
 Finally, although other methods are used for surveillance of HAI, the ability to 
identify HAI in administrative data allows researchers to identify relationships and costs 
through secondary analysis of large datasets. Administrative discharge data or claims 
data are currently the most consistent and readily available sources of information to 
researchers. While coding and coding practice changes would enable researchers to 
better identify CAUTI or SSI from administrative data, other sources of information may 
be on the horizon, such electronic healthcare records (EHR). As healthcare informatics 
evolves, the availability of EHR information may prove to be better equipped in 
providing researchers with the necessary information to identify CAUTI and SSI. Since 
EHR data is unlikely to contain cost or payment information, EHR data sources may 
allow us to accurately identify HAI, but may limit our ability to cost HAI. 
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APPENDIX 
DIAGNOSIS AND PROCEDURE CODES FOR PPH AND HAI IDENTIFICATION 
 
Condition to identify ICD-9-CM code or 
HCPCs code 
Source  
Diabetes 24900 
CMS Chronic Condition Warehouse and 
Elixhauser/HCUP comorbidities 
Diabetes 24901 
CMS Chronic Condition Warehouse and 
Elixhauser/HCUP comorbidities 
Diabetes 24910 
CMS Chronic Condition Warehouse and 
Elixhauser/HCUP comorbidities 
Diabetes 24911 
CMS Chronic Condition Warehouse and 
Elixhauser/HCUP comorbidities 
Diabetes 24920 
CMS Chronic Condition Warehouse and 
Elixhauser/HCUP comorbidities 
Diabetes 24921 
CMS Chronic Condition Warehouse and 
Elixhauser/HCUP comorbidities 
Diabetes 24930 
CMS Chronic Condition Warehouse and 
Elixhauser/HCUP comorbidities 
Diabetes 24931 
CMS Chronic Condition Warehouse and 
Elixhauser/HCUP comorbidities 
Diabetes 24940 
CMS Chronic Condition Warehouse and 
Elixhauser/HCUP comorbidities 
Diabetes 24941 
CMS Chronic Condition Warehouse and 
Elixhauser/HCUP comorbidities 
Diabetes 24950 
CMS Chronic Condition Warehouse and 
Elixhauser/HCUP comorbidities 
Diabetes 24951 
CMS Chronic Condition Warehouse and 
Elixhauser/HCUP comorbidities 
Diabetes 24960 
CMS Chronic Condition Warehouse and 
Elixhauser/HCUP comorbidities 
Diabetes 24961 
CMS Chronic Condition Warehouse and 
Elixhauser/HCUP comorbidities 
Diabetes 24970 
CMS Chronic Condition Warehouse and 
Elixhauser/HCUP comorbidities 
Diabetes 24971 
CMS Chronic Condition Warehouse and 
Elixhauser/HCUP comorbidities 
Diabetes 24980 
CMS Chronic Condition Warehouse and 
Elixhauser/HCUP comorbidities 
Diabetes 24981 
CMS Chronic Condition Warehouse and 
Elixhauser/HCUP comorbidities 
Diabetes 24990 
CMS Chronic Condition Warehouse and 
Elixhauser/HCUP comorbidities 
Diabetes 24991 
CMS Chronic Condition Warehouse and 
Elixhauser/HCUP comorbidities 
Diabetes 25000 
CMS Chronic Condition Warehouse and 
Elixhauser/HCUP comorbidities 
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Condition to identify ICD-9-CM code or 
HCPCs code 
Source  
Diabetes 25001 
CMS Chronic Condition Warehouse and 
Elixhauser/HCUP comorbidities 
Diabetes 25002 
CMS Chronic Condition Warehouse and 
Elixhauser/HCUP comorbidities 
Diabetes 25003 
CMS Chronic Condition Warehouse and 
Elixhauser/HCUP comorbidities 
Diabetes 25010 
CMS Chronic Condition Warehouse and 
Elixhauser/HCUP comorbidities 
Diabetes 25011 
CMS Chronic Condition Warehouse and 
Elixhauser/HCUP comorbidities 
Diabetes 25012 
CMS Chronic Condition Warehouse and 
Elixhauser/HCUP comorbidities 
Diabetes 25013 
CMS Chronic Condition Warehouse and 
Elixhauser/HCUP comorbidities 
Diabetes 25020 
CMS Chronic Condition Warehouse and 
Elixhauser/HCUP comorbidities 
Diabetes 25021 
CMS Chronic Condition Warehouse and 
Elixhauser/HCUP comorbidities 
Diabetes 25022 
CMS Chronic Condition Warehouse and 
Elixhauser/HCUP comorbidities 
Diabetes 25023 
CMS Chronic Condition Warehouse and 
Elixhauser/HCUP comorbidities 
Diabetes 25030 
CMS Chronic Condition Warehouse and 
Elixhauser/HCUP comorbidities 
Diabetes 25031 
CMS Chronic Condition Warehouse and 
Elixhauser/HCUP comorbidities 
Diabetes 25032 
CMS Chronic Condition Warehouse and 
Elixhauser/HCUP comorbidities 
Diabetes 25033 
CMS Chronic Condition Warehouse and 
Elixhauser/HCUP comorbidities 
Diabetes 25040 
CMS Chronic Condition Warehouse and 
Elixhauser/HCUP comorbidities 
Diabetes 25041 
CMS Chronic Condition Warehouse and 
Elixhauser/HCUP comorbidities 
Diabetes 25042 
CMS Chronic Condition Warehouse and 
Elixhauser/HCUP comorbidities 
Diabetes 25043 
CMS Chronic Condition Warehouse and 
Elixhauser/HCUP comorbidities 
Diabetes 25050 
CMS Chronic Condition Warehouse and 
Elixhauser/HCUP comorbidities 
Diabetes 25051 
CMS Chronic Condition Warehouse and 
Elixhauser/HCUP comorbidities 
Diabetes 25052 
CMS Chronic Condition Warehouse and 
Elixhauser/HCUP comorbidities 
Diabetes 25053 
CMS Chronic Condition Warehouse and 
Elixhauser/HCUP comorbidities 
Diabetes 25060 
CMS Chronic Condition Warehouse and 
Elixhauser/HCUP comorbidities 
Diabetes 25061 CMS Chronic Condition Warehouse and 
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Condition to identify ICD-9-CM code or 
HCPCs code 
Source  
Elixhauser/HCUP comorbidities 
Diabetes 25062 
CMS Chronic Condition Warehouse and 
Elixhauser/HCUP comorbidities 
Diabetes 25063 
CMS Chronic Condition Warehouse and 
Elixhauser/HCUP comorbidities 
Diabetes 25070 
CMS Chronic Condition Warehouse and 
Elixhauser/HCUP comorbidities 
Diabetes 25071 
CMS Chronic Condition Warehouse and 
Elixhauser/HCUP comorbidities 
Diabetes 25072 
CMS Chronic Condition Warehouse and 
Elixhauser/HCUP comorbidities 
Diabetes 25073 
CMS Chronic Condition Warehouse and 
Elixhauser/HCUP comorbidities 
Diabetes 25080 
CMS Chronic Condition Warehouse and 
Elixhauser/HCUP comorbidities 
Diabetes 25081 
CMS Chronic Condition Warehouse and 
Elixhauser/HCUP comorbidities 
Diabetes 25082 
CMS Chronic Condition Warehouse and 
Elixhauser/HCUP comorbidities 
Diabetes 25083 
CMS Chronic Condition Warehouse and 
Elixhauser/HCUP comorbidities 
Diabetes 25090 
CMS Chronic Condition Warehouse and 
Elixhauser/HCUP comorbidities 
Diabetes 25091 
CMS Chronic Condition Warehouse and 
Elixhauser/HCUP comorbidities 
Diabetes 25092 
CMS Chronic Condition Warehouse and 
Elixhauser/HCUP comorbidities 
Diabetes 25093 
CMS Chronic Condition Warehouse and 
Elixhauser/HCUP comorbidities 
COPD 490 
CMS Chronic Condition Warehouse and 
Elixhauser/HCUP comorbidities 
COPD 491 
CMS Chronic Condition Warehouse and 
Elixhauser/HCUP comorbidities 
COPD 4910 
CMS Chronic Condition Warehouse and 
Elixhauser/HCUP comorbidities 
COPD 4911 
CMS Chronic Condition Warehouse and 
Elixhauser/HCUP comorbidities 
COPD 49120 
CMS Chronic Condition Warehouse and 
Elixhauser/HCUP comorbidities 
COPD 49121 
CMS Chronic Condition Warehouse and 
Elixhauser/HCUP comorbidities 
COPD 49122 
CMS Chronic Condition Warehouse and 
Elixhauser/HCUP comorbidities 
COPD 4918 
CMS Chronic Condition Warehouse and 
Elixhauser/HCUP comorbidities 
COPD 4919 
CMS Chronic Condition Warehouse and 
Elixhauser/HCUP comorbidities 
COPD 492 
CMS Chronic Condition Warehouse and 
Elixhauser/HCUP comorbidities 
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Condition to identify ICD-9-CM code or 
HCPCs code 
Source  
COPD 4928 
CMS Chronic Condition Warehouse and 
Elixhauser/HCUP comorbidities 
COPD 494 
CMS Chronic Condition Warehouse and 
Elixhauser/HCUP comorbidities 
COPD 4940 
CMS Chronic Condition Warehouse and 
Elixhauser/HCUP comorbidities 
COPD 4941 
CMS Chronic Condition Warehouse and 
Elixhauser/HCUP comorbidities 
COPD 496 
CMS Chronic Condition Warehouse and 
Elixhauser/HCUP comorbidities 
Hypertension 36211 
CMS Chronic Condition Warehouse and 
Elixhauser/HCUP comorbidities 
Hypertension 4010 
CMS Chronic Condition Warehouse and 
Elixhauser/HCUP comorbidities 
Hypertension 4011 
CMS Chronic Condition Warehouse and 
Elixhauser/HCUP comorbidities 
Hypertension 4019 
CMS Chronic Condition Warehouse and 
Elixhauser/HCUP comorbidities 
Hypertension 40200 
CMS Chronic Condition Warehouse and 
Elixhauser/HCUP comorbidities 
Hypertension 40201 
CMS Chronic Condition Warehouse and 
Elixhauser/HCUP comorbidities 
Hypertension 40210 
CMS Chronic Condition Warehouse and 
Elixhauser/HCUP comorbidities 
Hypertension 40211 
CMS Chronic Condition Warehouse and 
Elixhauser/HCUP comorbidities 
Hypertension 40290 
CMS Chronic Condition Warehouse and 
Elixhauser/HCUP comorbidities 
Hypertension 40291 
CMS Chronic Condition Warehouse and 
Elixhauser/HCUP comorbidities 
Hypertension 40300 
CMS Chronic Condition Warehouse and 
Elixhauser/HCUP comorbidities 
Hypertension 40301 
CMS Chronic Condition Warehouse and 
Elixhauser/HCUP comorbidities 
Hypertension 40310 
CMS Chronic Condition Warehouse and 
Elixhauser/HCUP comorbidities 
Hypertension 40311 
CMS Chronic Condition Warehouse and 
Elixhauser/HCUP comorbidities 
Hypertension 4039 
CMS Chronic Condition Warehouse and 
Elixhauser/HCUP comorbidities 
Hypertension 40391 
CMS Chronic Condition Warehouse and 
Elixhauser/HCUP comorbidities 
Hypertension 40400 
CMS Chronic Condition Warehouse and 
Elixhauser/HCUP comorbidities 
Hypertension 40401 
CMS Chronic Condition Warehouse and 
Elixhauser/HCUP comorbidities 
Hypertension 40402 
CMS Chronic Condition Warehouse and 
Elixhauser/HCUP comorbidities 
Hypertension 40403 CMS Chronic Condition Warehouse and 
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Condition to identify ICD-9-CM code or 
HCPCs code 
Source  
Elixhauser/HCUP comorbidities 
Hypertension 40410 
CMS Chronic Condition Warehouse and 
Elixhauser/HCUP comorbidities 
Hypertension 40411 
CMS Chronic Condition Warehouse and 
Elixhauser/HCUP comorbidities 
Hypertension 40412 
CMS Chronic Condition Warehouse and 
Elixhauser/HCUP comorbidities 
Hypertension 40413 
CMS Chronic Condition Warehouse and 
Elixhauser/HCUP comorbidities 
Hypertension 40490 
CMS Chronic Condition Warehouse and 
Elixhauser/HCUP comorbidities 
Hypertension 40491 
CMS Chronic Condition Warehouse and 
Elixhauser/HCUP comorbidities 
Hypertension 40492 
CMS Chronic Condition Warehouse and 
Elixhauser/HCUP comorbidities 
Hypertension 40493 
CMS Chronic Condition Warehouse and 
Elixhauser/HCUP comorbidities 
Hypertension 40501 
CMS Chronic Condition Warehouse and 
Elixhauser/HCUP comorbidities 
Hypertension 40509 
CMS Chronic Condition Warehouse and 
Elixhauser/HCUP comorbidities 
Hypertension 40511 
CMS Chronic Condition Warehouse and 
Elixhauser/HCUP comorbidities 
Hypertension 40519 
CMS Chronic Condition Warehouse and 
Elixhauser/HCUP comorbidities 
Hypertension 40591 
CMS Chronic Condition Warehouse and 
Elixhauser/HCUP comorbidities 
Hypertension 40599 
CMS Chronic Condition Warehouse and 
Elixhauser/HCUP comorbidities 
Hypertension 4372 
CMS Chronic Condition Warehouse and 
Elixhauser/HCUP comorbidities 
Hypertension 64210 
CMS Chronic Condition Warehouse and 
Elixhauser/HCUP comorbidities 
Hypertension 64211 
CMS Chronic Condition Warehouse and 
Elixhauser/HCUP comorbidities 
Hypertension 64212 
CMS Chronic Condition Warehouse and 
Elixhauser/HCUP comorbidities 
Hypertension 64213 
CMS Chronic Condition Warehouse and 
Elixhauser/HCUP comorbidities 
Hypertension 64214 
CMS Chronic Condition Warehouse and 
Elixhauser/HCUP comorbidities 
Hypertension 64200 
CMS Chronic Condition Warehouse and 
Elixhauser/HCUP comorbidities 
Hypertension 64201 
CMS Chronic Condition Warehouse and 
Elixhauser/HCUP comorbidities 
Hypertension 64202 
CMS Chronic Condition Warehouse and 
Elixhauser/HCUP comorbidities 
Hypertension 64203 
CMS Chronic Condition Warehouse and 
Elixhauser/HCUP comorbidities 
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Condition to identify ICD-9-CM code or 
HCPCs code 
Source  
Hypertension 64204 
CMS Chronic Condition Warehouse and 
Elixhauser/HCUP comorbidities 
Congestive Heart Failure 39891 
CMS Chronic Condition Warehouse and 
Elixhauser/HCUP comorbidities 
Congestive Heart Failure 4280 
CMS Chronic Condition Warehouse and 
Elixhauser/HCUP comorbidities 
Congestive Heart Failure 4281 
CMS Chronic Condition Warehouse and 
Elixhauser/HCUP comorbidities 
Congestive Heart Failure 4282 
CMS Chronic Condition Warehouse and 
Elixhauser/HCUP comorbidities 
Congestive Heart Failure 42820 
CMS Chronic Condition Warehouse and 
Elixhauser/HCUP comorbidities 
Congestive Heart Failure 42821 
CMS Chronic Condition Warehouse and 
Elixhauser/HCUP comorbidities 
Congestive Heart Failure 42822 
CMS Chronic Condition Warehouse and 
Elixhauser/HCUP comorbidities 
Congestive Heart Failure 42823 
CMS Chronic Condition Warehouse and 
Elixhauser/HCUP comorbidities 
Congestive Heart Failure 4283 
CMS Chronic Condition Warehouse and 
Elixhauser/HCUP comorbidities 
Congestive Heart Failure 42830 
CMS Chronic Condition Warehouse and 
Elixhauser/HCUP comorbidities 
Congestive Heart Failure 42831 
CMS Chronic Condition Warehouse and 
Elixhauser/HCUP comorbidities 
Congestive Heart Failure 42832 
CMS Chronic Condition Warehouse and 
Elixhauser/HCUP comorbidities 
Congestive Heart Failure 42833 
CMS Chronic Condition Warehouse and 
Elixhauser/HCUP comorbidities 
Congestive Heart Failure 4284 
CMS Chronic Condition Warehouse and 
Elixhauser/HCUP comorbidities 
Congestive Heart Failure 42840 
CMS Chronic Condition Warehouse and 
Elixhauser/HCUP comorbidities 
Congestive Heart Failure 42841 
CMS Chronic Condition Warehouse and 
Elixhauser/HCUP comorbidities 
Congestive Heart Failure 42842 
CMS Chronic Condition Warehouse and 
Elixhauser/HCUP comorbidities 
Congestive Heart Failure 42843 
CMS Chronic Condition Warehouse and 
Elixhauser/HCUP comorbidities 
Congestive Heart Failure 4289 
CMS Chronic Condition Warehouse and 
Elixhauser/HCUP comorbidities 
Prenatal care CPT 5430 Texas Medicaid provider procedures manual 
Prenatal care CPT 99201 Mod TH Texas Medicaid provider procedures manual 
Prenatal care CPT 99202 Mod TH Texas Medicaid provider procedures manual 
Prenatal care CPT 99203 Mod TH Texas Medicaid provider procedures manual 
Prenatal care CPT 99204 Mod TH Texas Medicaid provider procedures manual 
Prenatal care CPT 99205 Mod TH Texas Medicaid provider procedures manual 
Prenatal care CPT 99211 Mod TH Texas Medicaid provider procedures manual 
Prenatal care CPT 99212 Mod TH Texas Medicaid provider procedures manual 
Prenatal care CPT 99213 Mod TH Texas Medicaid provider procedures manual 
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Condition to identify ICD-9-CM code or 
HCPCs code 
Source  
Prenatal care CPT 99214 Mod TH Texas Medicaid provider procedures manual 
Prenatal care CPT 99215 Mod TH Texas Medicaid provider procedures manual 
Prenatal care 0500F Blue Cross/ Blue Shield coding advice 
Prenatal care 0501F Blue Cross/ Blue Shield coding advice 
Prenatal care 0502F Blue Cross/ Blue Shield coding advice 
Dehydration 2765 AHRQ Tech Specs 
Dehydration 27650 AHRQ Tech Specs 
Dehydration 27651 AHRQ Tech Specs 
Dehydration 27652 AHRQ Tech Specs 
Dehydration 2760 AHRQ Tech Specs 
Dehydration 00861 AHRQ Tech Specs 
Dehydration 00862 AHRQ Tech Specs 
Dehydration 00863 AHRQ Tech Specs 
Dehydration 00864 AHRQ Tech Specs 
Dehydration 00865 AHRQ Tech Specs 
Dehydration 00866 AHRQ Tech Specs 
Dehydration 00867 AHRQ Tech Specs 
Dehydration 00869 AHRQ Tech Specs 
Dehydration 0088 AHRQ Tech Specs 
Dehydration 0090 AHRQ Tech Specs 
Dehydration 0091 AHRQ Tech Specs 
Dehydration 0092 AHRQ Tech Specs 
Dehydration 0093 AHRQ Tech Specs 
Dehydration 5589 AHRQ Tech Specs 
Bacterial Pneumonia 481 AHRQ Tech Specs 
Bacterial Pneumonia 4822 AHRQ Tech Specs 
Bacterial Pneumonia 48230 AHRQ Tech Specs 
Bacterial Pneumonia 48231 AHRQ Tech Specs 
Bacterial Pneumonia 48232 AHRQ Tech Specs 
Bacterial Pneumonia 48239 AHRQ Tech Specs 
Bacterial Pneumonia 48241 AHRQ Tech Specs 
Bacterial Pneumonia 48242 AHRQ Tech Specs 
Bacterial Pneumonia 4829 AHRQ Tech Specs 
Bacterial Pneumonia 4830 AHRQ Tech Specs 
Bacterial Pneumonia 4831 AHRQ Tech Specs 
Bacterial Pneumonia 4838 AHRQ Tech Specs 
Bacterial Pneumonia 485 AHRQ Tech Specs 
Bacterial Pneumonia 486 AHRQ Tech Specs 
Urinary Tract Infection 59010 AHRQ Tech Specs 
Urinary Tract Infection 59011 AHRQ Tech Specs 
Urinary Tract Infection 5902 AHRQ Tech Specs 
Urinary Tract Infection 5903 AHRQ Tech Specs 
Urinary Tract Infection 59080 AHRQ Tech Specs 
Urinary Tract Infection 59081 AHRQ Tech Specs 
Urinary Tract Infection 5909 AHRQ Tech Specs 
Urinary Tract Infection 5950 AHRQ Tech Specs 
Urinary Tract Infection 5959 AHRQ Tech Specs 
Urinary Tract Infection 5990 AHRQ Tech Specs 
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Condition to identify ICD-9-CM code or 
HCPCs code 
Source  
Asthma 493 
CMS Chronic Condition Warehouse and 
Elixhauser/HCUP comorbidities 
Asthma 49301 
CMS Chronic Condition Warehouse and 
Elixhauser/HCUP comorbidities 
Asthma 49302 
CMS Chronic Condition Warehouse and 
Elixhauser/HCUP comorbidities 
Asthma 4931 
CMS Chronic Condition Warehouse and 
Elixhauser/HCUP comorbidities 
Asthma 49311 
CMS Chronic Condition Warehouse and 
Elixhauser/HCUP comorbidities 
Asthma 49312 
CMS Chronic Condition Warehouse and 
Elixhauser/HCUP comorbidities 
Asthma 4932 
CMS Chronic Condition Warehouse and 
Elixhauser/HCUP comorbidities 
Asthma 49321 
CMS Chronic Condition Warehouse and 
Elixhauser/HCUP comorbidities 
Asthma 49322 
CMS Chronic Condition Warehouse and 
Elixhauser/HCUP comorbidities 
Asthma 49381 
CMS Chronic Condition Warehouse and 
Elixhauser/HCUP comorbidities 
Asthma 49382 
CMS Chronic Condition Warehouse and 
Elixhauser/HCUP comorbidities 
Asthma 4939 
CMS Chronic Condition Warehouse and 
Elixhauser/HCUP comorbidities 
Asthma 49391 
CMS Chronic Condition Warehouse and 
Elixhauser/HCUP comorbidities 
Asthma 49392 
CMS Chronic Condition Warehouse and 
Elixhauser/HCUP comorbidities 
Angina 4111 AHRQ Tech Specs 
Angina 41181 AHRQ Tech Specs 
Angina 41189 AHRQ Tech Specs 
Angina 4130 AHRQ Tech Specs 
Angina 4131 AHRQ Tech Specs 
Angina 4139 AHRQ Tech Specs 
Coronary Artery bypass 
procedure 36.10 CDC Surgical Site Infection Table 
Coronary Artery bypass 
procedure 36.11 CDC Surgical Site Infection Table 
Coronary Artery bypass 
procedure 36.12 CDC Surgical Site Infection Table 
Coronary Artery bypass 
procedure 36.13 CDC Surgical Site Infection Table 
Coronary Artery bypass 
procedure 36.14 CDC Surgical Site Infection Table 
Coronary Artery bypass 
procedure 36.15 CDC Surgical Site Infection Table 
Coronary Artery bypass 
procedure 36.16 CDC Surgical Site Infection Table 
Coronary Artery bypass 36.17 CDC Surgical Site Infection Table 
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Condition to identify ICD-9-CM code or 
HCPCs code 
Source  
procedure 
Coronary Artery bypass 
procedure 36.19 CDC Surgical Site Infection Table 
Coronary Artery bypass 
procedure 36.2 CDC Surgical Site Infection Table 
Hip prosthetic procedure 00.70 CDC Surgical Site Infection Table 
Hip prosthetic procedure 00.71 CDC Surgical Site Infection Table 
Hip prosthetic procedure 00.72 CDC Surgical Site Infection Table 
Hip prosthetic procedure 00.73 CDC Surgical Site Infection Table 
Hip prosthetic procedure 00.85 CDC Surgical Site Infection Table 
Hip prosthetic procedure 00.86 CDC Surgical Site Infection Table 
Hip prosthetic procedure 00.87 CDC Surgical Site Infection Table 
Hip prosthetic procedure 81.51 CDC Surgical Site Infection Table 
Hip prosthetic procedure 81.52 CDC Surgical Site Infection Table 
Hip prosthetic procedure 81.53 CDC Surgical Site Infection Table 
Knee prosthetic 
procedure 00.80 CDC Surgical Site Infection Table 
Knee prosthetic 
procedure 00.81 CDC Surgical Site Infection Table 
Knee prosthetic 
procedure 00.82 CDC Surgical Site Infection Table 
Knee prosthetic 
procedure 00.83 CDC Surgical Site Infection Table 
Knee prosthetic 
procedure 00.84 CDC Surgical Site Infection Table 
Knee prosthetic 
procedure 81.54 CDC Surgical Site Infection Table 
Knee prosthetic 
procedure 81.55 CDC Surgical Site Infection Table 
SSI  
51920 and one of procs 
03610-03619 McNutt, 2010 
SSI  8942 Sherman, 2006; Stevenson2008 
SSI  99661 Sherman, 2006; Stevenson2008 
SSI  99662 Sherman, 2006; Stevenson2008 
SSI   99663 Sherman, 2006; Stevenson2008 
SSI   99666 Sherman, 2006; Stevenson2008 
SSI   99667 Sherman, 2006; Stevenson2008 
SSI   99671 Sherman, 2006; Stevenson2008 
SSI   99672 Sherman, 2006; Stevenson2008 
SSI   9980 Sherman, 2006; Stevenson2008 
SSI   99831 Sherman, 2006; Stevenson2008 
SSI   99832 Sherman, 2006; Stevenson2008 
SSI   99851 Sherman, 2006; Stevenson2008 
SSI   99859 Sherman, 2006; Stevenson2008 
SSI   9986 Sherman, 2006; Stevenson2008 
SSI   99883 Sherman, 2006; Stevenson2008 
SSI   9993 Sherman, 2006; Stevenson2008 
SSI   32081 Sherman, 2006; Stevenson2008 
SSI   32082 Sherman, 2006; Stevenson2008 
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Condition to identify ICD-9-CM code or 
HCPCs code 
Source  
SSI   32089 Sherman, 2006; Stevenson2008 
SSI   3200 Sherman, 2006; Stevenson2008 
SSI   3201 Sherman, 2006; Stevenson2008 
SSI   3202 Sherman, 2006; Stevenson2008 
SSI   3203 Sherman, 2006; Stevenson2008 
SSI   3207 Sherman, 2006; Stevenson2008 
SSI   3209 Sherman, 2006; Stevenson2008 
SSI   3210 Sherman, 2006; Stevenson2008 
SSI   3211 Sherman, 2006; Stevenson2008 
SSI   3212 Sherman, 2006; Stevenson2008 
SSI   3213 Sherman, 2006; Stevenson2008 
SSI   3214 Sherman, 2006; Stevenson2008 
SSI   3218 Sherman, 2006; Stevenson2008 
SSI  3220 Sherman, 2006; Stevenson2008 
SSI   3221 Sherman, 2006; Stevenson2008 
SSI   3222 Sherman, 2006; Stevenson2008 
SSI   3229 Sherman, 2006; Stevenson2008 
SSI   3240 Sherman, 2006; Stevenson2008 
SSI   3241 Sherman, 2006; Stevenson2008 
SSI   3249 Sherman, 2006; Stevenson2008 
SSI   42090 Sherman, 2006; Stevenson2008 
SSI   42091 Sherman, 2006; Stevenson2008 
SSI   42099 Sherman, 2006; Stevenson2008 
SSI   4219 Sherman, 2006; Stevenson2008 
SSI   42290 Sherman, 2006; Stevenson2008 
SSI   42291 Sherman, 2006; Stevenson2008 
SSI   5131 Sherman, 2006; Stevenson2008 
SSI   5192 Sherman, 2006; Stevenson2008 
SSI   6821 Sherman, 2006; Stevenson2008 
SSI   6822 Sherman, 2006; Stevenson2008 
SSI   6823 Sherman, 2006; Stevenson2008 
SSI   6824 Sherman, 2006; Stevenson2008 
SSI   6826 Sherman, 2006; Stevenson2008 
SSI   6827 Sherman, 2006; Stevenson2008 
SSI   6829 Sherman, 2006; Stevenson2008 
SSI   7280 Sherman, 2006; Stevenson2008 
SSI   73000 Sherman, 2006; Stevenson2008 
SSI   73001 Sherman, 2006; Stevenson2008 
SSI   73002 Sherman, 2006; Stevenson2008 
SSI   73003 Sherman, 2006; Stevenson2008 
SSI   73004 Sherman, 2006; Stevenson2008 
SSI   73005 Sherman, 2006; Stevenson2008 
SSI   73006 Sherman, 2006; Stevenson2008 
SSI   73007 Sherman, 2006; Stevenson2008 
SSI   73008 Sherman, 2006; Stevenson2008 
SSI   73009 Sherman, 2006; Stevenson2008 
SSI   73020 Sherman, 2006; Stevenson2008 
SSI   73021 Sherman, 2006; Stevenson2008 
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Condition to identify ICD-9-CM code or 
HCPCs code 
Source  
SSI   73022 Sherman, 2006; Stevenson2008 
SSI   73023 Sherman, 2006; Stevenson2008 
SSI   73024 Sherman, 2006; Stevenson2008 
SSI   73025 Sherman, 2006; Stevenson2008 
SSI   73026 Sherman, 2006; Stevenson2008 
SSI   73027 Sherman, 2006; Stevenson2008 
SSI   73028 Sherman, 2006; Stevenson2008 
SSI   73029 Sherman, 2006; Stevenson2008 
SSI   73030 Sherman, 2006; Stevenson2008 
SSI   73031 Sherman, 2006; Stevenson2008 
SSI   73032 Sherman, 2006; Stevenson2008 
SSI   73033 Sherman, 2006; Stevenson2008 
SSI   73034 Sherman, 2006; Stevenson2008 
SSI   73035 Sherman, 2006; Stevenson2008 
SSI   73036 Sherman, 2006; Stevenson2008 
SSI   73037 Sherman, 2006; Stevenson2008 
SSI   73038 Sherman, 2006; Stevenson2008 
SSI   73039 Sherman, 2006; Stevenson2008 
SSI   73090 Sherman, 2006; Stevenson2008 
SSI   73091 Sherman, 2006; Stevenson2008 
SSI   73092 Sherman, 2006; Stevenson2008 
SSI   73093 Sherman, 2006; Stevenson2008 
SSI   73094 Sherman, 2006; Stevenson2008 
SSI   73095 Sherman, 2006; Stevenson2008 
SSI   73096 Sherman, 2006; Stevenson2008 
SSI   73097 Sherman, 2006; Stevenson2008 
SSI   73098 Sherman, 2006; Stevenson2008 
SSI   73099 Sherman, 2006; Stevenson2008 
SSI   8900 Sherman, 2006; Stevenson2008 
SSI   8901 Sherman, 2006; Stevenson2008 
SSI   8902 Sherman, 2006; Stevenson2008 
SSI   8910 Sherman, 2006; Stevenson2008 
SSI   8911 Sherman, 2006; Stevenson2008 
SSI   8912 Sherman, 2006; Stevenson2008 
SSI   8940 Sherman, 2006; Stevenson2008 
SSI   8941 Sherman, 2006; Stevenson2008 
CAUTI 996.64 McNutt, 2010 
CAUTI 59000 Sherman, 2006 
CAUTI  59001 Sherman, 2006 
CAUTI  59010 Sherman, 2006 
CAUTI  59011 Sherman, 2006 
CAUTI  5902 Sherman, 2006 
CAUTI  5903 Sherman, 2006 
CAUTI  59080 Sherman, 2006 
CAUTI  5909 Sherman, 2006 
CAUTI  5950 Sherman, 2006 
CAUTI  5951 Sherman, 2006 
CAUTI  5952 Sherman, 2006 
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Condition to identify ICD-9-CM code or 
HCPCs code 
Source  
CAUTI  5953 Sherman, 2006 
CAUTI  59581 Sherman, 2006 
CAUTI  59589 Sherman, 2006 
CAUTI  5959 Sherman, 2006 
CAUTI  5990 Sherman, 2006 
CAUTI  9975 Sherman, 2006 
CAUTI 59081 ahrq PQI 12 
CAUTI 996.31 icd9.chrisenders.com 
CAUTI 57.94 icd9.chrisenders.com 
CAUTI 97.64 icd9.chrisenders.com 
VAP 4800 Sherman, 2006 
VAP 31.1 Stevenson, 2008 
VAP 31.2 Stevenson, 2008 
VAP 31.21 Stevenson, 2008 
VAP 31.29 Stevenson, 2008 
VAP 9601 Restrepo,2010 
VAP 9602 Restrepo,2010 
VAP 9603 Restrepo,2010 
VAP 9604 Restrepo,2010; Stevenson, 2008 
VAP 9605 Restrepo,2010 
VAP 9670 Restrepo,2010; Stevenson, 2008 
VAP 9671 Restrepo,2010; Stevenson, 2008 
VAP 9672 Restrepo,2010; Stevenson, 2008 
VAP  4801 Sherman, 2006 
VAP  4802 Sherman, 2006 
VAP  4803 Sherman, 2006 
VAP  4808 Sherman, 2006 
VAP  4809 Sherman, 2006 
VAP  481 Sherman, 2006 
VAP  4820 Sherman, 2006 
VAP  4821 Sherman, 2006 
VAP  4822 Sherman, 2006 
VAP  48230 Sherman, 2006 
VAP  48231 Sherman, 2006 
VAP  48232 Sherman, 2006 
VAP  48239 Sherman, 2006 
VAP  48240 Sherman, 2006 
VAP  48241 Sherman, 2006 
VAP  48249 Sherman, 2006 
VAP  48281 Sherman, 2006 
VAP  48282 Sherman, 2006 
VAP  48283 Sherman, 2006 
VAP  48284 Sherman, 2006 
VAP  48289 Sherman, 2006 
VAP  4829 Sherman, 2006 
VAP  4830 Sherman, 2006 
VAP  4831 Sherman, 2006 
VAP  4838 Sherman, 2006 
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Condition to identify ICD-9-CM code or 
HCPCs code 
Source  
VAP  485 Sherman, 2006 
VAP  486 Sherman, 2006 
VAP  4870 Sherman, 2006 
 
